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Executive summary  
 
Background 
This project developed as a result of the activities of the Research Teams at the Centre for Health 
Economics, University of York, and ScHARR at the University of Sheffield in the methods and 
application of decision analysis and value of information analysis as a means of informing the 
research recommendations made by NICE, as part of its Guidance to the NHS in England and Wales, 
and informing the deliberations of the NICE Research and Development Committee.   
 
Bayesian decision analysis and value of information analysis (DA-VOI)  provides a methodological 
framework which explicitly considers the uncertainty surrounding the decision of a health care system 
to adopt a health technology.  Specifically, using existing evidence, these methods focus on the 
likelihood of making a wrong decision if the technology is adopted. The value of additional research is 
based on the extent to which further information will reduce this decision uncertainty.  This framework 
values the additional information, which may be generated by further research, in a way which is 
consistent with the objectives and the resource constraints of heath care provision (the cost-
effectiveness threshold).  This allows a comparison of the potential benefits of further research with 
the costs of further investigation, a comparison and prioritisation of alternative research 
recommendations, both within and between Technology Assessments, as well as an assessment of 
the value of investing resources in research or other activities, such as the provision of health service.  
In this sense it provides a unified and coherent framework for prioritisation of research and the use of 
heath care technologies.    
 
Objectives 
The specific objectives of the pilot study were to: 
• Demonstrate the benefits of using appropriate decision analytic methods and value of information 
analysis to inform research recommendations. 
• Establish the feasibility and resource implications of applying these methods in a timely way, to 
inform NICE. 
• Identify critical issues and methodological challenges to the use of value of information methods 
for research recommendations (with particular regard to the new reference case as a suitable 
basis for this type of analysis). 
 
The project consists of a series of case studies based on recent technology assessment reports 
completed by the York and Sheffield group for NICE.   These included: 
• Screening for age related macular degeneration (AMD) 
• Glycoprotein IIb/IIIa antagonists for acute coronary syndrome (GPAs) 
• Clopidogrel and dipyridamole in the secondary prevention of occlusive vascular events (CLO) 
• Neurominidase inhibitors for the treatment of influenza (NIs) 
• Liquid based cytology screening for cervical cancer (LBC) 
• Beta interferon and glatiramer acetate in the management of MS (MS) 
 
The purpose was to establish the feasibility and requirements of value of information analysis once 
submissions and Technology Assessment Reports (TARs) are conducted within the reference case 
specified in the recent methods guidance. Therefore case studies were selected on the basis that the 
existing TAR comes as close to the new reference case analysis as possible 
  
Results 
With the exception of screening for AMD all the other case studies met the original selection criteria 
for inclusion. Screening for AMD was not included in the original TAR for AMD. However, it was a 
recommendation for further research and the analysis for this case study is based on a screening 
model for AMD which was developed for the NCCHTA.  The other five associated TARs included an 
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appropriate decision analytic model probabilistic analysis.  In each case the existing TAR came close 
to the new reference case. However, any specific shortcomings are highlighted in each case study 
chapter.  The more general issue of whether the existing references case is a sufficient basis for DA-
VOI is discussed in chapter 8 and suggests that with the ongoing development of more detailed 
methods guidance on modelling, probabilistic analysis and evidence synthesis, a well conducted 
reference case analysis will provide a sufficient basis for value of information analysis. The core tasks 
and initial reanalysis of the case studies were completed in a timely way and within the proposed 
timeframe (4 weeks).  It is anticipated that the additional resources required to move from a well 
conducted reference case analysis to full value of information analysis will be less than required within 
this pilot study which was based on pre reference case assessment reports.  
 
The decision uncertainty surrounding the choice between strategies was characterised in the form of 
cost-effectiveness acceptability curves and frontiers.  In each case the decision model was 
reanalysed and value of information analysis conducted. The Expected Value of Perfect Information 
(EVPI) surrounding each decision problem for the population of England and Wales, and the EVPI 
associated with particular model inputs was established using appropriate non-parametric methods  
 
The value of research differed substantially across the 6 technology appraisals (EVPI ranged from 
£2.8m to £865m).  In some cases the analysis indicated that the original research recommendations 
should not be regarded as a priority, e.g., the EVPI surrounding LBC for was low (£2.8m).  In other 
cases it indicated that additional research should be commissioned, e.g., the EVPI surrounding CLO 
for stroke patients was high (£865).  
 
The analysis indicated which comparators should be included in future research and also suggested 
other parameters that could be excluded.  Estimates of value of information for the decision problem 
and for groups of parameters were also presented for relevant patient sub groups, e.g., the value of 
information different across the patient groups considered in the CLO and AMD case study. A number 
of case studies presented scenarios to explore alternative views of the relevant evidence e.g., 
inclusion of related and “unrelated events” in the assessment of CLO and impact of restricting 
consideration of evidence at 6 months in GPAs ; different structural assumptions regard mechanism 
of action, e.g., additive nature of information gains during screening for AMD;  as well as the impact 
on value of information when relevant alternative may have been excluded from the original scope of 
the appraisal, e.g., the including the potential role of clopidigrel in the GPA case study.   
 
The implications for the value of research in each of the areas were presented at a general level, as 
well as for the design of any future research in terms of features such as the relevant patient groups 
and comparators, and whether experimental design was likely to be required. The full reporting of the 
analysis conducted, and a discussion of the results for each of the case studies, can be found in 
Chapters 2 to 7. The case studies also highlighted a number of more general methodological issues 
including: consideration of all comparators, synthesising direct and indirect evidence, and considering 
structural as well as parameter uncertainty which are more fully discussed in chapter 8.  
 
Conclusions and recommendations  
Demonstration of benefits 
The framework proved by DA-VOI was successfully implemented for each of the 6 case studies and 
provides the value of additional information, which may be generated by further research.  This is 
consistent with the objectives of the heath care system (maximise the health gains of the population 
of England and Wales) and is based on the same resource constraints (the cost-effectiveness 
threshold which is used to develop guidance on use of the technology).   
• For a particular assessment, this allows comparison of the potential benefits of further 
research (EVPI) with the costs of further investigation.  If the potential benefits exceed the 
additional costs (including opportunity costs to patients) then further investigation maybe 
required to support guidance on use.  The EVPI associated with the groups of parameters 
indicates the type of evidence that will be most valuable and therefore the type of studies that 
should be recommended. 
• It also allows comparisons to be made across different technology assessments and 
prioritisation between alternative research recommendations, as well as a comparison 
between the value of investing resources in research or other activities such as the provision 
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of health service.  In this sense it provides a unified and coherent framework for prioritisation 
of both research and the use of heath care technologies 
 
The reference case as a sufficient basis for VOI 
The results of any analyses are conditional on the use of appropriate model structure, appropriate 
synthesis of evidence and characterisation of other uncertainties.  This is important for estimates of 
expected cost-effectiveness but even more important for estimates of value of information which are 
particularly sensitive to these issues.  The existing reference case and methodological guidance 
requires supplementary guidance on the detailed use of methods to ensure that the adequacy of 
reference case submission can be assessed and that an adequate reference case analysis will 
provide sufficient basis for value of information analysis.  This process of developing detailed 
methodological guidance is underway, coordinated by the National Decision Support Unit.  It is 
important that in identifying and recommending methods the full characterisation of decision 
uncertainty should be a primary concern.  
 
Critical issues and methodological challenges 
It should be recognised that the key challenges for this type of analysis are not the VOI methods 
themselves but structuring decision problems, synthesis of evidence and the characterisation of 
uncertainty (required for estimating costs and effects as well as VOI).  The development of methods in 
these areas is ongoing and will require continued support from a variety of sources.  Particular issues, 
many of which have been highlighted in the case studies, include: 
• Ensuring a sufficiently wide scope for the assessment to include all the relevant alternative 
strategies.  This includes other technologies as well as different clinical policies (start and 
stop criteria) for a single technology.  The exclusion of alternative strategies may not change 
the overall guidance on use of a technology but in some cases it may have a substantial 
impact on the value of information and on research recommendations. 
• Dealing simultaneously with heterogeneity (variability by observed patient characteristics), 
variability (variability by unobserved characteristic) and uncertainty. 
• Reflecting the additional uncertainty due to potential biases in the evidence, which may come 
from different types of study and/or suffer from publication bias.  
• Modelling the exchangeability of the evidence with the parameters required in the model and 
reflecting any additional uncertainty. 
• The inclusion or exclusion of unrelated events from the evidence and the potential role of prior 
elicitation from “experts”. 
• The potential role of using priors elicited from “experts” within the NICE process and 
appropriate methods of elicitation of priors.     
• Exploring and reflecting the additional uncertainty surrounding alternative but credible 
structural assumptions. 
• Establishing efficient methods of searching for evidence on all model parameters not simply 
those associated with measures of effect.  
• The synthesis of both direct and indirect evidence for measures of effect but also for other 
model parameters. 
 
Many of these issues are being addressed though various programmes of research around the UK.  
However these areas of research require further development and continued support.  In additional it 
should be recognised that these issues require multidisciplinary working with collaboration across 
many different centres.  Infrastructure support to facilitate full collaboration across these areas of work 
should be sort from a variety of sources.   As all these methods evolve, it should be recognised that 
the detail of what is required within an adequate reference case analysis will also develop over time.  
 
 
 
 
 iv A pilot study of value of information analysis    
 
Other issues specific to VOI include: 
• Estimating the effective population that may benefits from additional evidence, including 
estimating time horizons for different technologies and incorporating this uncertainty in the 
estimates of value of information  
• Estimating the value of information for correlated parameters 
• Estimating the overall value of information based on estimates of the value of information for 
patient subgroups 
• Presenting the value of information and the value of full implementation of guidance on use 
with in the same framework of analysis 
 
Again work is currently ongoing on all of these issues but continued support from a number of sources 
for this methods work as well as support for an infrastructure of collaboration is needed. 
 
Feasibility and resource implications 
The pilot demonstrates that VOI is feasible within reasonable time lines, even based on pre reference 
case analysis.  The use of VOI as part of the reference case (taking account of the recommendations 
made above) is for most types of models limited, not by time and resource requirements, but by the 
capacity to conduct this type of analysis and the dissemination of these methods.  Therefore training 
in VOI methods should be considered as a cost-effective means of easing these capacity constraints.   
 
However, complex and computationally expensive models (patient level simulations) make 
probabilistic analysis and therefore VOI potential very time and resource intensive.  There are 
therefore 2 issues that should be addressed: 
• It should be recognised that using patient level simulation is very costly in the sense that it may 
prevent reliable estimates of cost-and effect, and decision uncertainty as well as VOI being 
presented.  In these circumstances it should be avoided if possible (by use of alternative 
structures and programming techniques).  More work is required to establish those circumstances 
were the use of patient level simulation unavoidable. 
• Where patient level simulation is required then there are techniques available to solve 
computationally expensive models, characterise uncertainty and estimate VOI.  Indeed these 
have been used in NICE submissions.  Further work is required to pilot their feasibility when 
patient level simulation is unavoidable and dissemination of appropriate methods.  
 
 
Implementation to inform research recommendations  
There are a range of possible options to implement DA-VOI within the NICE process, to inform 
research recommendations.  These are more fully discussed in chapter 9.  In this chapter we avoid 
making recommendations for implementation but outline possible options with some assessment of 
their strengths and weaknesses for NICE to consider.  In general there a two levels at which DA-VOI 
could be implemented: 
• DA-VOI could be implemented at the TAR stage of the process, either selectively or ultimately 
becoming part of the reference case for the Assessment Report.  This would mean that the 
analysis would be available to inform the research recommendations made by the Appraisals 
Committee which generally to date have not been based on any formal analytic framework or 
evidence.  The advantage of this would be that the decisions about the use of a technology 
and the evidence required to support the guidance could be appropriately considered at the 
same time. 
• Alternatively DA-VOI could be implemented in a similar way to the case studies presented 
here: as a supplementary analysis to and existing TAR once guidance on use and research 
recommendations have been made.  This would then provide an analysis that could inform 
the deliberations of the NICE Research and Development Committee in considering which of 
the research recommendations made should be regarded as a priority.  Potential ways of 
identifying which of the research recommendations should be considered for DA-VOI and are 
outlined in chapter 9.  Although this approach may reduce the resource requirements (it may 
not if DA-VOI is in addition to the TAR) and in the short run avoid the current capacity 
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problems in conducting this type of analysis there will always be a danger that some very 
valuable research requirements will be missed and other less valuable evidence requirements 
will be prioritised. 
• However, these two alternatives need not be viewed as substitutes.  The latter maybe 
regarded as the most feasible way of progressing in the short run. But, as capacity and 
methods develop, a move towards making DA-VOI a routine part of the TAR and the research 
recommendations in the guidance more firmly grounded on evidence and an explicit analysis 
may be achievable in the medium term. 
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1. Introduction and overview of methods 
 
1.1 Introduction 
 
This project developed as a result of the activities of the Research Teams at the Centre for 
Health Economics, University of York, and ScHARR at the University of Sheffield in the 
methods and application of decision analysis and value of information analysis (DA-VOI) as a 
means of informing the research recommendations made by NICE as part of its Guidance to 
the NHS in England and Wales and informing the deliberations of the NICE Research and 
Development Committee.   
 
The specific project proposal was developed following a presentation of the potential role of 
DA-VOI in identifying those circumstances were additional evidence will be required to 
support guidance on the use of particular technologies and prioritise research 
recommendations made by the Appraisals Committee.  In addition the framework of analysis 
allows decision makers to identify what type of evidence would be most valuable and the type 
of studies which should be conducted to better inform guidance decisions in the future.   
 
1.2 Objectives 
 
The specific objectives of the pilot study were to: 
 
? Demonstrate the benefits of using appropriate decision analytic methods and value of 
information analysis to inform research recommendations. 
? Establish the feasibility and resource implications of applying these methods in a 
timely way, to inform NICE. 
? Identify critical issues and methodological challenges to the use of value of 
information methods for research recommendations (with particular regard to the new 
reference case as a suitable basis for this type of analysis). 
 
The project consists of a series of case studies based on recent technology assessment 
reports completed by the York and Sheffield group for NICE.  The purpose is to establish the 
feasibility and requirements of value of information analysis once submissions and 
Technology Assessment Reports (TARs) are conducted within the reference case specified in 
the recent methods guidance.   Therefore case studies were selected and reported on the 
following basis: 
 
? The existing TAR comes as close to the new reference case analysis as possible.  
? The VOI analysis will be conducted using the case studies as they were developed 
and reported in the respective TARs.  
? Any shortcomings with respect to the new reference case will be discussed, 
particularly if these have implications for the feasibility and reliability of value of 
information analysis.  
? In each case, an assessment will be made of the suitability of the new reference case 
as a suitable basis of value of information analysis.  
? Issues required for value of information analysis, which are not currently part of the 
reference case, will be highlighted. 
? Selection of case studies will be made to highlight particular issues and challenges 
for value of information analysis. 
 
A series of six case studies were selected based on recent technology assessment reports 
completed by York and Sheffield for NICE.  These included: 
 
? Screening for age related macular degeneration (AMD) 
? Glycoprotein IIb/IIIa antagonists for acute coronary syndrome (GPAs) 
? Clopidogrel and dipyridamole in the secondary prevention of occlusive vascular 
events (CLO) 
? Neurominidase inhibitors for the treatment of influenza (NIs) 
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? Liquid based cytology screening for cervical cancer (LBC) 
? Beta interferon and glatiramer acetate in the management of MS (MS) 
 
A brief and non-technical overview of DA-VOI methods is presented below followed by brief 
reports on each of the case studies in chapters 2-7.  Each case study chapter is intended to 
be a supplement to the original TAR on which the decision analytic model and probabilistic 
analysis is based. For full details of the analysis each chapter should be read in conjunction 
with the associated TAR.  However, each case study chapter is intended to stand-alone and 
can be read independently of the rest of this report.  Each case study chapter follows a 
common format including: the background to the original Appraisal and Guidance; a brief 
description of methods referencing the original TAR, a reporting of results for the adoption 
decision (estimates of cost-effectiveness and decision uncertainty) and for research 
recommendations (the value of information for the decision problem and for groups of model 
parameters), and a discussion of implications for research reconditions as well as some of the 
methodological issues raised specific to the case study.   
 
Chapter 8 provides a general discussion of the results and the methodological issues and 
challenges raised during the pilot.  It also includes an assessment of whether the new 
reference case will provide a good basis for value of information analysis and identifies some 
key issues in modelling such as, evidence synthesis, computation, bias, and structural 
uncertainty, which need to be addressed for the future application of DA-VOI.  Chapter 9 
provides a brief discussion of the feasibility of using DA-VOI to inform research 
recommendations, resource requirements and outlines possible strategies for the 
implementation of value of information methods to inform research recommendations within 
the NICE process. A summary of the key findings and conclusions are provided in chapter 10. 
 
1.3 An overview of methods 
 
Bayesian decision theory and value of information analysis provides an analytic framework 
which can be used to establish the value of acquiring additional information to inform a 
decision problem.  These methods have firm foundations in statistical decision theory7 8 and 
have been successfully used in other areas of research such as engineering and 
environmental risk analysis.9 10 26 More recently these methods have been extended to setting 
priorities in the evaluation of health care technologies.11-16 In addition they have been usefully 
applied to a number of different health technologies,17-22 including a series of case studies 
taken from guidance issued by NICE.23 
 
The application of these methods requires three core tasks to be completed:  (i) the 
construction of a decision analytic model to represent the decision problem; (ii) a probabilistic 
analysis of this model to characterise the current decision uncertainty; and (iii) establishing 
the value of additional information.19 
 
1.4 Decision analysis 
 
Evaluative research is useful insofar as it informs the choice between alternative strategies for 
patient management.  Decision analysis presents these decision problems and the key inputs 
to these decisions explicitly.27 28  Decision modelling requires all of the relevant inputs to the 
decision to be explicitly identified, and facilitates the synthesis of data from a variety of 
sources.16 Randomised trials are a crucial source of parameter estimates for decision models, 
particularly estimates of the magnitude of treatment effects.  Other sources of data – for 
example, the baseline risk and resource implications of particular clinical events – may be 
taken from non-trial sources such as observational studies and administrative datasets. In 
some circumstances, where no evidence exists for particular inputs, clinical judgement may 
also be incorporated. 
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1.5 Probabilistic analysis 
 
All decisions about the cost-effectiveness of interventions are based on uncertain information 
about variables such as clinical effects, health-related quality of life and resource use.  
Decision analytic models and methods of evidence synthesis can be used to combine 
evidence on each parameter to assess the extent of uncertainty in the decision.28  The extent 
and the quality of the evidence available, for each of the inputs, can be reflected in probability 
distributions assigned to these estimates, where more uncertainty about an input (less 
information or information of poorer quality) is represented by assigning a more diffuse 
distribution.  Without access to patient level data, these distributions are assigned based on 
secondary sources (e.g. published literature, meta- analysis and evidence synthesis). The 
choice of the type of distribution and its parameters for a particular model input is not 
arbitrary, but should be based on the existing evidence and what the type of distribution would 
be most appropriate. For example, probabilities should be represented by Beta distributions, 
which are bounded by zero and one, and their parameters can be based on either the number 
of observations or on mean and variance. 3 28-30  
 
The uncertainty surrounding the decision problem can be characterised by ‘propagating’ 
these distributions through the model using Monte Carlo simulation methods, where values 
for the input parameters are drawn at a random from the probability distributions which have 
been assigned.3 28-30 This random sampling is repeated a large number of times.  The output 
of these simulations provides a distribution of expected costs and outcomes for each strategy 
being compared.  The uncertainty surrounding the cost-effectiveness of a technology, for a 
range of thresholds for cost-effectiveness, can be represented as a cost-effectiveness 
acceptability curve (CEAC).11 Figure 1.1 illustrates an example of a CEAC where the 
probability that the intervention is cost effective increases as the willingness to pay for 
additional heath (QALY) or the threshold for cost-effectiveness increases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Cost-effectiveness acceptability curve example 
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If the objective underlying health technology assessment is to make decisions that are 
consistent with maximising health gains from available resources, then decisions should be 
based on expected cost-effectiveness given the existing information (i.e. using the mean 
differential costs and outcomes between the scenarios being compared).  This does not 
necessarily mean that the intervention which has the highest probability of being cost-
effective should be adopted.  For example, in figure 1.1 if the threshold for cost-effectiveness 
was just greater than £51,682 (the ICER) then the intervention should be adopted even 
though the probability that it is cost-effective is less than 0.5 (0.472).  This is because the 
distribution of the additional net benefits (where health outcomes are re-scaled in monetary 
terms using the cost-effectiveness threshold)31 32is positively skewed, with a mean greater 
than its median value. The adoption decision can be represented with a CEAC by including a 
cost-effectiveness frontier, which indicates which of the alternatives will be cost-effective.11  
 
Although decisions should be based on expected cost-effectiveness given the existing 
information, this does not mean that adoption decisions can simply be based on little, or poor 
quality, evidence, as long as the decision to conduct further research to support adoption (or 
rejection) is made simultaneously.12 19 
 
1.6 The value of information 
 
Decisions based on existing information will be uncertain, and there will always be a chance 
that the wrong decision will be made. If the wrong decision is made, there will be costs in 
terms of health benefit and resources forgone.  Therefore, the expected cost of uncertainty is 
determined jointly by the probability that a decision based on existing information will be 
wrong and the consequences of a wrong decision.  The expected costs of uncertainty can be 
interpreted as the expected value of perfect information (EVPI), since perfect information can 
eliminate the possibility of making the wrong decision. If the objective of the health care 
system is to maximise gains in health outcome subject to a budget constraint then this is also 
the maximum that the health care system should be willing to pay for additional evidence to 
inform this decision in the future, and it places an upper bound on the value of conducting 
further research.12 13 17 19 33 However, there may be other objectives of health care provision 
such as equity. If these other objectives can be identified and valued then these can be 
incorporated into the analysis and the societal value of information.12 
 
This general idea is illustrated in Figure 1.2. With current information, decisions must be 
made before we know how the uncertainties (p(x)) will be resolved - i.e. we must make a 
decision now based on the expected values of the all of the model inputs  (choose “std” in 
Figure 2).  However, with perfect information we can make our decisions once we know how 
these uncertainties (p(x)) are resolved - i.e., we can make different decisions for different 
resolutions of the uncertainties (choose “std” if 1-p(x) but choose “Ex” if p(x)).  The EVPI is 
simply the difference between the payoff (expected net benefit) with perfect and current 
information.21 33   
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Figure 1.2: Calculating EVPI example 
 
We can work out EVPI directly from the simulated output from our model as it relates to the 
individual patient.9 21 33 34  For example, if there are two alternative interventions (t = 1,2) 
interventions, with unknown parameters θ. Then given the existing evidence, the optimal 
decision is the intervention that generates the maximum expected net benefit:  
 
 maxt Eθ B(t, θ),  
 
i.e., the maximum net benefits over all the iterations from the simulation because each 
iteration represents a possible future realisation of the existing uncertainty (a possible value of 
θ). 
 
With perfect information, the decision-maker would know how the uncertainties would resolve 
(which value θ will take) before making a decision and could select the intervention that 
maximises the net benefit given a particular value of theta: 
 
maxt B(t, θ). 
 
However, the true values of θ are unknown (we don’t know which value θ will take), 
Therefore, the expected value of a decision taken with perfect information is the found by 
averaging the maximum net benefit over the joint distribution of θ: 
 
Eθ maxt B(t, θ),  
 
i.e., first calculate the maximum net benefit for each iteration from the simulation (for a 
particular value of θ), then take the average over these maximum net benefits (over the 
possible values of θ). 
 
The expected value of perfect information for an individual patient is simply the difference 
between the expected value of the decision made with perfect information about the uncertain 
parameters θ, and the decision made on the basis of existing evidence: 
 
Eθ maxt B(t, θ) - maxt Eθ B(t, θ). 
 
This provides the EVPI surrounding the decision as a whole for each time this decision is 
made (for an individual patient or individual episode). However, once information is generated 
to inform the decision for an individual patient or patient episode then it is available to inform 
the management of all other current and future patients as well.  Therefore, for research 
prioritisation it is important that EVPI is expressed for the total population of patients who 
stand to benefit from additional information over the expected lifetime of the technology.  This 
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requires some assessment of the effective lifetime of the technology (the period over which 
information about the decision will be useful), estimates of incidence over this period and 
prevalence in the first year.   The EVPI associated with future patients is discounted to 
provide the total EVPI for the population of current and future patients. If this population EVPI 
exceeds the expected costs of additional research, then it is potentially cost-effective to 
conduct further research.12 13 
 
Figure 1.3 illustrates the population EVPI for the example used in Figure 1.1. When the 
threshold for cost-effectiveness (maximum value of health outcome) is low, the technology is 
not expected to be cost-effective and additional information is unlikely to change that decision 
(EVPI is low). In these circumstances the EVPI increases with the threshold because both the 
decision uncertainty increases (tendig to increase the EVPI) and the consequences of 
information changing the decision are valued more highly.   Conversly, when the threshold is 
higher than the ICER, the intervention is expected to be cost-effective and this decision is less 
likely to be changed by further research as the threshold is increased.   In these 
circumstances the decision uncertainty falls as the threshold increases (tending to reduce the 
EVPI), but the consequences of information changing the decision are valued more highly 
(tending to increase the EVPI).  For higher values of the threshold the EVPI falls because in 
this case the reduction in decision uncertainty off sets the increased value of information 
changing decision.  However,  the EVPI will ultimately increase with very high values of the 
threshold because decision uncertainty will fall at a declining rate with the threshold 
increasing at a constant rate i.e.,  the effect of the value of changes in decision will ultimately 
off set the reduction in decision  uncertainty.  In this particular case, the population EVPI 
reaches maximum when the threshold is equal to the expected incremental cost-effectiveness 
ratio of this technology.  In other words, the EVPI reaches a maximum when we are most 
uncertain about whether to adopt or reject the technology based on existing evidence.12 13 17 
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However, most decision problems involve more than two alternatives.  The principles of 
calculating EVPI remain the same but the EVPI curve can take a variety of shapes depending 
on whether the alternatives being considered are cost-effective at some value of the threshold 
(there will be a number of peaks or a discontinuities in the EVPI curve at threshold values 
equal to the ICER of each of the alternatives) or if some of the alternatives are dominated or 
extendedly dominated (the peak or discontinuity will be in negative threshold space i.e., we 
would only wish to adopt the alternative if your willing to pay to reduce heath outcome).   
 
It should be clear from this discussion of EVPI suggests that the value of further research will 
depend on both the uncertainty surrounding estimates of cost and effect but also on how cost-
effective or cost ineffective a technology is expected to be given existing evidence, and the 
size of the patient population that could benefit from additional research.  One implication is 
that it is perfectly possible that the value of further research about a new technology, which is 
substantially cost-effective based on existing evidence, will be very low even if there is 
uncertainty surrounding the parameters, i.e., there may be uncertainty in cost and outcomes 
but the decision uncertainty and therefore the EVPI may still be low.  In these circumstances 
the technology should be adopted and no further research is required to support this decision.   
 
The value of reducing the uncertainty surrounding particular input parameters in the decision 
model can also be established (partial EVPI). This type of analysis can be used to focus 
further research by identifying those inputs for which more precise estimates would be most 
valuable.  In some circumstances, this will indicate which endpoints should be included in 
further experimental research. In other circumstances, it may focus research into getting more 
precise estimates of particular inputs which may not necessarily require experimental design 
and can be provided relatively quickly.  The analysis of the value of information associated 
with each of the model inputs (partial EVPI) is, in principle, conducted in a very similar way to 
the EVPI for the decision as a whole.9 17 21 33 34 In this case the expected value with perfect 
information is found by taking the maximum expected net benefit given perfect information 
only about the parameter of interest (calculating expected net benefits over all the other 
uncertain parameters the model) and then averaging over all the possible value of the 
parameter of interest.  The EVPI for the parameter is again simply the difference between the 
expected net benefit with  perfect information and the expected value with current information 
(the same as for decision EVPI). However, this does require substantial additional 
computation for models where the relationship between the inputs and expected cost and 
outcomes is not linear, for example in Markov models.21 33  
 
Figure 1.4 illustrates the partial EVPIs associated with the decision EVPI in Figure 1.3 at a 
threshold of £40,000 per QALY.  In this example, the EVPI associated with reduction in 
symptom days is relatively high and suggests that further experimental research may be 
worthwhile.  However, other inputs with lower partial EVPI, such as the baseline probability of 
hospitalisation, may not require experimental research but may also be important if the costs 
of further investigation (resources and delay) are low.  It should be noted that the partial 
EVPIs will not sum to the overall EVPI due to the interactions within the model structure.   
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Figure 1.4: Partial EVPI example 
 
1.7 Prioritising research recommendations 
 
The EVPI places an upper bound on the societal returns to further investigation. The EVPI for 
the decision problem can be used as a first hurdle for proposed research.12 13 17 19 21  If the 
costs of investigation exceed the EVPI, then the proposed research will not be cost-effective, 
i.e., the population EVPI can be used to rule out research recommendations which will not be 
worth while for a societal perspective. 
 
For those decision problems where the EVPI exceeds the costs of research it is possible to 
compare EVPIs across patient groups and different technologies to prioritise research 
recommendations.  In general, additional research will be more valuable for a patient groups 
or technology where the EVPI is higher.  However, it should be noted that this direct 
comparison requires some assessment of the cost of proposed research.  For example, even 
where the EVPI is lower research in that area may not be a lower priority if the costs of further 
investigation are expected to be substantially lower.   In principle it would be useful to 
explicitly compare the marginal benefits and costs of research proposals in prioritising 
research. The same framework of DA-VOI can be extended to establish the expected value of 
sample information for particular research designs and to compare these marginal benefits of 
research to the marginal costs.  However, this type of analysis is beyond the scope of the 
current pilot.12 14 18 33   
 
The EVPI associated with groups of model parameters can be used to focus potentially cost-
effective research on those inputs for which more precise estimates would be most valuable.  
This may indicate which endpoints should be included in further experimental research, or it 
may focus research on getting more precise estimates of particular inputs, which may not 
necessarily require experimental design and can be provided relatively quickly.17 21 33 
 
1.8 Conclusion 
 
Bayesian decision analysis and value of information analysis provides a methodological 
framework which explicitly considers the uncertainty surrounding the decision of a health care 
system to adopt a health technology.  Specifically, using existing evidence, these methods 
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focus on the likelihood of making a wrong decision if the technology is adopted. The value of 
additional research is based on the extent to which further information will reduce this 
decision uncertainty.  This framework values the additional information, which may be 
generated by further research, in a way which is consistent with the objectives and the 
resource constraints of heath care provision (the cost-effectiveness threshold).  This allows a 
comparison of the potential benefits of further research with the costs of further investigation, 
a comparison and prioritisation of alternative research recommendations, both within and 
between Technology Assessments, as well as an assessment of the value of investing 
resources in research or other activities, such as the provision of health service.  In this sense 
it provides a unified and coherent framework for prioritisation of research and the use of heath 
care technologies. 
10 A pilot study of value of information analysis 
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2. The cost-effectiveness and value of information associated with 
repeat screening for age related macular degeneration  
 
2.1 Background 
 
2.1.1 Condition and technology 
 
Age-related macular degeneration (AMD) is a degenerative condition of the macula. It is one 
of the most common causes of vision loss in people over 50. The disease varies in severity, 
from a slight loss in vision to near blindness. AMD is classified as either wet (neovascular) or 
dry (non-neovascular), it is neovascular AMD that progresses most rapidly and causes the 
more severe vision loss.  About 10% of patients who suffer from macular degeneration have 
wet AMD.  If one eye develops neovascular membrane, the other eye is at moderate risk of 
having the same problem. Neovascular AMD is further defined by its location in the choroidal 
neovascular vessels (subfoveal, justafoveal or extra-foveal) and by its pattern of leakage 
(classic, occult, mixed or recurrent).(1) 
 
Treatments for certain types of AMD have developed over the last few years and include 
confluent argon laser photocoagulation, verteporfin photodynamic therapy (PDT), 
radiotherapy and transpupillary thermotherapy.1 
 
2.1.2 Technology Assessment Review 
 
Photodynamic therapy for age related macular degeneration has recently been appraised by 
the National Institute for Clinical Excellence (NICE).2The evidence from the Assessment 
Report, and the provisional guidance issued by NICE, indicated that PDT will only be 
potentially cost-effective for the treatment of AMD in the better seeing eye (after 1st eye 
involvement) and only for certain types of AMD (neovascular, predominantly classic, 
subfoveal) AMD can progress rapidly (declining visual acuity) and is a significant cause of 
blindness.  Early PDT can halt or slow the decline in visual acuity.  Earlier treatment with PDT 
at better starting visual acuities is more cost-effective, and treatment is not recommended for 
starting visual acuities lower than 20/100. 
 
2.1.3 NICE guidance 
 
In September 2003, NICE issued guidance on the use of PDT for age-related macular 
degeneration. The guidance recommended the following3 
 
1. Photodynamic therapy (PDT) is recommended for the treatment of wet age-related 
macular degeneration for individuals who have a confirmed diagnosis of classic with 
no occult subfoveal choroidal neovascularisation (CNV) and best-corrected visual 
acuity 6/60 or better. PDT should be carried out only by retinal specialists with 
expertise in the use of this technology. 
 
2. PDT is not recommended for the treatment of people with predominantly classic 
subfoveal CNV associated with wet age-related macular degeneration, except as part 
of ongoing or new clinical studies that are designed to generate robust and relevant 
outcome data, including data on optimum treatment regimens, long-term outcomes, 
quality of life and costs. 
 
3. The use of PDT in occult CNV associated with wet age-related macular degeneration 
was not considered because the photosensitising agent (verteporfin) was not licensed 
for this indication when this appraisal began. No recommendation is made with 
regard to the use of this technology in people with this form of the condition. 
 
4. Patients currently receiving treatment with PDT could experience loss of well being if 
their treatment is discontinued at a time they did not anticipate. Because of this, all 
NHS patients who have begun a course of treatment with PDT at the date of 
publication of this guidance should have the option of continuing to receive treatment 
until their clinical condition indicates that it is appropriate to stop. 
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2.1.4 Research recommendations 
 
The recommendations for further research, issued as part of the NICE guidance were that: 
 
? Several randomised controlled trials of PDT are ongoing, including two placebo-
controlled trials of verteporfin PDT, one in patients with minimally classic CNV using 
standard or reduced laser settings, and one in patients with occult CNV. 
 
? The Committee recommended that further research is needed on the use of PDT for 
individuals with predominantly classic subfoveal CNV related to ARMD. The primary 
objectives of this research should be to determine the optimum treatment regimen 
and long-term benefit of PDT, and to add to the current evidence on quality of life for 
this group of individuals. 
 
? At present it is not known whether population screening for ARMD would be practical 
or cost effective. Research on screening for ARMD is being commissioned by the UK 
HTA programme. 
 
2.2 Methods 
 
Given that treatment with PDT is more effective the earlier it is initiated in the course of the 
disease, there is a prima facie case that screening would be cost-effective by identifying 
patients with AMD before their visual acuity declines.  A self-screening test of central vision 
distortion called the Amsler grid4 is available and it has been suggested that this could be 
used as a basis of screening.2 
 
Following the conclusions of the Assessment Report undertaken for NICE2 and the provisional 
guidance regarding the use of PDT, we have focused on the use of weekly self-screening 
following 1st eye involvement with neovascular AMD.  This self-screening strategy is 
compared to two alternatives: no screen but diagnosis and treatment of eligible AMD following 
self-referral (due to declining visual acuity) to an ophthalmologist (this strategy is consistent 
with provisional NICE guidance); and a strategy of no screening and no PDT.  The analysis 
reported here has assessed the cost-effectiveness of, and potential value of future research 
for, these alternative strategies. Full detail of this model can be seen in a forthcoming HTA 
report.(5) 
 
Although the structure of the model developed was consistent with published evidence 
regarding the natural history of the disease, a number of structural assumptions were 
questioned after consultation with clinical experts. Alternative structural assumptions, 
consistent with these alternative clinical opinions, were therefore explored 
 
2.2.1 Model structure  
 
The structure of the decision model is illustrated in Figure 2.1.  A Markov process6 is used to 
model the incidence of 2nd eye neovascular AMD over 10-years and the associated decline 
in visual acuity following undiagnosed 2nd eye involvement.   
 
Patients enter the model with neovascular AMD previously diagnosed in the 1st eye. Two 
alternative starting visual acuities are modelled, 20/40 or 20/80. The implication of this is that 
the worse seeing individuals would generally receive PDT or no PDT at a lower visual acuity.  
Each week patients can decide to self-screen (comply) using the Amsler grid, which is an A4 
sheet of paper containing a series of lines, which appear distorted if a change in vision has 
occurred. 
 
Patients with positive screen results (self diagnosed) will refer for a full eye exam by an 
ophthalmologist. Patients may also self-refer due to declining visual acuity, measured as a 
loss of 1 or more lines.  In the base case model at a loss of 4 or more lines, all patients will 
have self-referred to the ophthalmologist (in the absence of data expert judgement was used 
to specify the probability that patients self refer on loss of visual acuity).  The full eye 
examination will identify patients with neovascular AMD in the 2nd eye (i.e. false positives are 
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identified).  Angiography is then undertaken in those with confirmed neovascular AMD to 
identify the type of neovascular disease that is present, and thus determine if the patient is 
eligible for PDT.  Since angiography is used to identify and monitor AMD in the clinical trials of 
PDT it is taken to be the gold standard test in this model.  
 
Patients with diagnosed AMD that is eligible for PDT will then either have PDT (screen + PDT 
and no screen + PDT strategy), or not have PDT (no screen + no PDT strategy).  Costs and 
QALYs associated with the use or non-use of PDT are then assigned.  The expected quality 
of life with PDT depends on the visual acuity at diagnosis, where patients with better visual 
acuities will experience better quality of life.  The costs of PDT are constant throughout the 
visual acuity groups.7 
 
2.2.2 Alternative structural assumptions 
 
Currently the effect of the Amsler grid, in terms of identifying patients with AMD, can occur 
before AMD develops and at each stage of visual acuity loss. However it may be that there is 
no additional benefit from the Amsler grid after a patient has developed a visual acuity 
problem (after a loss of one or more lines). Also patients only refer to see an ophthalmologist 
once they have a decline in visual acuity, when there are noticeable changes in their eyesight. 
However given that patients in the model have already had first eye involvement and may 
therefore be expected to be more vigilant in recognising changes in their vision, patients may 
refer when there is no loss in visual acuity (AMD state). This may be because they are using 
other stationary objects to imitate the Amsler grid. These alternative structural assumptions 
were modelled. 
 
A 10-year time horizon was used in the model as, during this period, almost all patients 
developed 2nd eye disease (96%), and this disease was diagnosed in most patients in both 
screen and no screen groups (92%).  In other words, all patients with 2nd eye involvement will 
be diagnosed at some point, the question is when and at what visual acuity this happens. 
Given the decision problem to be addressed, an NHS perspective was used for the analysis.  
Health benefits are expressed in terms of QALYs. 
 
2.2.3 The evidence 
 
A full list of all the parameters and their sources is presented in table 2.1.  The incidence of 
2nd eye neovascular AMD,8 the eligibility for PDT (sub-types of AMD),9 the sensitivity and 
specificity of the Amsler grid screen10 and compliance with self screening(11 were all based on 
observational studies.  Beta distributions were assigned to reflect the amount of evidence 
available for each of these parameters using measures of variance reported in the studies. 
Although two trials of PDT for AMD are available, only the TAP trial included predominantly 
classic AMD.   The decline in visual acuity for undiagnosed 2nd eye involvement was based on 
the 2- year results of the control arm of the TAP trial of PDT2 as reported in the NICE 
Assessment Report, with beta distributions assigned to these transition probabilities.   
 
No evidence was available regarding the probability that patients will self-refer following each 
decline in visual acuity.  Therefore, expert judgments from a primary care physician with 
specialist research interest in AMD were used with beta distributions reflecting the additional 
uncertainty about range of possible values. 
 
All cause mortality was also incorporated in the model (for a males and female population 
aged 55-64) based on UK life tables.(12)   
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Figure 2.1: Model structure for AMD self-screening 
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Table 2.1: Sources of data 
 
Parameters Value Distribution Source 
Incidence of 2nd eye 
neovascular AMD 
 
Yr 1 = 0.00198 
Yr 2 = 0.00404 
Yr 3 = 0.00685 
Yr 4 = 0.0124 
Yr 5 = 0.0114 
Beta distributions 
Alpha = 9, Beta = 95 
Alpha = 18, Beta = 56 
Alpha = 17, Beta = 36 
Alpha = 11, Beta = 12 
Alpha = 5, Beta = 6 
(8) 
Progression of visual acuity 
with 2nd eye involvement 
 
VA0 to VA1 = 
0.014 
VA1 to VA2 = 
0.062 
VA2 to VA3 = 
0.062 
VA3 to VA4 = 
0.060 
Beta distributions 
Alpha = 2.93, Beta = 204.06 
Alpha = 12.54, Beta = 189.16 
Alpha = 12.44, Beta = 187.70 
Alpha = 11.93, Beta = 186.19 
(2) 
Accuracy of Amsler grid 
Sensitivity 
 
Specificity 
 
0.59 
 
0.04 
Beta 
Alpha = 65.65, Beta = 44.35 
Alpha = 5.28, Beta = 104.72 
(10) 
Compliance with self 
screening 
0.55 Beta 
Alpha = 49, Beta = 40 
(11) 
Eligibility for PDT (AMD sub-
groups) 
0.56 Beta 
Alpha = 17, Beta = 829 
(9) 
Self referral on decline in VA  
VA1 = 0.2 
VA2 = 0.6 
VA3 = 0.8 
VA4 = 1 
Beta distributions 
Alpha = 2, Beta = 8 
Alpha = 6, Beta = 4 
Alpha = 8, Beta = 2 
Constant 
Clinical 
judgement 
QALYs with PDT  
VA0 = 2.34 
 
VA1 = 2.26 
 
VA2 = 2.12 
 
VA3 = 2.10 
 
VA4 = 2. 
Gamma distributions 
Alpha = 193.58, Beta = 0.012 
Alpha = 218.58, Beta = 0.010 
Alpha = 406.31, Beta = 0.005 
Alpha = 404.02, Beta = 0.005 
Alpha = 370.49, Beta = 0.005 
(7) 
QALYs without PDT  
VA0 = 2.17 
 
VA1 = 2.12 
 
VA2 = 2.03 
 
VA3 = 2.01 
 
VA4 = 1.99 
 
Gamma distributions 
Alpha = 217.67, Beta = 0.010 
Alpha = 178.15, Beta = 0.011 
Alpha = 287.43, Beta = 0.007 
Alpha = 286.02, Beta = 0.007 
Alpha = 287.30, Beta = 0.006 
(7) 
Costs of PDT £6475.35 Constant (7) 
Costs of diagnosis and screen £55.88 + £112 + 
£108 
Constant (2, 13) 
 
Costs and QALYs associated with the use of and non-use of PDT at the different visual acuity 
levels (20/40, 20/50, 20/64, 20/80, 20/100, 20/126) are taken from the output of a cost-
effectiveness model of PDT developed as part of the NICE appraisal of PDT.7 The authors 
used a Markov model to estimate the costs and outcomes of PDT with verteporfin using 
patient level data taken from the TAP trial.14 Two-year (within-trial estimate) and 5 year time 
periods were used to assess cost and outcomes. Time-trade-off methods were used by 
Brown et al(15) to elicit utilities for various visual acuity levels in the model, and utility 
decrements from adverse events were estimated through expert panel.15 Gamma distributions 
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were assigned to expected QALY gains on PDT using the reported means and variances 
taken from the simulated model output. Costs used in the model were taken from Meads, et 
al.2 and the model output suggested that costs were constant across visual acuity states.  
 
The costs of ophthalmologist screening and angiography (diagnosis) were based on the NICE 
Assessment Report..2 Given that the Amsler grid only constitutes an A4 sheet of paper, if self-
administered, the costs of self-screening are zero. 
 
2.2.4 Probabilistic analysis 
 
To reflect uncertainty in the parameters in the model, they were incorporated as probability 
distributions,16 full details of which are available elsewhere.5 Monte Carlo simulation was used 
to propagate the prior distributions assigned to model inputs and estimate the expected costs 
and outcomes associated with each alternative therapy and incremental cost effectiveness 
ratios were calculated. The simulation estimates mean expected costs and QALYs and their 
associated distributions. 
 
The results of the model are presented in two ways.  Firstly, mean costs and QALYs for the 
various comparators are presented and their cost-effectiveness compared, estimating 
incremental cost-effectiveness ratios as appropriate, using standard decision rules.17 Given 
that mean costs and QALYs gained are estimated with uncertainty, the output from the 
simulations were then used to generate cost-effectiveness acceptability curves18;19 for the 3 
strategies.  
 
2.2.5 Value of information analysis 
 
The output of these simulations was also used to estimate the expected value of perfect 
information (EVPI)20,21 for individual patients.  Population EVPIs were based on the incidence 
of 2nd eye AMD (not differentiated by type or visual acuity) taken from the NICE Assessment 
Report2 and alternative assumptions about the expected lifetime of the technology of 5, 10 
and 15 years.  An analysis of the parameter EVPIs associated with groups of model inputs 
was also conducted.   
 
2.3 Results  
 
2.3.1 Adoption decisions 
 
The results for both 20/40 and 20/80 starting visual acuity patients can be seen in Table 2.2. 
As expected, the screen and treatment option has the highest costs for both 20/40 and 20/80 
starting visual acuities, £3651 and £3662 respectively. The no screen and no treatment 
strategy is associated with the lowest costs for both starting visual acuities. Treatment with 
PDT is associated with additional QALYs, therefore the 2 strategies that involve treatment 
have higher QALYs than the no treatment strategy. However there are large differences 
between the numbers of QALYs gained in the screen + treat and no screen + treat strategies. 
This is because the screening allows patients be diagnosed at a better visual acuity level, that 
is before it has declined significantly, and those higher visual acuity groups are associated 
with better outcomes (QALYs). 
 
Cost-effectiveness and decision uncertainty are extremely similar for both males and females, 
hence we have only reported the results for males here. 
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Table 2.2: Results from the base case model 
 
 Mean QALYs Mean costs ICER 
Starting visual acuity = 20/40 
Screen and treat 1.2136 £3,651 £12,892 
No screen and treat 0.9836 £2,643 E dominated 
No screen and no treatment 0.9377 £98  
Starting visual acuity = 20/80 
Screen and treat 1.0915 £3,662 £17,757 
No screen and treat 0.9215 £2,644 E dominated 
No screen and no treatment 0.8908 £98  
 
For patients with a starting visual acuity of 20/40, screening can be regarded as cost-effective 
when compared to no treatment, with an incremental cost per additional QALY of £12,892.  
The strategy of no screen but treatment on diagnosis is not cost-effective when compared to 
no treatment (incremental cost per additional QALY equals  £54,446) and is subject to 
extended dominance.17 
 
The cost-effectiveness of screening is, however, uncertain.  The probability that each 
intervention is cost-effective is reported in Figure 2.2 and shows that the probability that no 
screen and treat will be cost-effective remains very close to zero over a range of cost-
effectiveness thresholds.  The probability that screening is cost-effective with a threshold for 
cost-effectiveness of £30,000 is 0.89.  
 
 
Figure 2.2: Cost-effectiveness acceptability curve for 20/40 model 
 
For patients with a lower starting visual acuity of 20/80 screening is less likely to be 
considered cost-effective when compared to no treatment (Figure 2.3), although the 
incremental cost per additional QALY equals of £17,757 is higher than in the group with 
higher starting visual acuity and is more uncertain (probability that screening is cost-effective 
with a threshold for cost-effectiveness of £30,000 is 0.73).  
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Figure 2.3: Cost-effectiveness acceptability curve for 20/80 model 
 
2.3.2 Research recommendations 
 
The population EVPI for both starting visual acuities is shown in Figure 2.4.  At a threshold for 
cost-effectiveness of £30,000, the population EVPI is £6.18 million assuming a 10-year 
lifetime for the technology  (£158 for individual patients) or £3.54 and £8.15 million assuming 
a lifetime of 5 and 15 years, respectively.  The population EVPI with starting visual acuity of 
20/80 is higher (because of increased decision uncertainty): £15.33 million assuming a 10 
year life time of the technology (£393 for individual patients), or £10.24 and £20.22 million 
assuming a lifetime of 5 and 15 years, respectively.  Estimates of EVPI for male and female 
populations are very similar. 
 
The EVPI for each of the groups of model inputs for the 20/40 model is illustrated in Figure 
2.5 for a threshold for cost-effectiveness of £30,000 and a 10-year lifetime for the technology.  
For patients with a starting visual acuity of 20/40, the value of information associated with the 
expected QALYs with or without PDT is £3.73 million.  The other groups of model inputs, such 
as screening accuracy, have no value of information associated with them.  At a starting 
visual acuity of 20/80 (Figure 2.6), the value of information associated with the expected 
QALY with or without PDT is £4.67 million and the value associated with the progression of 
visual acuity is just below £194,000.  The other groups of model inputs have no value of 
information associated with them.  
 
In general, individual EVPIs will not sum to the EVPI for the decision as a whole.  In this case 
many of the groups of model inputs have no value associated with them.  This does not mean 
that the uncertainty surrounding their values is unimportant (together, they generate the EVPI 
for the decision), but it does mean that more information about these inputs individually may 
not be valuable. 
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Figure 2.4: Population EVPI for 20/40 and 20/80 models 
 
 
Figure 2.5: EVPI for model inputs: starting visual acuity of 20/40   
(Lifespan: 10 years. Threshold: £30,000) 
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Figure 2.6: EVPI for model inputs: starting visual acuity of 20/80 
(Lifespan: 10 years. Threshold: £30,000) 
 
2.3.3 Alternative structural assumptions 
 
Two alternative assumptions regarding the effect of the Amsler grid were explored: 
 
Scenario 1: The Amsler grid provides no additional benefit, in terms of identifying those 
patients with AMD after a loss in visual acuity  
Scenario 2: All patients’ will self refer after a loss in visual acuity (1 line) 
 
The results of the 2 models using these alternative assumptions are presented in Tables 2.3-
2.6 below. 
 
 
Table 2.3: Costs and outcomes for model assuming no additional effect of the Amsler 
grid after a loss of visual acuity 
 
 Mean QALYs Mean Costs ICER 
Starting visual acuity = 20/40 
Screen and treat 1.2128 £3,650 £12,828 
No screen and treat 0.9816 £2,637 E dominated 
No screen and no treatment  0.9359 £98  
Starting visual acuity = 20/80 
Screen and treat 1.0885 £3,653 £17,855 
No screen and treat 0.9202 £2,640 E dominated 
No screen and no treatment 0.8894 £98  
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Table 2.4: Simulation results (£30,000 threshold value) for model assuming no 
additional effect of the Amsler grid after a loss of visual acuity 
 
 Probability cost-effective EVPI assuming 10-year 
lifetime 
Starting visual acuity = 20/40 
Screen and treat 0.88 
No screen and treat 0.02 
No screen and no treatment 0.10 
£6,686,984 
Starting visual acuity = 20/80 
Screen and treat 0.72 
No screen and treat 0.03 
No screen and no treatment 0.25 
£15,865,519 
 
Table 2.5: Costs and outcomes for model assuming all patients’ will self refer after a 
loss in visual acuity 
 
 Mean QALYs Mean Costs ICER 
Starting visual acuity = 20/80 
Screen and treat 1.2183 £3,663 £16, 178 
No screen and treat 1.0648 £2,743 E dominated 
No screen and no treatment 0.9980 £99  
 
Screen and treat 1.0908 £3,652 £23,162 
No screen and treat 0.9737 £2,739 E dominated 
No screen and no treatment 0.9374 £99  
 
Table 2.6: Simulation results (£30,000 threshold value) for model assuming all patients’ 
will self refer after a loss in visual acuity 
 
 Probability cost-effective EVPI assuming 10-year 
lifetime 
Starting visual acuity = 20/40 
Screen and treat 0.66 
No screen and treat 0.12 
No screen and no treatment 0.22 
£30,466,013 
Starting visual acuity = 20/80 
Screen and treat 0.52 
No screen and treat 0.09 
No screen and no treatment 0.39 
£40,179,821 
 
For both starting visual acuities changing the assumption of the additive effect of the Amsler 
grid had little effect on the costs and QALYs. Screening is still regarded as cost-effective 
when compared to no treatment. This is because the majority of patients are diagnosed 
through the self-screen before any loss in visual acuity. Decision uncertainty is however 
sensitive to structural assumptions, with the probability that screen + treat is cost effective 
reduced from 0.89 in the base case 20/40 model to 0.66 in scenario 2. The population EVPI 
for these alternative assumptions increases for both scenarios in the 20/40 and 20/80 starting 
visual acuity models. 
 
2.4 Discussion  
 
2.4.1 Interpretation 
 
Self-screening following 1st eye neovascular AMD appears to be a potentially cost-effective 
intervention for patients with initial visual acuities ranging from 20/40 to 20/80.  However, the 
cost-effectiveness of self-screening is uncertain and, at a threshold for cost-effectiveness of 
£30,000 per additional QALY, the value of information surrounding the decision problem is 
significant, particularly when patients have lower initial visual acuities.  The EVPI may exceed 
the cost of further investigation, which suggests that further research will be potentially cost-
effective.  The EVPI associated with model inputs indicates that more evidence about the 
impact of PDT on expected quality of life, and the quality of life for those not treated with PDT, 
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would be most valuable and would require experimental design.  It also suggests that 
additional evidence about other inputs individually, such as screening accuracy alone, maybe 
of little value.  However, this does not mean that additional information about all the model 
inputs combined would not be valuable. 
 
2.4.2 Alternative model structures 
 
Structural uncertainty regarding the effect of the Amsler grid was also explored using 2 
alternative structural assumptions:  Amsler grid provides no additional benefit, in terms of 
identifying those patients with AMD after a loss in visual acuity or all patients’ will self refer 
after a loss in visual acuity. Although the cost-effectiveness results were not sensitive to 
structural assumptions the EVPI was particularly sensitive to model specification, it is 
therefore it is crucial to determine the most appropriate model structure when using VOI 
analysis to inform research prioritisation. 
 
2.4.3 Caveats 
 
This model has focused on self-screening patients with 1st eye neovascular AMD.  A policy of 
self-screening for AMD before first eye involvement could be considered and could be 
modelled.  However the results of this model and previous analysis in the TAR demonstrates 
that such a policy would not be cost-effective for a number of reasons: treatment will not be 
cost-effective in the worse seeing eye as it will not have an impact on overall visual acuity; the 
very low incidence in this group of patients will generate very large number of false positive 
results and unnecessary eye examinations; and the gains in quality of life offered by this 
strategy will be only be realised a number of years in the future for the small number of  
patients who have treatable neovascular AMD in the fist eye but develop untreatable 
neovascular AMD in the second eye.  Since this strategy will not be cost-effective the decision 
uncertainty and EVPI surrounding this policy would also be very low.   A policy of regular (3 
monthly) repeated eye examinations could also be considered but again this analysis 
indicates that this strategy would also not be cost-effective because it would be very costly 
(many more negative eye examinations) and is unlikely to be effective as VA can decline 
rapidly in the period between examinations.   
 
2.4.4. Methodological issues 
 
The value- of information analysis has demonstrated 2 important issues relating to this 
particular decision problem: 
 
1. The importance of defining an appropriate model structure. Although in this case 
alternative model structure did not change the adoption decision they did substantially 
change the value of information estimates generated. 
 
2. It is apparent from this analysis that the scope of the original NICE assessment 
report(2), as dictated by the Department of Health remit, was not wide enough, and 
should have included a component to identify patients with AMD. 
 
2.4.5. Relationship with the research recommendations provided by NICE 
 
The EVPI analysis provided here specifically addresses one of the research 
recommendations specified by NICE.  It is apparent from this analysis that screening a 
population at risk for AMD can offer benefits in terms of early identification and hence 
treatment, and that policies to identify patients at risk must be evaluated simultaneously with 
policies for appropriate treatment. 
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Appendix. Reference case evaluation: Repeat screening for age related macular 
degeneration 
 
 
 
 
Element of health 
technology assessment 
Reference case Criteria met by 
assessment? 
Comment 
Defining the decision 
problem 
The scope developed 
by the Institute 
Yes  
Comparator Alternative therapies 
routinely used in the 
NHS  
Yes  
Perspective on costs NHS and PSS Yes  
Perspective on 
outcomes 
All health effects on 
individuals 
Yes  
Type of economic 
evaluation 
Cost-effectiveness 
analysis 
Yes  
Synthesis of evidence 
on outcomes 
Based on a systematic 
review 
No Review of literature we 
comprehensive but not systematic 
Measure of health 
benefits 
Quality adjusted life 
years (QALYs) 
Yes  
Description of health 
states for calculation of 
QALYs 
Health states described 
using a standardised 
and validated generic 
instrument 
No 
Method of preference 
elicitation for health 
state valuation 
Choice-based method, 
for example, time trade-
off, standard gamble 
(not rating scale) 
No 
Source of preference 
data 
Representative sample 
of the public 
No 
Outcomes of treatment taken from a 
previous study, submitted as part of 
the NICE assessment  
Discount rate An annual rate of 3.5% 
on both costs and 
health effects 
No The discount rates for costs and 
health outcomes recommended at the 
time of the NICE assessment were 
used. 
Equity position An additional QALY has 
the same weight, 
regardless of the other 
characteristics of the 
individuals receiving the 
health benefit 
Yes  
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3. Glycoprotein IIb/IIIa antagonists for the treatment of acute coronary 
syndromes  
 
3.1 Background 
 
3.1.1 Condition and technology 
 
Acute Coronary Syndromes (ACS) is a term that includes a range of patients with a similar 
underlying pathology.  At one end of the spectrum are those patients with evidence of ST 
elevation on a resting electrocardiogram (ECG) who are eligible for treatment with 
thrombolysis and who may subsequently develop Q-wave on their ECG – this is a full 
myocardial infarction (MI). At the other, are patients who are classified as having either 
unstable angina or non-Q-wave MI.  Non-Q-wave MI is the term used when the cardiac 
enzymes are elevated to the range indicating that MI has occurred, but a Q-wave does not 
develop on ECG tracings. Unstable angina represents a spectrum of clinical states that fall 
between stable angina and acute MI and includes new onset angina and angina occurring 
>24 hours post-MI.   
 
Not only is unstable angina an unspecific diagnostic category, but patients present with 
varying degrees of atherosclerosis (stenosis size, location and plaque fragility), thrombus 
formation (low or high platelet content) and vasospasm.  Each of these contributes to the 
morbidity and mortality of the disease and, therefore, represents a potential target for 
intervention with medical therapy. Aspirin and heparin are typically used to reduce thrombus 
formation, and nitrates are used to help reduce vasospasm and cardiac oxygen requirements.  
Interventional therapy typically involves percutaneous coronary intervention (PCI), such as 
angioplasty, or coronary artery bypass surgery. NHS Hospital Episode Statistics suggest the 
incidence of unstable angina is around 1000 cases per million total population per year, or 
about 10 per acute hospital per week [1].   
 
Glycoprotein IIb/IIIa antagonists (GPA) are a class of drugs to prevent platelet aggregation in 
the acute treatment of patients with non-ST-elevation ACS. The aim of these drugs is to 
reduce the risk of cardiac death and acute MI. Two broad groups of GPA are licensed in the 
UK:  Abciximab (ReoPro®, Eli Lilly) is a monoclonal antibody targeted at the receptor (also 
known as a ‘large molecule’ GPA); while Eptifabtide (Intergrilin®, Schering Plough) and 
Tirofiban (Aggrastat®, MSD) are more conventional pharmacological receptor antagonists 
(also known as ‘small molecule’ GPAs).   
 
GPAs are used in two general ways to manage ACS patients.  Firstly, as an adjunct to PCI; 
for those patients who undergo such a procedure, Abciximab is the GPA which is mainly used 
for this purpose.  GPAs can be also used as a form of medical management for non-ST-
elevation ACS patients regardless of whether or not they subsequently go on to have a PCI. 
Tirofiban and Eptifabtide are mainly used for this indication. 
 
3.1.2 Technology Assessment Review 
 
In 2000, NICE commissioned two rapid reviews on the use of GPAs in cardiology. One 
focussed on the role of GPAs in ACS [2]; the other considered the use of GPAs alongside PCI 
[3].  Whilst the first of these reviews concluded that there was a small benefit in the use of 
GPAs as part of medical management for non ST elevation ACS, the second demonstrated a 
consistent benefit in the use of GPAs alongside PCI. In 2002 a systematic review update was 
commissioned [4]. The main conclusions relating to clinical effectiveness were that: 
 
• The effectiveness of GPAs as adjuncts to PCI was confirmed further. 
• Evidence for the use of GPAs in situations where PCI is not undertaken (i.e. 
alongside medical management) was weakened. 
• There is no evidence for the clinical superiority of Tirofiban or Eptifabtide over 
Abciximab. 
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In terms of the cost effectiveness of the use of GPAs in the UK, there were serious limitations 
to the published evidence [5]. For example, the majority of RCTs evaluating the efficacy of 
GPAs had been undertaken outside the UK where clinical practice is quite different; the RCTs 
had short follow-up, typically of just 30 days or 6 months and none had directly compared the 
various ways in which GPAs could be used in ACS patients in the UK. Because of this, a 
separate model was developed to assess the long term cost effectiveness of the use of GPAs 
in the UK NHS.  The model evaluated three GPA-based strategies in comparison with usual 
care: 
  
• GPAs as part of initial medical management (Strategy 1);  
• GPAs in patients with planned PCI where GPAs are started once a decision to 
undertake PCI has been made (Strategy 2);  
• GPAs as an adjunct to PCI where the agent is used at the time of PCI or is started up 
to 1 hour before the procedure (Strategy 3); and  
• No use of GPAs (Strategy 4).  
 
The conclusion of the report was that GPAs used as part of medical management (Strategy 1) 
was the most cost effective use of resources, with ICERs ranging from £4,605 to £11,671 (in 
comparison with usual care (Strategy 4)). The strategy of using GPAs as an adjunct to PCI 
was found to be economically inferior to medical management under all scenarios. Further 
details of the model are provided in Section 3.2. 
 
3.1.3 NICE guidance 
 
In September 2002, NICE issued guidance on the use of GPAs for the treatment of ACS [6]. 
The guidance recommended the following: 
 
1. That GPAs should be considered as part of medical management for patients with 
unstable angina or non ST elevation MI and that the management pathway should 
also include other pharmacological interventions and, where appropriate, early 
coronary angioplasty with a view to revascularisation either by PCI or coronary artery 
bypasses graft surgery.  
2. Intravenous use of GPAs is recommended as part of initial medical management in 
patients who are at high risk of subsequent MI or death. 
3. Where PCI does not occur or is not immediately available, medical management with 
GPAs is still recommended. 
4. In determining risk clinicians should take into account a combination of risk factors 
including clinical investigations such as ECG changes. 
5. Cardiac troponin testing is useful for diagnosing ACS, but that GPA treatment can be 
initiated before the results of a Troponin test is known. 
6. If PCI is indicated but is delayed beyond the medical management phase, GPAs are 
recommended as an adjunct to the PCI. 
7. GPAs should be considered as an adjunct to PCI for all patients with diabetes and for 
those patients undergoing complex procedures. In procedurally uncomplicated 
elective PCI, where the risk of adverse sequalae is low, the use of GPAs is not 
recommended. 
8. GPAs are not currently licensed for use as an adjunct to thrombolytic therapy. 
 
3.1.4 Research recommendations 
 
The recommendations for further research, issued as part of the NICE guidance were that: 
 
• The effects of GPAs in current UK practice should be investigated in carefully 
designed research to assess their benefits in non-ST elevation ACS patients who are 
not scheduled for PCI. 
• Research should be carried out to investigate the efficacy of GPAs in subgroups such 
as women. 
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• The results of the CURE trial may lead to a consideration of the use of Clopidogrel for 
the management of patients with ACS. Research is required to establish the relative 
roles of GPAs and Clopidogrel in the short term management of ACS patients. 
• Research is required to establish the statistical relationship between clinical risk 
factors and Troponin levels. 
 
3.2 Methods 
 
3.2.1 Model structure 
 
The model developed as part of the assessment review process, and used here, took the 
perspective of the UK NHS for costing and adopted a lifetime horizon. Health outcomes were 
measured in terms of QALYs. It consisted of a short term component and a long term 
extrapolation.  
 
Short term model 
The short term component of the model characterised the period up to 6 months following an 
episode of ACS. Three mutually exclusive outcomes were modelled: non-fatal myocardial 
infarction (MI), death and ischemic heart disease (IHD) without MI during the short term 
period.  Figure 3.1 provides the short term model structure. 
 
 
 
Figure 3.1 Short term component of the GPA Model 
 
 
 
D Death (revasc. PCI)
C Repeat revasc. PCI
E MI (revasc. PCI)
B Repeat revasc. IHD
F Death (revasc. CABG)
(Repeat revasc. CABG)
G MI (revasc. CABG)
IHD
A Acute PCI
H Death (no repeat revasc.)
(No repeat revasc.)
I MI (no repeat revasc.)
IHD
Strategy 
K Death (CABG)
J CABG
L MI (CABG)
IHD
O Death (6 mnth revasc. PCI)
N 6 mnth revasc. PCI
P MI (6 mnth revasc. PCI)
IHD
M 6 mnth revasc.
Q Death (6 mnth revasc. CABG)
(6 mnth revasc. CABG)
R MI (6 mnth revasc. CABG)
IHD
S Death (no revasc.)
(No revasc.)
T MI (no revasc.)
IHD
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Baseline event rates were taken from a UK source, PRAIS-UK. This is an observational 
cohort registry of 1046 patients admitted to 56 UK hospitals with acute coronary syndromes 
during 1998-9 [7]. These data provided the path probabilities for Strategy 4 (see Table *.1) and 
the resource use estimates. Further details regarding the input data can be found in the main 
modelling report [5]. 
 
Table 3.1 Baseline probabilities used in the short term model  
(The node refers to the labels in Figure 3.1) 
 
Node Description Probability Parameters of the beta 
distribution 
   α β 
A Acute PCI 0.05 53 980 
B Repeat revasc. 0.048 8 157 
C Repeat revasc. PCI 1.00 - - 
D Death (revasc. PCI) 0.00 0.01 7.99 
E MI (revasc. PCI) 0.13 1 7 
F Death (revasc. CABG) 0.00 - - 
G MI (revasc. CABG) 0.00 - - 
H Death (no repeat revasc.) 0.03 5 152 
I MI (no repeat revasc.) 0.03 5 147 
J CABG 0.05 47 933 
K Death (CABG) 0.11 5 42 
L MI (CABG) 0.07 3 39 
M 6 month revasc 0.05 48 885 
N 6 month revasc PCI 0.48 23 25 
O Death (6 month revasc. PCI) 0.09 2 21 
P MI (6-month revasc. PCI) 0.10 2 19 
Q Death (6-month revasc. CABG) 0.00 0.01 24.99 
R MI (6-month revasc. CABG) 0.16 4 21 
S Death (no revasc.) 0.08 68 817 
T MI (no revasc.) 0.05 40 777 
 Baseline risk of gastrointestinal bleeding:  
 (i) Undergoing PCI in acute period 0.00 0.01 52.99 
 (ii) Undergoing CABG in acute 
period 
0.02 1 46 
 (iii) No initial revasc. 0.01 12 921 
 
To model the effect of GPAs (Strategies 1-3), the baseline event probabilities were 
augmented using the relative risks associated with GPAs (compared to standard care). For 
the base case model, the estimates of the relative risk of events for each strategy, that were 
incorporated into the model, were based on a random effects Meta analyses of all of the 
available trial evidence relevant for each strategy. This required three key considerations:  
 
• Firstly, it was necessary to address the question of whether the relative risks 
associated with GPAs, which were estimated within the clinical trials, should be 
adjusted to reflect differences in UK practice.  To inform this decision, a meta-
regression analysis was undertaken to establish whether, across published trials and 
taking each strategy separately, the relative risk in a trial was related to the absolute 
baseline risk in that study.  No statistically significant association was found, but this 
may reflect the small number of trials in the analysis.  For this reason, the relative 
risks from the trials were incorporated into the model without adjustment, which is 
equivalent to assuming that relative risks are transportable across health care 
systems whilst the baseline risks in those studies are not. 
  
• Secondly, not all trials reported their end-points over the required period of follow-up 
(i.e. six months); some simply reported end-points at 30 days.  In the base-case 
analysis, in the absence of 6-month data, the relative risk reductions reported at 30 
days were assumed to apply at 6 months. The use of an alternative assumption was 
explored whereby 30-day relative risks were extrapolated to six months assuming a 
constant hazard ratio.  This produced very similar results to the assumption of 
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constant relative risks, so the latter was used in the base-case analysis due to its 
relative simplicity.   
 
• Finally, a further complexity of the trial evidence was that the three GPAs licensed in 
the UK had been used in more than one way in the trials.  This was the case despite 
the fact that the drugs are licensed for more specific purposes (see above). Despite 
this mismatch it was decided to include all trials in the meta-analyses.  The principle 
behind this was that the most reliable estimate of overall treatment effects of GPAs 
would be generated by using as much experimental evidence as was available in 
ACS patients.   
 
Table 3.2 details the pooled relative risk estimates used in the base case model. Further 
details relating to the individual trials from which the pooled estimates are derived can be 
found in the modelling report [5]. 
 
Table 3.2 Relative risk data incorporated into the model 
 Relative risks (95% confidence intervals) 
 Non-fatal MI Death Revasca PCIa CABGa GI Bleed 
S1 0.94  
(0.87, 1.02) 
0.81  
(0.70, 0.93) 
0.94  
(0.87, 1.02) 
0.97  
(0.91, 1.03) 
1.00  
(0.94, 1.06) 
1.37 
(1.00, 1.87) 
S2 0.70 
(0.48, 1.03) 
1.22 
(0.61, 2.46) 
1.02 
(0.84, 1.24) 
1.04  
(0.84, 1.29) 
0.76  
(0.49, 1.17) 
2.02 
(1.02, 4.00) 
S3 0.67 
(0.57, 0.79) 
0.77 
(0.57, 1.05) 
0.87 
(0.76, 0.98) 
0.82  
(0.73, 0.93) 
0.87  
(0.72, 1.05) 
1.29 
(0.92, 1.91) 
S: Strategy. a: Repeat revascularisation rate for Strategies 2 and 3 
 
Long term extrapolation 
If patients survived the 6 months following ACS, their long-term costs and QALYs were 
estimated using a simple 4-State Markov model populated using probability and resource use 
data from two cohorts of the Nottingham Heart Attack Register (NHAR) [8, 9]. Figure 3.2 details 
the structure of the model. 
 
Figure 3.2 Extrapolation component of the GPA model 
 
The cycle time of the model was 1 year.  Transition probabilities were estimated using 
survival analysis techniques, and costs were based on the mean annual resource use within 
the most recent cohort of the NHAR. Table 3.3 details the transition probabilities used in the 
model (+ 95% confidence intervals) and the mean (+ SD) annual cost associated with each 
Health State. In addition to these costs, a transition cost was applied when patients moved 
into the ‘Death’ State. Future costs were discounted at a rate of 6%, and benefits at 2%. The 
quality adjustment of life years was undertaken assuming a single utility for all living patients 
based on data in the published literature [10]. The value used in the model was 0.8 with a 
standard deviation of 0.09.  
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Table 3.3 Transition Probabilities  
To state:  
From state: IHD Non-fatal MI Post-MI Dead 
IHD 
£1421 (£944)a 
0.9049 
(0.8896, 0.9186) 
0.0186 
(0.0133, 0.0254) - 
0.0765 
(0.0643, 0.0904) 
Non-fatal MI 
£3966 (£1722) a - - 
0.7900 
(0.7177, 0.8471) 
0.2100 
(0.1529, 0.2822) 
Post-MI 
£1587 (£1091) a - - 
0.9266 
(0.9024, 0.9466) 
0.0734 
(0.0534, 0.0976) 
Dead  - - - 1 - 
a Derived from the Monte Carlo simulation 
 
3.2.2 Probabilistic analysis 
 
The model was fully probabilistic and incorporated distributions to reflect the uncertainty 
associated with the input data. Baseline event probabilities were modelled as Beta 
distributions. For resource use estimates, the probability of a particular resource use was 
characterised by a beta distribution, and length of stay data were incorporated as lognormal 
distributions. Relative risks, transition probabilities and utility estimates were also incorporated 
as lognormal distributions. 
 
3.2.3 Sensitivity analyses 
 
Detailed sensitivity analyses were undertaken in three key areas in order to determine the 
robustness of the base case model. These related to: 
 
? Variations in the sources of data used to populate the base-case model;  
? Variations in the baseline event rates using non-UK specific sources of data;  
? The inclusion of additional strategies to those considered in the base-case model.  
 
However, for the purpose of this report, we focus on just two sensitivity analyses to illustrate 
two methodological issues. The first relates to the use of available evidence. This is 
demonstrated by focusing on the data used to establish the relative risks associated with 
GPAs. The second focuses on the issue of appropriate comparators; this is demonstrated by 
including an additional strategy to the model. Specifically, two alternative scenarios are 
reported here: 
 
1. In establishing the relative risk of events in the short term model, only data from trials 
reporting at six-months were incorporated into the Meta analyses.  
2. Clopidogrel was considered as an additional Strategy, in addition to the three GPA-
based strategies and usual care.  Relative risk data for Clopidogrel was taken from 
the published results of the CURE trial [11]. 
 
The results of the remainder of the sensitivity analyses can be found in the modelling report 
[5]. 
 
3.2.4 Value of information analysis 
 
Value of information analysis was undertaken for the base case model and for the two 
scenario analyses described above. In each case, the EVPI was estimated for the full model 
and for groups of parameters within it. For groups of parameters with positive EVPI, the EVPI 
on individual parameters was estimated. The parameters were grouped as follows: 
 
• Baseline probabilities 
• Relative risk data for each Strategy under consideration 
• Short term costs 
• Long term net benefits (incorporating QALYs and long term costs) 
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As described above, NHS Hospital Episode Statistics suggest the incidence of UA is around 
1000 cases per million total population per year. Based on current estimates of the UK 
population, this implies an annual incidence of around 59,756 [12]. This figure was used to 
estimate the population EVPI for this decision problem. A 6% annual rate of discount was 
applied.  
 
3.3 Results 
 
3.3.1 Adoption decisions 
 
Table 3.4 details the expected cost and QALYs, and ICERs for the base case model and for 
the two scenarios modelled under sensitivity analyses. ICERs were estimated using standard 
decision rules [13]. In all cases, strategy 2 is ruled out because it is more costly and less 
effective than Strategy 3 and Strategy 3 is ruled out because of extended dominance. 
Moreover, in the second sensitivity analysis, Clopidogrel is also ruled out due to extended 
dominance. Strategy 1 (GPAs used as part of medical management), results in an ICER of 
between £5,736 and £8,750 compared with Strategy 4 (usual care) 
 
Table 3.4 Expected costs and QALYs for each Strategy under alternative scenarios 
Strategy Average Cost Average QALYs ICER 
Base case model 
1 £12,688 7.7875 £5,736a 
2 £12,207 7.6839 D 
3 £12,188 7.6910 ED (£25,556 b) 
4 £12,119 7.6883  
Scenario 1: Relative risk data taken from 6-month trials only 
1 £12,611 7.7352 £8,750a 
2 £12,194 7.6725 D 
3 £12,179 7.6787 ED (£41,579 b) 
4 £12,100 7.6768  
Scenario 2: Clopidogrel as a fifth strategy 
1 £12,790 7.7630 £5,769a 
5  £12,594 7.7173 ED (£7,026 c) 
2 £12,307 7.6591 D 
3 £12,287 7.6662 ED (£26,296 b) 
4 £12,216 7.6635  
D: Dominated ED: Extended dominance 
a ICER Strategy 1 versus Strategy 4 b ICER Strategy 3 versus Strategy 4 c ICER Strategy 5 versus 
Strategy 4 
 
Figure 3.3 details the cost-effectiveness acceptability curves (CEACs) and the cost 
effectiveness frontier for the base case model. These incorporate the uncertainty within the 
model in relation to both the estimates of expected cost and QALYs, and the threshold for 
cost-effectiveness (maximum willingness to pay for an additional QALY). The CEACs detail 
the probability that each Strategy is cost-effective over a range of threshold values, and the 
frontier details the probability that the optimum strategy is cost effective. Strategy 4 has the 
highest probability of cost-effectiveness at low values of lambda. At values over £5,738, 
Strategy 1 is optimum.  Consequently, the results from the base-case analysis demonstrate 
that if the health service is prepared to pay over £5,738 per QALY then Strategy 1 is always 
the optimal decision. Similar patterns result from the two scenarios reported as sensitivity 
analyses. 
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Figure 3.3 CEACs and Frontier for the base case model 
 
3.3.2 Research recommendations 
 
EVPI is between £42.97 and £57.81 per patient for threshold values between £10,000 and 
£50,000. The population EVPI for the base case model ranges from £11,464,710 (5 years, 
threshold = 30K) to £35,561,534 (15 years, threshold = 50K) depending on assumptions 
regarding the lifespan of the technology and the value of lambda (see Figure 3.4). If the 
lifespan of the technology is ten years and the threshold for cost-effectiveness is £30,000, the 
EVPI for the full model is £20,031,809 (EVPI per episode at a threshold of £30,000 is £42.97). 
 
Figure 3.5 details the base case EVPI results for groups of parameters, assuming a ten year 
life span and that the threshold is £30,000. All of the uncertainty in the model is encapsulated 
within the relative risks associated with Strategy 1. Isolating the EVPI for the individual 
relative risk parameters identified that the relative risk of death for patients not undergoing an 
acute PCI procedure was the only parameter associated with positive EVPI. This does not 
imply that there is no value in obtaining further information on other parameters; it means that 
there is no value on obtaining further information on those parameters individually. In other 
words, whilst there may be value in obtaining information on all of the model parameters 
combined (as together there is positive EVPI for the decision), there is no value in obtaining 
individual information on those model inputs that have zero EVPI. For example, there is no 
value in obtaining further information on the relative risk of death in patients who receive, or 
who are scheduled to receive, GPAs at the time of a PCI procedure (i.e. Strategies 2 and 3) if 
these data are obtained separately from further information associated with the relative risk of 
death in patients who receive GPAs as part of medical management who do not undergo an 
acute PCI procedure (i.e. Strategy 1). 
 
The pattern is the same across all assumed lifespan of the technology. When the threshold 
for cost-effectiveness is lowered to £10,000, there is some positive EVPI is the parameters 
associated with long term outcomes, but these are small compared with the relative risk data 
(e.g. for a lifespan of 10 years and threshold at £10,000, the EVPI for the long term net 
benefit is £480,373 compared with a value of £20,047,419 for the relative risks associated 
with Strategy 1). 
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Figure 3.4 Population EVPI for the base case model 
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Figure 3.5 EVPI for groups of parameters in the base case model
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3.3.3 Scenario analyses 
 
Figure 3.6 details the total population EVPI for the base case model and the two scenario 
analyses over a range of values for lambda, under an assumed lifespan for the technology of 
ten years. The total EVPI increases in both of the scenarios investigated though sensitivity 
analysis. This is because, in both cases, the probability that the optimum strategy is cost 
effective falls in comparison with the base case model. For example, under Scenario 1, where 
the relative risk data are derived from a smaller number of trials, the probability that the 
optimum strategy is cost-effective is below 0.7 for all Lambda values above the ICER.  
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Figure 3.6 Population EVPI under alternative assumptions  
 
Table 3.5 details the EVPI values (assuming a lifespan of 10 years and a threshold of 
£30,000) for the sensitivity analysis which used only those trials reporting at 6 months to 
derive the relative risk estimates for the three GPA strategies. The parameters with positive 
EVPI follow the same pattern as the base case model, but the value of the decision 
uncertainty increases 8-fold. The EVPI for the relative risk of death in patients not undergoing 
an acute PCI under Strategy 1 is marginally greater that the EVPI for all of the relative risks 
for Strategy 1 combined. This is likely to be due to small correlations between values of the 
input variables, occurring as a result of the Monte Carlo process.   
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Table 3.5 EVPI under alternative relative risk estimate assumptions 
 Episode EVPI Population EVPI 
Full model 834.33 388,963,186 
Groups of parameters   
Baseline probabilities 0 0 
Relative risks S1 799.13 372,553,107 
Relative risks S2 0 0 
Relative risks S3 0 0 
Short term costs 0 0 
Long term net benefits 1.82 848,934 
Individual parameters (S1)   
RR PCI 0 0 
RR Death (acute) 0 0 
RR MI (acute) 0 0 
RR CABG 0 0 
RR Death (non acute) 799.95 372,934,171 
RR MI (non acute) 0 0 
Lifespan: 10 years. Threshold: £30,000 
 
Under the second Scenario analysis, the scope of the model is widened to include an 
additional strategy. When Clopidogrel is evaluated alongside the use of GPAs, although the 
optimal decision remains the same (i.e. the use of GPAs as medical management), the 
uncertainty associated with that decision increases, hence EVPI increases (at an assumed 
lifespan of 10 years and a threshold of £30,000, the population EVPI is £171,382,025). Figure 
3.7 details the population level EVPI values for the full model, groups of parameters and 
individual parameters. Both the relative risks associated with Strategy 1 (GPAs as medical 
management) and Strategy 5 (Clopidogrel) are associated with positive EVPI (RR S1: 
£85,041,201, RR S5: £68,136,978), and for both cases, it is the relative risk associated with 
death in patients who do not undergo an acute PCI that drives the uncertainty in the model. 
As with the first scenario analysis, the EVPI on the individual parameters is marginally greater 
than on the EVPI for the group of parameters containing it. 
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(Lifespan: 10 years. Threshold: £30,000) 
Figure 3.7 The effect of the inclusion of an additional strategy on EVPI values 
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3.4 Discussion 
 
3.4.1 Interpretation 
 
The EVPI for the base case model indicates there is potentially considerable value in further 
research to reduce the uncertainty associated with the a-priori decision.  Using base-case 
assumptions, EVPI is between £47.71 and £57.81 per patient for threshold values between 
£10,000 and £50,000. Translating this to a population figure, the EVPI is between £20 million 
and £26.9 million, assuming the lifespan of the technology is ten years.  
 
EVPI is driven almost exclusively by the relative risk of death in patients not undergoing an 
initial PCI in Strategy 1. This would suggest that future research should be directed toward 
reducing the uncertainty associated with the relative risk of death in patients who are 
prescribed GPAs who have ACS and do not undergo a PCI procedure in the acute phase. 
 
When the data used to derive relative risk estimates are restricted to those trials reporting at 6 
months, the uncertainty associated with the optimal decision increases, increasing the EVPI 
8-fold. This is not surprising; by using fewer data to derive relative risk estimates, the 
uncertainty associated with those estimates will inevitably increase due to the smaller number 
of trials included in the Meta analyses. However, this result places further emphasis on the 
need to obtain further research evidence on the risk reduction associated with the use of 
GPAs as part of medical management, for patients who do no undergo an acute PCI. Given 
that the data used in this model suggested that 95% of patients admitted to hospital with 
acute coronary syndrome do no undergo a PCI procedure, this represents a large proportion 
of the patient group. 
 
When the scope of the model is widened to include Clopidogrel as a treatment option 
Strategy 1 remains the optimal decision but EVPI increases. This is because there are only 
small differences in cost and outcome between the Clopidogrel option and Strategy 1. 
Although Strategy 1 remains the optimal decision, there is around a one third probability that 
Clopidogrel is cost-effective. This uncertainty explains the high EVPI. The results of this 
scenario, suggest that further research to identify the relative benefits of Clopidogrel and 
GPAs as part of medical management, and compared with the current service provisions 
would be of benefit. 
 
3.4.2 Caveats 
 
Although it is clear from the partial EVPI analysis that the relative risk of death in patients not 
undergoing an acute PCI who are given GPAs (or Clopidogrel) as part of their medical 
management is the key parameter driving decision uncertainty, as cautionary note is required 
regarding the way in which risk was handled within the model.  As described in the 
introduction, ACS includes a range of patients with important different characteristics which 
are likely to affect prognosis.  As such, the trials from which the relative risk data are derived 
include patients with a variety of characteristics. For example, the medical management trials, 
which provide the relative risks for Strategy 1 in the model, include patients of a variety of 
ages, with and without ST depression and with and without troponin positivity1.  Moreover, the 
PRAIS-UK data, which provided the basline risks, and the NHAR data, which was used in the 
long-term extrapolation included patients with a variety of different risk factors. The model 
therefore reflects an ‘average risk’ patient across all risk groups. This hetrogeniety must be 
bourne in mind in interpreting the EVPI results as it is likely that the value of further research 
will be assocaited with the use of GPAs in patients who are defined, a priori, as high risk.  
 
A further consideration relates to the way in which the PRAIS-UK data reflects current 
practice in the UK. Although these data do provide the best estimates of current practice, the 
rate of PCI is on the increase in the UK. At present, the model assumes that, on average, 5% 
of patients have an acute PCI. Consequently it is the relative risk of death in patients not 
undergoing PCI (i.e. the remaining 95% of patients) driving the uncertainty that is associated 
                                                 
1 These are examples of risk factors for ACS patients.  
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with Strategy 1. As the proportion of patients receiving acute PCI increases, there may be 
value in obtaining further information on both acute and non acute PCI patients. 
Finally, it must be noted that the data used to model the relative cost-effectiveness of 
Clopidogrel was not identified systematically and were taken from a single trial. However, this 
analysis was undertaken to illustrate a particular methodological issue as opposed to 
establishing cost-effectiveness per se.   
 
3.4.3 Methodological issues 
 
Notwithstanding the caveats outlined above, the value-of-information analysis carried out here 
has demonstrated two important points:  
 
1. That the data incorporated into a model has to reflect all available evidence. If 
selected data are omitted as inputs into the model, then the resultant EVPI statistics 
will be artificially high. This is shown in this chapter when the EVPI statistics 
associated with Scenario 1 are compared with the base case model results. To 
exclude evidence will result in an overestimate of the value of additional research and 
will ultimately bias research priority setting. 
 
2. The original scope of the model did not take account of the use of Clopidogrel as an 
alternative treatment for these patients. When this is included, whilst the optimal 
decision doesn’t change, the decision uncertainty does. Therefore, it is crucial that 
the scope of the work is defined appropriately from the outset, as this will have 
massive implications for the results of the EVPI analysis, and hence the need for 
future research in the area.   
 
3.4.4 Relationship with the research recommendations provided by NICE 
 
The NICE guidance provided four specific future research recommendations and the EVPI 
analysis provided here lends support to two of these. From this analysis it is clear that there is 
a need to establish the benefits of GPAs in patients not scheduled for PCI and that in 
establishing the optimal use of resources for the treatment of ACS patients, competing 
interventions, such as GPAs versus Clopidogrel, should be evaluated together. As described 
above, a limitation of this model was the way in which risk was incorporated. For this reason, 
the recommendations relating to the identification of risk factors and the efficacy GPAs in 
specific subgroups cannot be explicitly addressed here. 
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Appendix. Reference case evaluation: Glycoprotein IIb/IIIa antagonists for the 
treatment of Acute Coronary Syndromes 
 
 
 
 
Element of health 
technology assessment 
Reference case Criteria met by 
assessment? 
Comment 
Defining the decision 
problem 
The scope developed 
by the Institute 
Yes  
Comparator Alternative therapies 
routinely used in the 
NHS  
Yes  
Perspective on costs NHS and PSS Yes  
Perspective on 
outcomes 
All health effects on 
individuals 
Yes  
Type of economic 
evaluation 
Cost-effectiveness 
analysis 
Yes  
Synthesis of evidence 
on outcomes 
Based on a systematic 
review 
Yes Systematic review undertaken previously 
on behalf of NICE[4]. 
Measure of health 
benefits 
Quality adjusted life 
years (QALYs) 
Yes  
Description of health 
states for calculation of 
QALYs 
Health states described 
using a standardised 
and validated generic 
instrument 
No 
Method of preference 
elicitation for health 
state valuation 
Choice-based method, 
for example, time trade-
off, standard gamble 
(not rating scale) 
No 
Source of preference 
data 
Representative sample 
of the public 
No 
Health state preference values were taken 
from a published source [10]. 
Discount rate An annual rate of 3.5% 
on both costs and 
health effects 
No The discount rates for costs and health 
outcomes recommended at the time of the 
NICE assessment were used. 
Equity position An additional QALY has 
the same weight, 
regardless of the other 
characteristics of the 
individuals receiving the 
health benefit 
Yes  
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4. Clopidogrel and modified-release dipyridamole in the secondary 
prevention of occlusive vascular events 
 
4.1 Background 
 
4.1.1 Condition and technology 
 
It is widely accepted that atherothrombosis is the most important cause of occlusive vascular 
events (OVEs).  The clinical manifestations of atherothrombosis include transient ischaemic 
attack (TIA), ischaemic stroke, unstable angina, myocardial infarction (MI) and intermittent 
claudication, a symptom associated with peripheral arterial disease (PAD).  Patients with 
symptomatic disease in one vascular bed are also likely to have diffuse disease, placing them 
at risk of subsequent events in additional vascular territories.  This is demonstrated in 
individuals with asymptomatic PAD who are twice as likely as normal subjects to suffer from 
concomitant coronary artery disease.[1] 
 
There are approximately 237,000 myocardial infarctions per year in England and Wales. The 
annual incidence rate for men aged 30-69 is around 600 per 100,000 population and for 
women the equivalent rate is 200 per 100,000 population.  Estimates from the National 
Service Frameworks indicate that there are around 110,000 new cases of stroke in England 
and Wales each year.  The economic burden from CHD in terms of direct health care costs 
and indirect costs (including informal care costs and loss of productivity) is high.  Overall the 
total annual cost of all CHD-related burdens equated to over £7 billion in 1999, the highest of 
all diseases in the UK for which comparable analyses have been undertaken.[1] 
 
Aspirin is the most widely prescribed antiplatelet agent, and in secondary prevention it 
reduces the risk of MI, stroke and vascular death by about 25%.  Two alternative antiplatelet 
agents, clopidogrel and modified-release (MR) dipyridamole, are licensed for the secondary 
prevention of OVEs.  Clopidogrel, a thienopyridine antiplatelet drug is unrelated to aspirin and 
therefore can be used in patients who show a genuine intolerance to aspirin; it is licensed for 
the secondary prevention of ischaemic stroke, MI and in patients with PAD.  Dipyridamole, an 
adenosine reuptake inhibitor and phosphodiesterase inhibitor, has both antiplatelet and 
vasodilating properties.  Modified-release dipyridamole is licensed for the secondary 
prevention of ischaemic stroke and TIAs either alone or in combination with aspirin. 
 
4.1.2 Technology Assessment Review 
 
NICE was commissioned by the Department of Health and the Welsh Assembly Government 
to conduct an appraisal of the clinical effectiveness and cost-effectiveness of two alternative 
antiplatelet agents, clopidogrel and modified-release dipyridamole, relative to prophylactic 
doses of aspirin for the secondary prevention of OVEs. 
 
The analysis considered four relevant subgroups: patients who present with non-
haemorrhagic stroke, patients who present with TIA, patients who present with MI and 
patients with symptomatic PAD.  Stroke, TIA, MI and PAD are all atherothrombotic 
manifestations, and it is clinically and biologically plausible that all patients with 
atherothrombosis receive similar benefits from treatment.  However, the evidence shows that 
the prognosis and baseline risk of recurrent OVEs differs according to the presenting event.  
Furthermore, licensing of antiplatelet drugs is limited according to the presenting event of 
patients in the clinical trials, and so each drug is not available in every subgroup.  For these 
reasons it was necessary to conduct separate analyses by subgroup.  The agents under 
comparison were aspirin, clopidogrel, MR-dipyridamole or the combination of aspirin and MR-
dipyridamole (ASA-MR-dipyridamole).  The analysis considered two options for treatment 
duration: lifetime treatment with each agent, or 2-year treatment with each agent followed by 
treatment with aspirin for the remainder of the patients’ lifetime.  The 2-year treatment period 
was chosen to reflect the length of the relevant clinical trials, and not as a result of selecting 
medically optimal treatment duration.  Full detail of the clinical and cost-effectiveness analysis 
can be seen in a forthcoming HTA report. 
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The review of the economic evidence from the literature and manufacturers’ submissions 
highlighted a number of potential limitations in existing studies assessing the cost-
effectiveness of clopidogrel and MR-dipyridamole in the secondary prevention of OVEs.  In 
order to overcome these limitations, it was necessary to undertake further modelling.  An 
‘extended’ probabilistic decision-analytic model was created, which used those models 
submitted by the manufacturers but employed a range of further analyses.  The model was 
developed to estimate costs from the perspective of the UK NHS, and health outcomes in 
terms of quality-adjusted life-years (QALYs).  The extended model was adapted from the 
model submitted to NICE by Sanofi-Synthelabo Ltd and Bristol-Myers Squib. 
 
4.1.3 NICE guidance 
 
In February 2004, NICE published the Appraisal Consultation Document2 (ACD)[2] on the use 
of clopidogrel and MR-dipyridamole in the secondary prevention of occlusive vascular events.  
The provisional guidance recommended the following for aspirin tolerant patients: 
1. For patients with stroke or TIA, ASA-MR-dipyridamole for 2 years, after which 
patients should revert to standard care, which includes aspirin monotherapy. 
2. For patients with MI or PAD, the recommended treatment is aspirin. 
 
4.1.4 Research recommendations 
 
The recommendations for further research contained in the ACD[2] were: 
? For patients at high risk of recurrent occlusive vascular events, with diabetes or who 
have had coronary surgery, further research is recommended into the effectiveness 
of clopidogrel. 
? For patients with stroke who are intolerant to aspirin, further research is 
recommended into comparing the effectiveness of MR-dipyridamole with clopidogrel. 
 
4.2 Methods 
 
4.2.1 Model structure 
 
The structure of the decision model for the stroke and TIA subgroups is shown in Figure 4.1.  
A cohort of patients (60 years of age) suffering from first-ever stroke or first-ever TIA are 
entered into the model which estimates the number of repeat strokes, fatal vascular events, 
and fatal non-vascular events over 40-years (lifetime).  The cycle length is one-year, and in 
the first year following a repeat event, the risk of further strokes or vascular death is higher 
than if the patient survives 1-year event-free.  The structure of the decision model for the MI 
and PAD subgroups is shown in Figure 4.2.  A cohort of patients (60 years of age) suffering 
from first-ever MI or from symptomatic PAD are entered into the model which estimates the 
number of repeat MIs, repeat strokes, fatal vascular events, and fatal non-vascular events 
over 40-years (lifetime). 
 
Figures 4.1 and 4.2 illustrate the fact that the model separates mortality into vascular and 
non-vascular causes.  One reason for doing this is to separate out related and unrelated 
events, and to make full use of baseline and treatment effect data relating to those events.  
The risk of vascular or non-vascular death (NVD), and more importantly, the proportion of 
deaths due to vascular or non-vascular events, changes with age and time from non-fatal 
vascular events.  To take the treatment relative risks on all-cause death observed during the 
trials, and to apply these to an age-related baseline risk of all-cause death, extrapolated over 
the lifetime of the patient cohort, would be assuming that the proportion of vascular to NVDs 
remained constant over that period, whereas the evidence shows that it does not.  The 
separation of deaths in this way is also problematic.  Both of the included randomised 
controlled trials (RCTs) had a follow-up period of 2 years.  Over this period, in a cohort of 
patients with an average age of around 60, the number of observed death events will not be 
large, and hence the number of observed vascular or NVDs will be even smaller.  This results 
                                                 
2 The guidance issued in the ACD is provisional and subject to change following the consultation 
procedure. 
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Figure 4.1: Structure of the extended model by University of York to assess cost-
effectiveness of clopidogrel and MR-dipyridamole in the secondary prevention of 
occlusive vascular events in patients who have experienced stroke or TIA. 
 
in greater uncertainty around the treatment effects on mortality.  Secondly, the separation 
introduces the issue of whether or not to include treatment effects on NVD, which would not 
exist if all-cause mortality had been used instead.  The inclusion of treatment effects on 
vascular mortality was expected as standard, however there was some question over the 
validity of including treatment effects on NVD.  Separate analyses were therefore undertaken 
to explore the impact of including and excluding the relative risk reductions reported in the 
trials for NVD. 
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Figure 4.2: Structure of the extended model by University of York to assess cost-
effectiveness of clopidogrel and MR-dipyridamole in the secondary prevention of 
occlusive vascular events in patients who have experienced MI or have been 
diagnosed with PAD. 
 
A full list of all the parameters and their sources is available elsewhere.[1] Tables 4.1 and 4.2 
provide details of the relative risks and cost data employed in the model.  The baseline was 
assumed to represent the risk of further events while receiving treatment with aspirin, which 
was current practice for patients with atherothrombosis at the time to which the evidence 
relates.  UK specific costs and utility estimated were incorporated into the model, and 
discounted at a rate of 6% and 1.5% per annum respectively.  The perspective taken was that 
of the UK NHS. 
 
Table 4.1: Relative risk parameters used in the model 
 Clopidogrel ASA-MR-dipyridamole MR-dipyridamole 
Event RR SE(ln(RR)) RR SE(ln(RR)) RR SE(ln(RR)) 
Non-fatal MI[3, 4] 0.808 0.0932 1.058 0.3364 1.935 0.2965 
Non-fatal 
stroke[3, 4] 0.948 0.0682 0.736 0.1071 0.981 0.0981 
Vascular 
death[4, 5] 0.925 0.0728 0.991 0.1257 1.056 0.1235 
Non-vascular 
death[4, 5] 1.087 0.1057 1.062 0.1706 0.981 0.1740 
Fatal bleed[6] 0.999 0.4470 1.749 0.6258 0.499 0.8653 
Non-fatal 
bleed[6] 0.938 0.1444 1.437 0.3237 0.374 0.4774 
RR = relative risk compared to aspirin; SE = standard error; ln = natural logarithm 
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Table 4.2: Unit cost estimates used in the model 
Item of resource use Mean Source 
Stroke:   
Year 1 following non-disabling 
event £5,907.34 Youman et al
[7] 
Subsequent years following 1-
year event free £1,052.17 Youman et al
[7] 
Year 1 following disabling event £13,213.60 Youman et al[7] 
Subsequent years following 1-
year event free £3976.61 Youman et al
[7] 
MI:   
Year 1 following event £1,587.00 Palmer et al[8] 
Subsequent years following 1-
year event free £3,966.00 Palmer et al
[8] 
PAD yearly cost £1,000  Submission by SSBMS 
Bleeding event £2,377.24 Lightowlers and McGuire[9] 
1 year supply:   
Aspirin £3.47 British National Formulary[10] 
Clopidogrel £460.29 British National Formulary [10] 
ASA-MR-dipyridamole £117.00 British National Formulary [10] 
MR-dipyridamole £117.00 British National Formulary [10] 
 
Cost of presenting stroke calculated by assuming 30.9% disabling events; cost of subsequent 
strokes calculated by assuming 35.6% disabling events (source ESPS-2). Cost of TIA equal 
to non-disabling stroke. 
 
Due to separate indications and licences for clopidogrel and MR-dipyridamole, different 
combinations of treatment strategies are compared in each patient subgroup. The full range 
of licensed agents is considered in all analyses.  Sensitivity analysis was used to address the 
assumption about treatment duration.  The first analysis considered lifetime treatment 
duration with each of the agents, and a second analysis considered only 2-year treatment 
duration for clopidogrel, MR-dipyridamole and ASA-MR-dipyridamole, with all patients 
subsequently receiving aspirin for the remainder of their lifetime.  These 2-year treatment 
strategies are detailed below: 
 
• Strategy 1: Treatment with aspirin for the remainder of the patient's lifetime. 
• Strategy 2: Treatment with clopidogrel for 2 years followed by treatment with aspirin 
for the remainder of the patient's lifetime. 
• Strategy 3: Treatment with ASA-MR-dipyridamole for 2 years followed by treatment 
with aspirin for the remainder of the patient's lifetime. 
• Strategy 4: Treatment with MR-dipyridamole for 2 years followed by treatment with 
aspirin for the remainder of the patient's lifetime. 
 
The combinations of strategies considered for each patient subgroup are as follows. 
 
• Stroke: Strategy 1 (aspirin), Strategy 2 (clopidogrel), Strategy 3 (ASA-MR-
dipyridamole) and Strategy 4 (MR-dipyridamole). 
• MI: Strategy 1 (aspirin) and Strategy 2 (clopidogrel). 
• PAD: Strategy 1 (aspirin) and Strategy 2 (clopidogrel). 
• TIA: Strategy 1 (aspirin), Strategy 3 (ASA-MR-dipyridamole) and Strategy 4 (MR-
dipyridamole). 
 
4.2.2 Probabilistic analysis 
 
The model was fully probabilistic and the uncertainty around model parameters was 
characterised using appropriate distributions. Baseline risks were estimated with a 
multinomial regression, and the coefficients from the regression were characterised with 
normal distributions. Uncertainty around relative risks was characterised by lognormal 
distributions, and were correlated via an indirect comparison with aspirin.  Full details of this 
are available elsewhere.[1] 
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4.2.3 Value of information analysis 
 
Value of information (VOI) analysis was not undertaken in the initial report.  Using the 
simulations that provided the cost-effectiveness estimates for the original assessment report, 
we estimated the expected value of perfect information (EVPI) for individual patients.  
Population EVPIs were then calculated using the incidence of stroke, TIA, MI and PAD as 
reported in the ACD.[2] Due to the similarities in the model for stroke and TIA patients, and in 
the model for MI and PAD patients, consideration of parameter EVPI is confined to only the 
stroke and MI subgroups. 
 
4.3 Results 
 
4.3.1 Adoption decisions 
 
Following the provisional guidance issued by NICE regarding the use of antiplatelets for the 
secondary prevention of OVEs[2], we focus on the analysis concerning a 2-year treatment 
duration followed by aspirin for the remainder of patients’ lifetimes (scenarios III and IV).  The 
issue of treatment duration will be addressed further in the discussion. 
 
Tables 4.3 to 4.6 display the mean costs and QALYs associated with each treatment strategy 
in each of the four subgroups, with incremental cost-effectiveness ratios estimated in the 
standard manner.[11] They also provide an estimate of the uncertainty surrounding the cost-
effectiveness of each treatment strategy for different thresholds for cost-effectiveness, and 
finally they provide an estimate of the per patient decision EVPI. 
 
Table 4.3: Estimated mean costs, effects and cost-effectiveness of each treatment 
strategy and decision EVPI for individual patients: stroke subgroup. 
Threshold for cost-
effectiveness: Strategy Treatment duration Cost QALY ICER  £10,000 £30,000 £50,000 
Scenario III: 2 year treatment duration, excluding treatment effects on non-vascular death 
Aspirin 2 years £30,680 9.77 - 0.26 0.14 0.10 
Clopidogrel 2 years £31,648 9.81 D 0 0.12 0.18 
ASA-MR-
dipyridamole 2 years £30,940 9.82 £5,500 0.62 0.62 0.60 
MR-
dipyridamole 2 years £30,758 9.73 D 0.12 0.13 0.12 
  Per patient EVPI £188 £691 £1,268 
Scenario IV: 2 year treatment duration, including treatment effects on non-vascular death 
Aspirin 2 years £30,544 9.75 - 0.35 0.22 0.18 
Clopidogrel 2 years £31,481 9.78 D 0 0.10 0.16 
ASA-MR-
dipyridamole 2 years £30,751 9.78 £7,968 0.52 0.53 0.52 
MR-
dipyridamole 2 years £30,621 9.71 D 0.14 0.15 0.15 
  Per patient EVPI £286 £1,008 £1,793 
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Table 4.4: Estimated mean costs, effects and cost-effectiveness of each treatment 
strategy and decision EVPI for individual patients: TIA subgroup (with baseline event 
rates set to 80% stroke). 
Threshold for cost-
effectiveness: Strategy Treatment duration Cost QALY ICER  £10,000 £30,000 £50,000 
Scenario III: 2 year treatment duration, excluding treatment effects on non-vascular death 
Aspirin 2 years £21,908 11.65 - 0.29 0.17 0.13 
Clopidogrel 2 years £22,811 11.69 £46,949 0 0.19 0.28 
ASA-MR-
dipyridamole 2 years £21,956 11.68 £2,241 0.58 0.51 0.47 
MR-
dipyridamole 2 years £22,052 11.62 D 0.13 0.14 0.12 
  Per patient EVPI £244 £932 £1,670 
Scenario IV: 2 year treatment duration, including treatment effects on non-vascular death 
Aspirin 2 years £22,085 11.70 - 0.35 0.25 0.21 
Clopidogrel 2 years £22,963 11.72 £52,339 0 0.12 0.43 
ASA-MR-
dipyridamole 2 years £22,111 11.71 £4,266 0.49 0.45 0.18 
MR-
dipyridamole 2 years £22,220 11.66 D 0.16 0.19 0.19 
  Per patient EVPI £348 £1,265 £2,255 
 
 
Table 4.5: Estimated mean costs, effects and cost-effectiveness of each treatment 
strategy and decision EVPI for individual patients: MI subgroup. 
Threshold for cost-
effectiveness: Strategy Treatment duration Cost QALY ICER  £10,000 £30,000 £50,000 
Scenario III: 2 year treatment duration, excluding treatment effects on non-vascular death 
Aspirin 2 years £18,284 8.90 - 0.83 0.29 0.22 
Clopidogrel 2 years £19,202 8.95 £17,081 0.17 0.71 0.78 
  Per patient EVPI £31 £274 £322 
Scenario IV: 2 year treatment duration, including treatment effects on non-vascular death 
Aspirin 2 years £18,182 8.87 - 0.88 0.39 0.31 
Clopidogrel 2 years £19,078 8.91 £21,448 0.12 0.61 0.70 
  Per patient EVPI £23 £387 £459 
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Table 4.6: Estimated mean costs, effects and cost-effectiveness of each treatment 
strategy and decision EVPI for individual patients: PAD subgroup. 
Threshold for cost-
effectiveness: Strategy Treatment duration Cost QALY ICER  £10,000 £30,000 £50,000 
Scenario III: 2 year treatment duration, excluding treatment effects on non-vascular death 
Aspirin 2 years £15,180 11.04 - 0.96 0.30 0.17 
Clopidogrel 2 years £16,041 11.08 £20,733 0.04 0.70 0.83 
  Per patient EVPI £5 £146 £116 
Scenario IV: 2 year treatment duration, including treatment effects on non-vascular death 
Aspirin 2 years £15,279 11.03 - 0.96 0.52 0.36 
Clopidogrel 2 years £16,123 11.05 £31,300 0.04 0.48 0.64 
  Per patient EVPI £4 £346 £393 
 
Treatment with clopidogrel is consistently the highest cost strategy, and treatment with aspirin 
is consistently the lowest cost strategy.  This is due almost entirely to the huge difference in 
acquisition costs for each the drugs.  The annual drug cost is £460.29 per patient for 
clopidogrel, compared to £117 for ASA-MR-dipyridamole and MR-dipyridamole, and only 
£3.47 for aspirin.  Where MR-dipyridamole is a relevant treatment strategy, it is consistently 
associated with the lowest number of QALYs, and is dominated in every analysis.  At a cost-
effectiveness threshold of £30,000 per QALY gained, it would appear that treatment with 
ASA-MR-dipyridamole is the most cost-effective strategy for patients in the stroke or TIA 
subgroup, and that treatment with clopidogrel is the most cost-effective treatment strategy for 
patients in the MI subgroup.  The most cost-effective treatment strategy for patients with PAD 
is not clear, as the inclusion of treatment effects on NVD causes the ICER for clopidogrel to 
exceed £30,000. 
 
The cost-effectiveness of each treatment strategy is uncertain, and the cost-effectiveness 
acceptability curves (CEACs)[12] in Figures 4.3 and 4.4 illustrate this uncertainty in the stroke 
subgroup, and the fact that none of the treatment strategies are ruled out entirely by the 
analysis.  The cost-effectiveness frontiers show the probability that the optimum strategy is 
cost effective. 
 
The inclusion of treatment effects on NVD increases the ICER associated with each strategy, 
and also increases the uncertainty surrounding the most optimal strategy.  This is to be 
expected as the trial data show that clopidogrel and ASA-MR-dipyridamole exhibit small, and 
statistically insignificant relative risk increases for NVD when compared to aspirin. 
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Figure 4.3: CEACs and frontier for stroke subgroup, model excluding treatment effects 
on NVD 
 
 
Figure 4.4: CEACs and frontier for stroke subgroup, model including treatment effects 
on NVD 
 
4.3.2 Research recommendations 
 
Population EVPI is large in each subgroup, ranging from £116mn to £865mn for an effective 
lifetime of the technology of 10 years and a cost-effectiveness threshold of £30,000.  Figures 
4.5 and 4.6 show that it increases with the threshold for cost-effectiveness for most of the 
range in each patient subgroup. 
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 Figure 4.5: Population EVPI, model excluding treatment effects on NVD 
 
Figure 4.6: Population EVPI, model including treatment effects on NVD 
 
The population EVPI is very high in each subgroup, and this is partly because such a large 
population of patients stand to benefit from any future research.  It is clear that the population 
EVPI is much higher in the stroke subgroup for most of the range, especially when compared 
to MI, which is more common.  This is in part due to the increase in treatment options for 
patients with stroke: four, compared to two for patients with MI.  Secondly, the treatment 
comparisons in the MI subgroup are taken directly from a RCT.  In contrast, the treatment 
comparisons in the stroke subgroup were only possible via an indirect comparison of 
clopidogrel and dipyridamole, as there was no trial evidence comparing both agents directly.  
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This indirect comparison inflates the variance around the relative risk parameters, thereby 
increasing the uncertainty around the optimal strategy. 
The EVPI is larger when the model includes treatment effects on the risk of NVD.  There are 
two levels of uncertainty around treatment effects on NVD.  Firstly, there is uncertainty as to 
their existence, and secondly, if they do exist there is great uncertainty around their 
magnitude and direction given that observed difference in numbers of events is extremely 
small.  EVPI reflects the latter of these.  Given a difference in numbers of 1 or 4 events, the 
possibility that such a difference is observed solely by chance or random variation is very 
high.  The problem is compounded when, as in the case of death, the consequence of even a 
small difference in numbers of events is large. 
 
4.3.3 EVPI for individual parameters 
 
To estimate EVPI for individual parameters, we first grouped the parameters into logical sets: 
baseline risk estimates, treatment relative risk estimates, estimates of utility and estimates of 
costs.  Of these groups, for every patient subgroup, only the estimates of the relative risks 
associated with each treatment had positive values of information, so we then explored the 
relative risk parameters individually.  The results of this analysis are shown in Figures 4.7 to 
4.10.  They reveal that the parameters accounting for almost all of the VOI were the treatment 
effects with respect to vascular mortality, and when they are included the treatment effects 
with respect to NVD. 
 
 
 
Figure 4.7: Partial EVPI on oindividual relative risks: stroke subgroup, excluding 
treatment effects on NVD 
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Figure 4.8: Partial EVPI on individual relative risks: stroke subgroup, including 
treatment effects on NVD 
 
 
 
Figure 4.9: Partial EVPI on individual relative risks: MI subgroup, excluding treatment 
effects on NVD 
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Figure 4.10: Partial EVPI on individual relative risks: MI subgroup, including treatment 
effects on NVD 
 
Key to Figures 4.7-4.10: clp_asa = relative risk of clopidogrel compared to aspirin; amd_clp = 
relative risk of ASA-MR-dipyridamole compared to clopidogrel (indirect); dip_clp = relative risk 
of MR-dipyridamole compared to clopidogrel (indirect) 
 
4.3.4 Discussion 
 
The initial guidance issued by NICE was based on both scenarios (i.e. both the model that 
included treatment effects on non-vascular mortality, and the one that excluded them), 
demonstrating the uncertainty over the relevance of treatment effects on non-vascular 
mortality.  This uncertainty is not captured in the model, or in the estimates of EVPI.  There 
are two related reasons for uncertainty over the inclusion of such treatment effects.  One such 
reason is the issue of related and unrelated events, and whether we might realistically expect 
these agents to have a treatment effect on non-vascular mortality.  A related uncertainty over 
the existence of these relative risk treatment effects is the lack of evidence, shown by the 
wide confidence intervals that include 1, and encompass both large relative risk reductions, 
as well as large relative risk increases.  One way to include this uncertainty in the model 
would be to use Bayesian methods.  The prior belief that antiplatelet agents are not expected 
to have a differential effect non-vascular mortality could be reflected with a prior distribution 
centred on a relative risk of 1.  The evidence from the trials could then be used to update this 
prior, and the small amount of evidence would probably mean that the prior would not be 
overwhelmed.  Another function of the prior could be to reduce the likelihood of observing 
large relative risk increases (or decreases), which would have the effect of contracting the 
confidence interval. 
 
An alternative way of handling this uncertainty is to follow the method used in the original 
analysis, and present different scenarios including and excluding the points of controversy.  
This allows decision makers to separate areas of modelling uncertainty from areas of 
evidence uncertainty.  In this example, both models for the stroke subgroup supported the 
use of ASA-MR-dipyridamole as the optimal treatment strategy.  Conversely, the two alternate 
models for the PAD subgroup gave conflicting results for a cost-effectiveness threshold of 
£30,000 per QALY, illustrating that if it were correct to include treatment effects on non-
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vascular mortality, a decision based on a model excluding them could be wrong.  On the other 
hand, if antiplatelets do not have a differential effect on non-vascular deaths, the inclusion of 
trial data with respect to treatment effects would be incorrect.  Their inclusion would 
unnecessarily inflate the uncertainty around the optimal strategy, and potentially change the 
optimal strategy.  The parameter EVPI around the relative risk of non-vascular death 
suggests that further research would be valuable to reduce the uncertainty around this 
parameter.  However, the use of only the trial data, and the failure to make use of other data 
sources available at the time, namely prior beliefs based on a range of evidence and 
experience, means that the model that includes treatment effects of non-vascular death 
probably overestimates the decision and parameter uncertainty.  Presenting the two models 
separately places a burden on the decision maker to incorporate their prior beliefs on the 
validity of the two structures, in order to make their decision based on a weighted average of 
the two results.  Thus presenting alternative scenarios reduces the transparency of the 
decision-making process, as opposed to the use of Bayesian methods to incorporate prior 
beliefs explicitly so that they are open to scrutiny. 
 
The relative risks of OVEs in figures 4.7 to 4.10 are based on the comparisons of clopidogrel 
to aspirin, ASA-MR-dipyridamole to clopidogrel, and MR-dipyridamole to clopidogrel.  The 
relative risks were incorporated in this manner because it had been necessary to make an 
indirect comparison between clopidogrel and dipyridamole.  To calculate a relative risk from 
an adjusted indirect comparison, one can use the following formulae: 
 
 RRBC = RRBA – RRCA; SE(RRBC)=√(SE(RRBA)2+SE(RRCA)2) 
 
Where RRBC is the (log) relative risk of treatment B compared to treatment C, and SE is the 
standard error.[13] Thus it was possible to calculate the relative risk of dipyridamole compared 
to clopidogrel, where treatment B is represented by ASA-MR-dipyridamole or MR-
dipyridamole, treatment C by clopidogrel and treatment A by aspirin.  By first calculating this 
indirect comparison, and then incorporating it into the model so that the relative risk of 
dipyridamole compared to aspirin was calculated via the relative risk of clopidogrel compared 
to aspirin, the treatment effects of each agent are correlated.  However, the use of an indirect 
comparison increases the uncertainty around the relevant treatment effects, compared to a 
direct comparison of the same treatments.  When incorporated in the manner of this model, 
the inflation of variance occurs around the treatment effects of ASA-MR-dipyridamole and 
MR-dipyridamole.  By incorporating the extra uncertainty caused by the indirect comparison in 
an uneven way, the model may overestimate the decision uncertainty around the optimal 
treatment strategy of ASA-MR-dipyridamole for the stroke subgroup.  More sophisticated 
modelling techniques involving the use of the variance-covariance matrix can be used to 
‘spread’ the increase in uncertainty due to the indirect comparison evenly across each 
treatment strategy.  Nevertheless, the uncertainty around the relevant treatment strategies 
could be reduced by a direct comparison of all agents. 
 
Finally, we return to the issue of treatment duration.  The use of a 2-year treatment strategy 
merely reflected the length of the included RCTs, and in practice patients prescribed 
clopidogrel or dipyridamole often continue on those treatments for longer than 2 years.  The 
lack of trial evidence on the long-term effects of these drugs does not prevent the modelling of 
longer treatment duration, and an analysis of lifetime treatment was presented by assuming 
that the treatment effect remained constant while the patient was on therapy.  This was 
presented as a separate analysis, allowing decision-makers to separate out areas of 
modelling uncertainty, but in fact lifetime treatment duration represents a relevant alternative 
strategy to 2-year treatment duration, and they need to be compared simultaneously in the 
model.  This is because the decision uncertainty about 2-year treatment strategies compared 
to lifetime treatment strategies cannot be informed by the separate models evaluating subsets 
of the full range of strategies.  The inclusion of more treatment strategies would likely 
increase the decision EVPI; also uncertainty in the treatment effects would be extrapolated 
further through the model for longer treatment durations, which would likely increase the value 
of acquiring more information on those effects.  The current model does not characterise the 
uncertainty around the optimal treatment duration, and therefore cannot inform about the 
value of acquiring information on the longer-term effects of clopidogrel and dipyridamole.  
Again, the decision over what treatment duration to model can be augmented by evidence 
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and experience outside of RCTs, which are typically not designed to ascertain the optimal 
duration. 
 
4.3.5 Summary 
 
At a cost-effectiveness threshold of £30,000 per QALY gained, it seems likely that EVPI will 
exceed the cost of further research.  For an estimated 5-year lifetime of the technology, the 
EVPI in each subgroup is in the range £66mn to £495mn.  Individual parameter EVPI reveals 
that a large proportion of this value is accounted for by the individual treatment effects on 
vascular mortality, and would seem that further investigation into the effects of clopidogrel, 
MR-dipyridamole and ASA-MR-dipyridamole on vascular death would be cost-effective, in 
particular a direct comparison of each agent in this area.  The VOI around the other individual 
model parameters is small or zero, but this does not mean that they may not have significant 
VOI in combination.  The results of further research into the effects of each agent on vascular 
mortality will almost certainly provide more evidence of the treatment effects on NVD, but 
would be unlikely to provide conclusive evidence as to whether they are related events that 
need to be included in the model.  The decision over which events are related to the 
treatments under consideration is a matter of judgement, which will be in part informed by trial 
evidence.  Simply to include any event recorded in the trial without considering whether it is 
related to the treatments in question will inflate the uncertainty in the model.  Where there is 
uncertainty over whether particular events should be fully excluded prior to analysis, by 
omitting them from the decision model, the event and the uncertainty over its relevance or 
existence can be explicitly included in the model with the use of Bayesian methods.  Finally, 
the research recommendations based on this model are confined to the 2-year analyses, and 
ignore uncertainty around the longer-term effects of clopidogrel and dipyridamole.  If the 
model had compared alternative treatment durations directly, the VOI around the treatment 
effects may have increased further, and the model could have informed about the most cost-
effective treatment duration, rather than basing that decision on the effect-driven and budget-
limited RCTs.
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Appendix: Clopidogrel and modified-release dipyridamole in the secondary prevention 
of occlusive vascular events. 
 
 
Element of health 
technology 
assessment 
Reference case Criteria met by assessment? Comment 
Defining the decision 
problem 
The scope developed 
by the Institute 
Yes  
Comparator Alternative therapies 
routinely used in the 
NHS  
Yes  
Perspective on costs NHS and PSS Yes  
Perspective on 
outcomes 
All health effects on 
individuals 
Yes  
Type of economic 
evaluation 
Cost-effectiveness 
analysis 
Yes  
Synthesis of evidence 
on outcomes 
Based on a systematic 
review 
Yes  
Measure of health 
benefits 
Quality adjusted life 
years (QALYs) 
Yes  
Description of health 
states for calculation of 
QALYs 
Health states described 
using a standardised 
and validated generic 
instrument 
Yes 
Method of preference 
elicitation for health 
state valuation 
Choice-based method, 
for example, time trade-
off, standard gamble 
(not rating scale) 
N/a 
Source of preference 
data 
Representative sample 
of the public 
N/a 
Health state preference values were taken 
from published sources, all of which used 
the EQ-5D to elicit public-based 
preferences from the relevant patient 
group in the UK. 
Discount rate An annual rate of 3.5% 
on both costs and 
health effects 
No The discount rates of 6% per annum for 
costs and 1.5% per annum for health 
outcomes recommended at the time of the 
NICE assessment were used. 
Equity position An additional QALY has 
the same weight, 
regardless of the other 
characteristics of the 
individuals receiving the 
health benefit 
Yes  
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5. The cost-effectiveness and value of information associated with 
treatment for influenza in otherwise healthy adults 
 
5.1 Background 
 
5.1.1 .Condition and technology 
 
Of the three main influenza virus strains (A, B and C), only types A and B are known to cause 
significant morbidity in humans. Influenza A occurs more frequently and is more virulent than 
influenza B; there have been significant outbreaks of influenza A in England and Wales in 
nine of the 11 years from 1990 to 2000. There are several subtypes of influenza A, of which 
H3N2 and H1N1 have co-circulated in humans since 1978. Outbreaks of influenza B have 
occurred in England and Wales four times in the 11 years from 1990 to 2000. There have 
been outbreaks of both influenza A and B in two of these years. Since 1990, about 74% of 
influenza has been caused by the influenza A virus, but this has varied from 20% to 97% from 
season to season.  
 
Influenza epidemics of varying intensity occur most winters. The condition is usually self-
limiting in people who are relatively healthy, with typical symptoms such as headache, fever, 
sore throat, cough and aching muscles and joints lasting several days. However, more 
severe, predominantly respiratory complications such as pneumonia and bronchitis, are the 
source of substantial morbidity and increased mortality associated with influenza epidemics. 
In England and Wales, an estimated 6,200 to 29,600 people died during each of the 
epidemics between 1975-76 and 1989-90[3]; about ten times the actual number of death 
certifications for influenza, suggesting that influenza is responsible for many hidden deaths. 
 
5.1.2 Technology Assessment Review 
 
The principal component of public health strategies aimed at controlling the burden of 
influenza is vaccination. In the UK NHS vaccination is offered to ‘high-risk’ groups with uptake 
levels running at 69% in 2002/3[ i ]. Two adamantanes (amantadine (Lysovir®) and 
rimantadine (Flumadine®)) have been produced since the mid-1960’s for both treatment and 
prevention although the latter does not have a UK license and clinical uptake of the former 
has been limited due to concerns over adverse events, resistance and its limited spectrum of 
activity (adamantanes operate only against the replication of influenza A).  
 
Neuraminidase inhibitors are a relatively new class of antiviral drugs that provide additional 
potential strategies for the control of influenza. Zanamivir (Relenza®) for the treatment of 
influenza is administered by means of a diskhaler® and was the subject of one of the first 
technology appraisals undertaken by the National Institute for Clinical Excellence (NICE)[ii], in 
the UK. Guidance issued in 2000 recommended NHS use should be limited to ‘high-risk’ 
groups [ iii ]. The launch of oseltamivir (Tamiflu®), taken orally and licensed for both 
prophylaxis and treatment, prompted further review of that guidance.  
 
5.1.3 NICE guidance 
 
In February 2003, NICE issued guidance on the use of zanamivir, oseltamivir and amantadine 
for the treatment of influenzaiv. The guidance pertains only to periods when it is known that 
influenza A or B is circulating, via surveillance schemes such as those operated by the Royal 
College of General Practitioners and the Public health Laboratory Service. It does not cover 
periods of pandemic influenza, impending pandemic or widespread epidemic of a new 
influenza strain.   
 
In relation to otherwise healthy adults, neither zanamivir, oseltamivir or amantadine were 
recommended for the treatment of influenza.  
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5.1.4 Research recommendations 
 
The recommendations for further research, issued as part of the NICE guidance in relation to 
otherwise healthy adults were that: 
? More needs to be known about the quality-of-life measurement of people with 
influenza. 
? A systematic evaluation of the feasibility of near-patient testing for influenza and the 
type of influenza is strongly recommended. 
? Modelling to include epidemiological and health-economic aspects of the treatment 
and prophylaxis of influenza would aid future considerations of the cost effectiveness 
of the anti-influenza drugs. 
? Monitoring the development of viral resistance to oseltamivir and zanamivir would be 
valuable. 
? The systematic collection of more information on hospitalisation rates and the 
frequency of complications for children with influenza would be highly desirable. 
? Any randomised trial of oseltamivir or zanamivir should include an amantadine arm as 
well as a placebo arm.  
 
5.1.5 Additions to the appraisal report 
 
The work presented here discusses only the cost-effectiveness of otherwise healthy adults. 
Neither those considered to be at elevated risk of influenza complications either due to age 
(over 65 years) or concommittant disease, or children are considered in this chapter.  
 
QALY estimates associated with influenza morbidity were based on three trials of oseltamivir 
in the original appraisal report v  (WV15670, WV15671 and WV15730) comprising over 
approximately 600 patients in total. Data from one additional trial have been made available 
since that time. M76001 comprises in excess of 300 placebo and 600 oseltamivir patients and 
have been incorporated here. The mean difference in Quality Adjusted Life Days (QALDs) 
between placebo and oseltamivir patients in the original three trials was 0.56. That difference 
decreases to 0.37 with the inclusion of M76001. This is a key driver in the cost-effectiveness 
estimates and therefore the results presented here differ significantly from those presented in 
the original TAR. 
 
5.2 Methods 
 
5.2.1 Description of the model  
 
A decision tree model was developed to assess cost-effectiveness of competing influenza 
treatments in terms of additional cost to the UK NHS per additional Quality Adjusted Life Year 
(QALY) gained and the principal features of this model are described in figure 5.1.  
 
The decision model is described in four separate stages. The decision problem for the UK 
National Health Service (NHS) is described at stage one, namely which of four alternative 
influenza treatment strategies should be adopted; amantadine (100mg daily); zanamivir 
(10mg twice daily); oseltamivir (75mg daily); or no drug treatment. Each treatment course 
lasts five days. The decision is relevant to a patient population that consists of those with 
influenza like illness who decide whether to consult with a GP (stage 2). This distinction is 
included in the model due to the likelihood that the proportion of individuals that consult will be 
dependent on the decision taken at stage 1, that is, more individuals will consult the GP if an 
effective drug is available. However, variations in the value of this parameter between the 
competing treatment strategies are only included in sensitivity analyses due to data 
limitations. It should be noted that the importance of this issue was identified by one-way 
sensitivity analysis in the original appraisal reportv and was cited as one of the reasons for 
rejection of oseltamivir in this patient groupiv.   
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Figure 5.1: Model Schematic 
 
It is assumed that treatment with any antiviral must be made within 48hours of symptom onset 
but the model allows for individuals to receive (ineffective) treatment after that time period 
since symptom onset may be insidious and difficult to accurately recall (stage 3). Prescription 
of antibiotics is often made at this initial GP consultation. Disease progression is described at 
stage 4. The first distinction made here is between those individuals that have genuine 
influenza rather than clinically indistinguishable conditions such as bacterial infections or 
other viruses (for example, respiratory syncytial virus [RSV]). Influenza may be either strain A 
or B and the distinction is important since amantadine is effective only for the treatment of 
influenza A. True influenza cases may experience complications which require a revisit to the 
GP and which may become more serious. The base case analysis includes only one serious 
influenza complication (pneumonia) since existing data were of limited value for a UK context 
in relation to both hospitalisations and mortality. This is unsurprising given that such 
complications are relatively rare and clinical trials are not powered to detect such differences. 
Several previous studies have extrapolated from intermediate datavi,vii. Results presented 
here do not include any such extrapolation.  
 
5.2.2 The evidence 
 
Parameter values are recorded in Tables 5.1 and 5.2. Data are primarily drawn from meta-
analysis of randomised controlled trial (RCT) data but where no such sources were available, 
or were considered either inappropriate or insufficient, they were supplemented or replaced 
with alternative data, often from multiple sources [v].  
 
The duration of symptoms for influenza positive persons receiving either no treatment or 
ineffective treatment (antiviral after 48 hours of symptom onset, amantadine for influenza B) 
was drawn from pooled analysis of patients receiving placebo in trials of both oseltamivir and 
zanamivir [v]. For both oseltamivir and zanamivir the mean reduction in symptom days was 
based on meta-analysis of trial data [v]. Meta analysis of trial data for amantadine was based 
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on the more limited outcome measure of duration of fever. Therefore, a meta-regression was 
constructed from oseltamivir RCTs which allowed the relationship between symptom and 
fever duration to be estimated [v] which was then applied to the observed mean reduction in 
fever from RCTs of amantadine at a dose of 100mg [viii]. 
 
Quality Adjusted Life Days (QALDs) were estimated to reflect the expected duration and 
severity of influenza illness for each of the four treatment strategies4 .  Four RCTs of 
oseltamivir versus placebo included patients’ own reports of quality of life (WV15670[ ix], 
WV15671[x], WV 15730[xi ], M76001[xii ]) over a period of 21 days. The incorporation of 
uncertainty inherent in both quality of life data and length of illness is an important component 
of the model and an alternative specification is explored as an additional structural sensitivity 
analysis. 
 
Other health related quality of life considerations included in the model were pneumonia [xiii], 
adverse events associated with amantadine (by assumption) and, in sensitivity analysis only, 
avoided deaths [xiv]. 
 
Cost data, also shown in table 1 and expressed in 2001 prices, were drawn predominantly 
from UK published sources [xv,xvi,xviixviii ]. All drug costs were inflated to include pharmacy 
prescribing fees and container allowances [xix].  
 
Data from the Royal College of General Practitioners’ (RCGP) network of sentinel practices 
was used to estimate the probability that ILI is influenza[xx] and the strain of influenza[xxi].  The 
probability that an individual will consult the GP is derived from estimates of the number of 
excess GP consultations in the UK [xxii,xxiii], the size of the UK population [xxiv] and the attack 
rate [v]. The probability of attending within 48 hours of symptom onset [xxv] was adjusted by 
the probability of rapid onset of symptoms based on random effects meta-analysis of 
published studies [v] to estimate the proportion of individuals that truly consult the GP within 
the time frame required in order to benefit from any antiviral treatment. Evidence exists that 
some patients receive antibiotics at this initial GP consultation [xxiii] but it was assumed that 
this would substantially reduce where antivirals were prescribed. RCGP data were used to 
estimate the proportion of patients that develop influenza complications requiring a repeat GP 
consultation [xxvi,xxvii] and this figure was adjusted by the relative risk of antibiotic use in 
several RCTs of zanamivir and oseltamivir [v]. This measure was considered the most realistic 
proxy measure for repeat GP consultations in NHS practice available from RCTs since repeat 
consultations themselves were often part of the study protocol. Similar meta-analysis of RCT 
data was used in relation to reduced incidence of pneumonia for the two neuraminidase 
inhibitors. No evidence of reductions in complications of any type was identified for 
amantadine. This chapter does not include models which extrapolate from intermediate 
endpoints, such as antibiotic use or pneumonia rates, to either hospitalisations or mortality.  
 
All costs and benefits accrue over a single influenza season with the exception of health 
benefits associated with avoided deaths. A discount rate of 1.5% is applied to these benefits. 
 
5.2.3 Probabilistic analysis 
 
Probability distributions were assigned to model parameters as indicated in tables 1 and 2. 
Cost and outcome parameters were assigned normal or lognormal distributions with the 
exception of quality of life scores. Beta distributions were assigned to the QALY score for no 
treatment and oseltamivir (which in turn are use to derive QALYs for amantadine and 
zanamivir), although QALDs are reported for ease of interpretation.  A number of different 
distributions were applied to parameters which were used to derive probabilities in the model. 
Normal distributions of logged odds ratios and relative risks were assigned. Other parameters 
were variously beta or lognormal as appropriate. Monte Carlo simulation was used to reflect 
parameter uncertainty in the model via cost effectiveness acceptability curves (CEACs) and 
associated frontiersxxviii. 
 
                                                 
4 QALDs are reported here rather than QALYs for ease of interpretation. A QALY is simply 1/365 of a 
QALD. Cost utility ratios are reported in terms of cost per QALY. 
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Table 5.1: Cost and outcome parameter values and probability distributions. 
 
Parameter description Mean Value (95% Confidence Interval) Probability distribution Source 
            
Mean length of illness - no treatment 7.690 6.856 to 8.596 Lognormal [v] 
Mean reduction in length of illness - amantadine 1.320 (0.112 to 2.852)* Derived from other variables [v] 
Mean reduction in length of fever - amantadine 1.007 0.097 to 1.925 derived from other variables [viii] 
Mean reduction in length of illness - zanamivir 1.683 0.812 to 2.575 Normal [v] 
Mean reduction in length of illness - oseltamivir 1.919 0.939 to 2.918 Normal [v] 
            
QALDs - no treatment 15.132 12.297 to 17.967 Beta** 
WV15670[ix], WV15671[x], 
WV15730[xi], M76001[xii]  
QALDs - amantadine Tx 15.390      derived from other variables   
QALDs - zanamivir Tx 15.456      derived from other variables   
QALDs - oseltamivir Tx 15.502 12.788 to 18.215 Beta** 
WV15670[ix], WV15671[x], 
WV15730[xi], M76001[xii] 
            
QALD loss amantadine adverse events 0.95      None Assumption 
QALY loss from death 18.987      None [xiv] 
QALD loss pneumonia 6.348      None [xiii]  
            
Costs           
GP visit 21.38      None [xv] 
Antibiotic 4.05      None [xvi,xix] 
Amantadine 3.38      None [xvi,xix] 
Zanamivir 24.98      None [xvi,xix] 
Oseltamivir 19.16      None [xvi,xix] 
Hospitalisation 3503.03 2012 to 5743 Lognormal [xvii] 
*2.5th to 97.5th percentiles, ** Note that the Beta was applied to the QALY score although QALDs are reported for ease of interpretation.  
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Table 5.2: Probability parameter values and probability distributions 
 
Parameter description Mean Value (95% Confidence Interval) Probability distribution Source 
ILI is influenza 0.46 0.425 to 0.494 Normal on Log of odds [xxi] 
Influenza is influenza A 0.684 0.484 to 0.884 Beta [xxii] 
Consulting the GP 0.282 (0.145 to 0.533)*     
Annual excess GP consultations due to influenza  623,520 388779 to 858263 Lognormal [xxiii,xxiv] 
Size of UK population 33,743,500        [xxv] 
Attack rate 0.066 0.037 to 0.112 Normal on log of odds [v] 
Consulting GP within 48hours (conditional on 
consulting) 0.178 (0.150 to 0.212)*     
Consult on Day 1 0.109 0.088 to 0.135 Normal on log of odds [xxvi] 
Consult on day 2 0.093 0.073 to 0.117 Normal on log of odds [xxvi] 
Rapid onset of symptoms 0.511 0.305 to 0.714 Normal on log of odds [v] 
Receive drug if after 48 hours 0.028 (0.015 to 0.045)*     
dependent on same variables as previous parameter            
Receive drug if before 48 hours 0.952 0.829 to 1.075 Beta Assumption 
Antibiotic at first visit - no treatment strategy 0.42 0.417 to 0.423 Normal on Log of odds [xxiv] 
Antibiotic at first visit - antiviral strategies 0.048 0.000 to 0.171 Beta Assumption 
Complication requiring return GP visit - no 
treatment/amantadine 0.371 0.362 to 0.380 Normal on Log of odds [xxvi,xxvii] 
Relative risk of complication - zanamivir 0.741 0.575 to 0.954 Normal on log of relative risk [v] 
Relative risk of complication - oseltamivir 0.423 0.160 to 0.930 Normal on log of relative risk [v] 
Pneumonia - no treatment/amantadine 0.034 0.008 to 0.020 Normal on log of odds [v] 
Relative risk of pneumonia - zanamivir 0.35 0.112 to 1.094 Normal on log of relative risk [v] 
Relative risk of pneumonia - oseltamivir 0.15 0.060 to 0.720 Normal on log of relative risk [v] 
Antibiotic if complication develops 0.814 0.806 to 0.822 Normal on Log of odds   
* 2.5th to 97.5th percentiles
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5.2.4 Sensitivity analyses 
 
The sampled QALY values used in the base case model for all four strategies are reliant upon 
the observed values in four RCTs for oseltamivir versus placebo. Despite the fact that 
oseltamivir has demonstrated a significant reduction in the length of influenza illness (at 
customary levels of statistical significance) compared to placebo [xxix] the quality of life data 
are not as clear. In over 45% of sampled values from the beta probability distributions, the 
quality of life score for oseltamivir is lower than that for no treatment. Several reasons for this 
are possible. Firstly, the alleviation of symptoms was defined in trials of oseltamivir by the 
absence or mild experience of feverishness, headache, sore throat, cough, myalgia, fatigue, 
and congestion [v]. However, quality of life may depend on symptoms other than those 
measured, for example ‘high temperature’ is also included in some trials of zanamivir, and 
may be affected by mild symptoms or minor complications of influenza not otherwise 
accounted for. Secondly, oseltamivir is associated with adverse events such as 
gastrointestinal disorder and vomiting which, whilst mild, may contribute to the observed 
values and which are not accounted for separately in the model.   
 
Notwithstanding these concerns, an alternative specification of the model (structural 
sensitivity analysis 1) used data on symptom days to estimate QALDs and thereby reduce the 
uncertainty inherent in the model, using the following relationship: 
 ( )( )[ ]110101 /. iii DDQQQQ −+=  
 
Where Qi refers to the QALD score for the ith sample, Di the difference in length of illness 
between intervention and no treatment for the ith sample. Subscript 0 denotes the no 
treatment option whilst subscript 1 refers to the active intervention (amantadine, zanamivir or 
oseltamivir).  
 
Sensitivity analyses 2 explores the impact of potential increases in the propensity for 
individuals to consult the GP. For otherwise healthy adults at low risk of influenza 
complications, relatively few individuals would make such consultations given the absence of 
an effective intervention. However, the availability of neuraminidase inhibitors increases the 
expected benefits of a GP consultation and therefore the proportion of individuals that make 
such consultations. This is a potentially important parameter value for the cost-effectiveness 
model since these additional consultations increase costs by a much larger proportion than 
benefits (all individuals will generate additional GP costs whilst only a small proportion will 
have any capacity to benefit). A beta distribution was used to increase sample values for the 
baseline probability of presenting to the GP. This was based on an assumed mean increase 
of 10% (2.5th and 97.5th percentiles, 0.28 to 34.76) and was applied to the neuraminidase 
inhibitor treatment strategies. 
 
5.2.5 Value of information analysis 
 
The Monte Carlo simulation output was also used to estimate the expected value of perfect 
information per person for the model as a whole, for individual parameters and groups of 
parameters. Parameters are grouped together as five potential study types. “GP surveillance” 
includes eight probability parameters; ILI is influenza; influenza is strain A; present to the GP 
within 48 hours of symptom onset; receive treatment if presenting before 48 hours; receive 
treatment if presenting after 48 hours; receive antibiotic at first GP consultation (which differs 
by strategy). “QALY study” refers to the two QoL parameters for no treatment and oseltamivir. 
The three individual trial options include the relevant parameters on complications requiring 
repeat GP consultations, rates of pneumonia and, for amantadine, adverse event profile.  
 
Population EVPI figures are calculated by estimating the size of the population and the 
expected period over which any decision will remain relevant with values for future years. We 
estimate the number of influenza like illnesses in the otherwise healthy adult population as 4.1 
million per annum[xxxxxxi] and the relevant time period as 5, 10 and 15 years. Figures are 
discounted to present values at 6% per annum. 
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5.3 Results  
 
Table 5.3: Base case expected costs and benefits. 
Strategy Mean Cost Mean QALD 
Cost per QALY- compared 
to No treatment 
Cost per QALY 
(ICER) 
No Treatment £10.96 6.917 -  
Amantadine £11.06 6.920 £13,122 £13,122 
Zanamivir £12.24 6.925 £53,383 dominated 
Oseltamivir £11.85 6.927 £30,868 £37,795 
 
5.3.1 The adoption decision 
 
Table 5.3 presents the mean costs, benefits and cost-effectiveness ratios for an individual in 
the community with influenza like illness. Differences in benefits (QALDs) between strategies 
are relatively small since for each strategy only a small proportion of patients actually receive 
effective antiviral treatment (either they do not visit the GP at all, do so after 48 hours, do not 
have influenza, or do not receive antiviral treatment). The cost effectiveness ratios indicate 
that for each additional QALY generated by the amantadine strategy compared to no 
treatment, an additional cost of £13k is incurred. Both of the neuraminidase inhibitors are 
more effective and more costly than amantadine. Oseltamivir dominates zanamivir and 
generates additional QALYs at £31k compared to no treatment and £38k compared to the 
next most effective treatment that is not dominated (amantadine). 
 
The base case CEACs shown in figure 5.2 indicate that where the maximum acceptable 
incremental cost effectiveness ration (MAICER) exceeds £10k, the degree of uncertainty 
associated with the optimal strategy is substantial and this is particularly the case for the 
range across which amantadine is optimal. In fact, where λ lies between £25k and £35k 
amantadine is the least likely of all four strategies to be cost-effective, yet is the optimal 
strategy. Just 13% of simulations are cost-effective at λ=£30k.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Cost effectiveness acceptability curve and frontier – base case analysis 
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The restructuring of the model in sensitivity analysis 1 does not impact on the central 
estimates of cost per QALY but reduces the extent to which sampled QALD values for 
oseltamivir fall below those of no treatment. The resultant reduction in uncertainty for all four 
strategies translates into the cost-effectiveness acceptability curve shown in figure 3. At a low 
λ level, no treatment remains the strategy most likely to be cost-effective and amantadine 
forms part of the cost-effectiveness acceptability frontier between λ values of approximately 
£14k and £38k at higher levels of probability than in the base case. Across this range, the 
probability that amantadine is cost-effective exceeds 0.5. At higher λ values, oseltamivir is the 
strategy most likely to be cost effective with a probability that peaks at approximately 0.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Cost effectiveness acceptability curve and frontier - structural sensitivity 
analysis 1. 
 
The cost effectiveness results associated with sensitivity analysis two are shown in table 5.4 
and demonstrate the sensitivity of the results to changes in the probability of consulting the 
GP. For oseltamivir, the ICER is in excess of £70,000 in this scenario.  
 
Table 5.4: Sensitivity analysis 2 - Cost and benefits  
Strategy Mean Cost Mean QALD 
Cost per QALY- 
compared to no treatment 
Cost per 
QALY (ICER)
No Treatment £10.71 6.917 -  
Amantadine £10.81 6.920 £12,259 £12,259 
Zanamivir £12.71 6.926 £79,946 dominated 
Oseltamivir £12.29 6.928 £54,303 £71,112 
 
5.3.2 Research recommendations 
 
EVPI for base case analysis 
Figure 5.4 plots the global EVPI per person as a function of λ between £0 - £100,000 for the 
base case analysis for 5yr, 10yr and 15yr lifespans of the technologies. EVPI is equal to 
£38m, £66m and £88m respectively where λ is £30,000 and these values continue to rise as λ 
increases. Table 5.5 summarises all EVPI results. 
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Figure 5.4: Global EVPI – Base case analysis. 
 
EVPI for individual parameters are shown in figure 5.5. The analysis was run on all 
parameters but only those that generate substantial value at some threshold value (between 
£0 and £100k) are displayed. The EVPI values for two parameters in particular dwarf all 
others. The uncertainty surrounding the quality of life scores for both oseltamivir and no 
treatment, which in turn are used to calculate scores for amantadine and zanamivir, continue 
to rise as λ increases. At a willingness to pay of £30k per QALY, the EVPI per person for the 
quality of life scores for oseltamivir and no treatment are £0.94 and £0.92 respectively, which 
equates to a population value of approximately £30m assuming a 10 yr lifetime 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Partial EVPI for individual parameters (Lifespan 10yrs, Threshold £30,000) 
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Table 5.5: Population EVPI (Threshold £30,000) 
 
 Base Case Sensitivity 1 Sensitivity 2 
 5yrs 10yr 15yrs 5yrs 10yr 15yrs 5yrs 10yr 15yrs 
         
Global 38,173,610 66,699,153 88,015,097 1,737,868 3,036,504 4,006,922 39,198,817 68,490,454 90,378,869 
          
Partial Parameters           
Prob ILI is influenza 0 0 0    0 0 0 
Prob influenza A  1,099 1,919 2,533    0 0 0 
Prob consult GP <48hrs  0 0 0    0 0 0 
Prob drug if after 48hrs 0 0 0    0 0 0 
Prob complication – no treatment 0 0 0    0 0 0 
Prob complication - amantadine 0 0 0    0 0 0 
RR comp - oseltamivir  0 0 0    0 0 0 
RR ad event – amantadine 0 0 0    572 999 1,316 
Prob pneumonia – no treatment 0 0 0    0 0 0 
Prob pneumonia - amantadine 0 0 0    0 0 0 
RR pneumonia – oseltamivir 0 0 0    0 0 0 
Reduction in fever -  amantadine 82,742 144,575 190,776 464,708 811,963 1,071,454    
Reduction in length of illness - zanamivir 0 0 0 0 0 0    
Reduction in length of illness - oseltamivir 242,574 423,840 559,291 963,479 1,683,446 2,221,447    
QALDs - no treatment 16,932,882 29,586,115 39,041,346 0 0 0    
QALDs - oseltamivir  17,420,460 30,438,042 40,165,536       
Prob consult GP (NIs available)  NA NA NA NA NA NA 2,720,431 4,753,295 6,272,368 
          
Groups of parameters          
GP surveillance 0 0 0       
QALY study 25,328,373 44,255,206 58,398,435       
Oselatmivir RCT 245,168 428,372 565,273       
Zanamivir RCT 0 0 0       
Amantadine RCT 132,399 231,334 278,247       
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A number of combinations of groups of parameters, corresponding to different potential study 
designs, were also examined (reported in table 5.5). Any study including utility measurement 
has the greatest impact but it also interesting to note that the expected value to be gained 
from additional RCTs of any of the three drugs is likely to be negligible unless quality of life 
measurement is included as part of the trial. 
 
5.3.3 EVPI for structural sensitivity analysis 1. 
 
The analysis was repeated for structural sensitivity analysis 1, described above. The 
correlation between quality of life and symptom days used in this specification reduces the 
degree of uncertainty in the model, as shown in figure 5.3, and inevitably this results in a 
lower global EVPI. Figure 5.6 shows that this figure falls substantially from £66m in the base 
case analysis to £3m assuming a lifetime of 10yrs and a threshold of £30,000. EVPI is not 
simply an increasing function of λ in this scenario since the dominant effect of uncertainty in 
the quality of life values is not present.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 6: Global EVPI per person – structural sensitivity analysis 1. 
 
The EVPI for four separate parameters, which differ in their impact on this specification of the 
model compared to the base case, was calculated and results are shown in figure 5.7. 
 
5.3.4 EVPI for structural sensitivity analysis 2. 
 
Additional value of information analyses were run using the specification of the model 
described as sensitivity analysis 2, above. Since QALY scores entered in a similar fashion to 
the base case, these effects continue to dominate and are not shown again separately. Table 
5.5 does highlight the value of information associated with the key parameter that differs in 
this specification from the base case – the increase in the probability that individuals consult 
the GP when they have ILI if neuraminidase inhibitors are available. Where the lifetime of the 
technology is assumed to be 10yrs this value is approximately £5m assuming a threshold 
value of £30,000. 
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Figure 5.7: Partial EVPI per person – structural sensitivity analysis 1. (Lifetime 10yrs, 
threshold £30,000) 
 
5.4 Discussion  
 
The base case model is associated with substantial uncertainty which is driven predominantly 
by the values associated with the QoL for influenza. EVI analysis supports the research 
recommendations made alongside NICE guidance, that quality of life measurement of people 
with influenza should be a research priority. Furthermore, the analysis indicates the 
importance of identifying the quality of life impacts of drugs which potentially make relatively 
small differences over a period of a few weeks. Days of illness with influenza are not 
homogenous either on or off treatment. 
 
The analysis also indicates that additional research on parameters that influence the cost 
effectiveness of amantadine (although this also determines the ICER for other interventions) 
may be valuable, specifically length of illness, the rate of adverse events and the probability 
that influenza is influenza A. Other parameters of potential importance are the risk of 
complications requiring a repeat GP consultation and the risk of pneumonia for oseltamivir, 
although these are in tun highly dependent on the threshold value of a QALY. At £30,000 the 
EVPI for these parameters is negligible. Maximum values are achieved around the mean 
ICER for oseltamivir of £38,000. 
 
The specification of the model is itself subject to uncertainty that is not reflected in analysis of 
the base case. Uncertainty reflected in both CEAcc and EVI analysis is limited to that which is 
defined by parameter probability distributions. Several alternative specifications of the model 
are presented as sensitivity analyses but the evidence base on which these specifications are 
based and/or the assumptions they entail are not considered sufficiently robust for 
incorporation in the base case. 
 
Firstly, it is feasible that influenza treatments reduce the likelihood of severe complications 
leading to hospitalisations or mortality and the inclusion of such effects, based on the proxy 
measure of pneumonia, substantially improves the cost-effectiveness ratios for both 
neuraminidase inhibitors (not reported here). 
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Secondly, the uncertainty in the base case model is driven substantially by quality of life data 
for oseltamivir and no treatment. An alternative specification that reduces the level of 
uncertainty is presented which generates quality of life scores for each of the drug 
interventions as a function of length of illness. However, it must be recognised that this 
apparent reduction in uncertainty is achieved only at the expense of over-simplification of the 
determinants of quality of life in this scenario, that is, only the impact of duration of a narrow 
set of symptoms are relevant.  
 
Thirdly, the potential impact of increasing GP consultations is explored both in terms of cost-
effectiveness and EVI. This analysis in particular is included to illustrate the sensitivity of both 
central estimates of cost-effectiveness and uncertainty analysis rather than directly inform 
decision makers, since the parameter values are somewhat arbitrary. The findings are 
important however in highlighting the potential value of additional research, particularly since 
such research could be relatively low cost to undertake. 
 
Finally, in this analysis it has been assumed that additional information on particular 
parameters generates value only through the reduction in decision uncertainty relating to the 
treatment of influenza in otherwise healthy adults. These drugs have prophylactic uses, both 
seasonal and post-exposure, and are also available for other patient groups (at-risk adults 
and, in the case of oseltamivir, children). Assessment of cost-effectiveness in these scenarios 
draws on several parameters reported here [v] and therefore the EVPI figures potentially 
underestimate the true value of eliminating uncertainty. One of the future challenges for value 
of information methods is to incorporate these additional considerations.  
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6. Liquid-based cytology for cervical screening  
 
6.1 Background 
 
6.1.1 Background to disease/condition 
 
Cervical cancer is the 3rd most common form of cancer amongst women, with an incidence 
rate of around 9.3 per 100,000, and a mortality rate of around 3.7 per 100,000 per annum. 
The NHS introduced its Cancer Screening Programme in 1988, since which time the 
incidence of and mortality resulting from cervical cancer have decreased by 40%. The 
coverage of the screening programme has increased steadily since its introduction, and in 
2002/3, 3.7 million women were screened; the majority of these women attended after an 
invitation from the screening programme.1 
 
The main risk factors for cervical cancer include age and the presence of the human 
papillomavirus (HPV), a sexually-transmitted disease. Cervical cancer is uncommon in 
women under 25 and over 64, and hence women outside these age bounds are only 
screened in exceptional circumstances. Under current guidelines, women in England and 
Wales begin screening at the age of 25, and are screened either every three or five years, up 
to the age of 64. Screening interval policies vary between health authorities, though it is now 
becoming increasingly common for women up to the age of 50 to be screened every three 
years, and every five years thereafter, up to the age of 64. Beyond this age, women are 
discharged from the screening programme unless their most recent test result shows an 
abnormality that warrants follow-up. The progression of cervical cancer is particularly slow, 
taking up to ten years to develop through several pre-invasive stages to full invasive cancer. 
 
Until recently, the most widely used technology for carrying out cervical screening has been 
the Pap smear, which is a quick method of gathering cells from the cervix for further 
examination. This method has a tendency to produce smears which are “inadequate”, that is 
there are insufficient cervical cells to facilitate a full examination, or the sample is 
contaminated with blood or mucus and so cannot be analysed adequately. The most recent 
data suggests that around 9% of all smears taken are found to be inadequate.2 This has cost 
implications for the screening programme because it means a large number of women have 
to be re-screened until an adequate smear is obtained. 
 
Liquid-based cytology (LBC) is a novel method of providing cervical cell samples for 
examination, which has recently been piloted and is intended to become the primary method 
of cervical screening. Its major advantage over the conventional Pap smear is that it reduces 
the proportion of tests which are inadequate from 9% to around 2%, by improving the ability to 
examine poorly taken samples. Samples are collected using a brush-like device rather than a 
spatula (which is used in Pap screening), the cells from which are then suspended in 
preservative fluid. Once in the cytology laboratory, any blood or other debris is removed from 
the suspension before a layer of the cells are deposited onto a slide for examination. LBC has 
also been found to improve the sensitivity and specificity of  cervical screening, and the fact 
that the cells are held in a preservative fluid has the added advantage that further tests can 
be carried out at a later date, for example, testing for the presence of HPV. 
 
6.1.2 Technology Assessment Review 
 
In 1999 the NCCHTA commissioned the School of Health and Related Research (ScHARR) 
at the University of Sheffield to carry out a rapid and systematic review of  the effectiveness 
and cost effectiveness of LBC for cervical screening compared with conventional smear 
testing.3 The review and modelling considered three treatment strategies: no screening, 
conventional Pap screening and LBC screening. For the latter two policies, a number of 
scenarios were modelled to assess the impact of different screening intervals on the results. 
Full probabilistic sensitivity analysis was undertaken to examine the uncertainty in model 
parameters.  
 
Following the submission of the original assessment, NICE did not recommend the use of 
LBC due to uncertainty surrounding its cost-effectiveness. The assessment was updated in 
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20034 to incorporate data from a series of LBC pilot studies and from literature published 
during the interim period. This review included updated analyses of the effectiveness and 
cost-effectiveness of LBC compared to Pap testing.  
 
6.1.3 Current NICE guidance 
 
NICE published guidance on the use of liquid-based cytology for cervical screening in 2003,1  
in which two key recommendations were made: 
 
1. LBC should be used as the primary means of processing samples in the cervical  
screening programme in England and Wales 
2. The NHS Cancer Screening Programme and Cervical Screening Wales may consider 
evaluating further the different LBC products available 
 
It is anticipated that the roll-out of LBC across England and Wales will take some time due to 
substantial implications in terms of staff training. The second recommendation relates to the 
decision as to which LBC product is preferable, which is yet to be made. The guidance is due 
to be reviewed again in August 2006. 
 
6.1.4 Research recommendations  
 
A number of recommendations have been made for further research into the use of LBC in 
cervical screening, from the NICE Guidance1 and the recent update of the HTA monograph.4 
The NICE guidance highlighted four main areas for further research: - 
 
1. Commissioning of high-quality studies to examine differences in performance 
between existing LBC products; 
2. Validation of the number of cells required per sample which are required to establish 
the adequacy of smears; 
3. Further reviews of LBC, clinical data relating to the sensitivity, specificity and rate of 
inadequate smears should be provided for EasyPrep, Cytoscreen and any future 
devices; 
4. Further evaluation of automated technologies for the analysis of cervical samples. 
 
The analysis conducted in the 2003 updated assessment4 provided a greater degree of 
certainty concerning the potential cost-effectiveness of LBC when compared to conventional 
Pap screening. It proposed that, although the modelling results had provided strong evidence 
that LBC is an economically attractive screening method, a full cost-effectiveness study of 
LBC based on a trial of its introduction in a low-prevalence population would provide more 
definitive answers. However, undertaking such a study would not be justifiable, given the 
large expenditure involved. Further research was recommended in the area of utility 
assessment, with a particular focus on the short-term impact of false-positive screening 
results. 
 
This EVPI assessment considers both the results of the original NICE assessment3 and the 
updated NICE assessment4 following the completion of the LBC pilot.5 The analysis 
presented here also incorporates the corresponding results obtained through an update of the 
previous models, to assess the impact of the use of the Reference Case6 discount rates and 
measurement of health benefits. 
 
6.2. Methods 
 
The LBC model was produced with the aim of assessing the impact of introducing LBC 
compared to conventional Pap screening, with outcomes focused on the incidence of cervical 
cancer, the associated mortality, and the cost-effectiveness. A cohort of 100,000 women aged 
18 was used, whose progression up to the age of 95 was simulated. The model measures 
health outcomes, resource utilisation and costs for the whole cohort. Life tables are used 
within the model the represent the risk of age-specific all-cause mortality. 
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The model uses the state transition methodology to simulate the natural history of cervical 
cancer, upon which the impact of screening is superimposed. The model uses a six-monthly 
cycle length using progression data from Sherlaw-Johnson et al.7 A constant cancer 
incidence rate is assumed between ages 18 and 64 years. No further incident cases are 
assumed to occur beyond the age of 64. 
 
The model uses five health states to reflect the progression of the disease from the initial pre-
invasive stages through to invasive cancer. The pre-invasive stage of the disease, which is 
known as cervical intraepithelial neoplasia (CIN) was classified into three states: CIN 1, CIN 2 
and CIN 3. The model assumes that regression from CIN to the disease-free state may only 
occur from CIN 1, and that the disease progresses through each pre-invasive stage in the 
absence of any screening / treatment intervention. The incidence of the disease was 
assumed to be the onset of CIN 1. 
 
The model assessed the impact of three screening policies: LBC, Pap smears, and no 
screening policy. Screening is assumed to taken up by 85% of the cohort, and women are 
assumed to either attend screening at regular intervals, or not at all.  Costs within the model 
concern the screening, diagnosis and treatment of patients, using unit costs of each smear 
test, LBC test, colposcopy (a more detailed examination of the cervix) and treatment of both 
pre-invasive disease and invasive cancer. Marginal costs of LBC over Pap screening were 
estimated using the associated increases in the costs of consumables and the capital cost of 
equipment.  
 
The model produces the following outcomes: 
 
? Health benefits of LBC versus the Pap screening and no screening policies, including 
number of cancers avoided, life years gained, quality adjusted life years gained; 
? Resource use, measured by the number of smears and colposcopies required; 
? Health economic outcomes including cost per cancer avoided, cost per life-year 
gained and cost per quality adjusted life year gained.  
 
The ScHARR model uses around thirty parameters which relate to discount rates, 
probabilities of transiting between health states, effectiveness of treatment, specificy and 
sensitivity of the screening tests, utility associated with health states, cost parameters, and 
test result characteristics. 
 
Uncertainty in the model was characterised through assigning statistical distributions with 
unique characteristics to each model parameters. For simplicity, triangular distributions were 
assigned to reflect the uncertainty in each parameter, and multivariate Monte Carlo sensitivity 
analysis was undertaken. Expected value of perfect information (EVPI) analysis was 
performed to identify those areas in which future research is expected to yield the greatest 
value. A global EVPI estimate was derived from the model, together with  estimates of partial 
EVPI for individual parameters within the model.  
 
As previously mentioned, the original model was updated in 2003 to incorporate new data 
from recent literature and pilot studies of LBC. The earlier model included probabilistic 
sensitivity analysis and EVPI analysis; however, the 2003 model incorporated only limited 
sensitivity analysis. For the purposes of the analysis presented here, the 2003 model has 
been updated to include the capacity for EVPI analysis, thus enabling a direct comparison to 
be made between the two models in terms of the reduction in uncertainty resulting from the 
collection of additional information during the interim period. The 2003 model measured 
health benefits in terms of quality adjusted life-years (QALYs); this has since been updated to 
incorporate the ability to measure these as either life-years gained (LYG) or QALYs, to allow 
comparison with the original model and to reflect the reference case criteria.6 
 
Given the lack of evidence regarding quality of life associated with invasive cancer, a fixed 
utility value of 0.6 was used in the 2003 model. Owing to the inherent uncertainty surrounding 
this estimate, the uncertainty surrounding this parameter was described using a triangular 
distribution with minimum and maximum values of 0.5 and 0.7 respectively.  
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For the purposes of this pilot study, three separate (but sequential) EVPI analyses were 
undertaken using the aforementioned three models. The differences between these 3 models 
are described in Table 6.1. 
 
Table 6.1  Differences between the 3 LBC models  
Scenario Model used Discount rates used Health outcome New data used? 
1 Original (2000) Costs @ 6%,  
utilities @ 6% 
LYG No 
2 Update (2003) Costs @ 6%, 
utilities @ 6% 
LYG Yes 
3 Update (2003) Costs @ 3.5%,  
utilities @ 3.5% 
QALYs Yes 
 
The comparison between Scenarios 1 and 2 is envisaged as a means of quantifying the 
reduction in uncertainty due resulting from the additional data collected from the pilot studies.5 
Scenario 3 represents the current decision uncertainty, and is closely based upon NICE 
Reference Case.6  
 
The 1-level EVPI algorithm was used in all cases in carrying out the EVPI analysis, 
necessitating a strong degree of linearity between the model inputs and outputs. There is 
naturally some uncertainty in precisely how linear a model needs to be in order for the 1-level 
algorithm to be both appropriate and accurate. The linearity of the model was assessed using 
linear regression, with the net benefits (NBs) as the dependent variables and the input 
parameter values as the dependent variables. The regression analysis yielded an adjusted r2 
value of 0.91, suggesting a relatively strong degree linearity. Whilst this was considered 
sufficiently linear to allow the 1-level EVPI algorithm to be used, it is important to note that the 
absence of perfect linearity can affect the ability of the 1-level algorithm to derive accurate 
estimates. Multivariate Monte-Carlo sampling was used to generate 5,000 samples of the 
base-case results, with the net benefits of each screening intervention being the outputs in 
each case.  
 
The original model simulated a cohort of 100,000 women aged 18, with screening 
commencing at the age of 21; in the updated model, a cohort of 360,000 was used to more 
accurately reflect the current female population in England and Wales of this age and who are 
therefore eligible for screening.  
 
6.3 Results 
 
6.3.1 Adoption decisions 
 
Tables 6.2 - 6.4 present the central estimates of cost-effectiveness for Scenarios 1-3 
respectively. Table 6.2 shows the incremental cost-effectiveness results for Scenario 1. 
 
Table 6.2 Cost-effectiveness results for Scenario 1 
 
Screening Policy 
Marginal 
discounted 
life-days 
gained 
compared 
with no 
screening 
Incremental life-
days gained 
Average 
discounted 
lifetime cost 
per woman 
Incremental 
discounted 
lifetime 
cost 
Incremental cost 
per life-year 
gained 
No screening - - £2.95 - - 
Screening at 5 
years - Pap 49.09 49.09 £164.02 
£161.07 
£1,197 
LBC 49.61 0.51 £165.56 £1.53 £1,095 
Screening at 3 
years - Pap 50.65 1.04 £255.36 £89.80 £31,519 
LBC 50.98 0.33 £257.66 £2.30 £2,522 
 
Table 6.2 shows that the use of LBC as opposed to Pap testing increases both costs and 
health benefits. The incremental cost per LYG for LBC is £1,095 for LBC screening using a 5-
year screening interval, and £2,522 using a 3-year screening interval. In order to provide a 
78 A pilot study of value of information analysis 
direct comparison between the cost-effectiveness results of the original NICE assessment 
and those following the collrection of further information within the LBC pilot study,5 Scenario 
2 uses a discount rate of 6% for both costs and LYGs. Table 6.3 shows that the incremental 
cost per LYG for LBC is £12,718 over a 5-year screening interval and £44,280 using a 3-year 
screening interval. It is evident from these results that the re-estimation of the unit costs of 
LBC has a substantial impact upon the central estimates of cost-effectiveness for the LBC 
screening programmes. 
 
 
Table 6.3 Cost-effectiveness results for Scenario 2  
 
Screening Policy 
Marginal 
discounted life-
days gained 
compared with 
no screening 
Incremental 
life-days 
gained 
Average 
discounted 
lifetime cost 
per woman 
Incremental 
discounted 
lifetime 
cost 
Incremental 
cost per life-
year gained 
   No screening - - £3.15 - - 
Screening at 5 
years  - Pap 6.94 6.94 £60.97 
£57.82 
£3,040 
           - LBC 7.08 0.14 £65.86 £4.89 £12,718 
Screening at 3 
years - Pap 7.29 0.21 £92.89 £27.03 £47,409 
          - LBC 7.35 0.03 £100.56 £7.67 £44,280 
 
 
The Scenario 3 considers the impact of using Reference Case6 discount rates (3.5% for both 
costs and health benefits), and measured health benefits in terms of QALYs, as opposed to 
LYG. Table 6.4 summarises the results of the cost-effectiveness analysis.  
 
 
Table 6.4 Cost-effectiveness results for Scenario 3 
 
Screening Policy 
Marginal 
discounted 
quality-adjusted 
life-days gained 
compared with 
no screening 
Incremental 
quality-
adjusted life-
days gained 
Average 
discounted 
lifetime cost 
per woman 
Incremental 
discounted 
lifetime 
cost 
Incremental 
cost per 
QALY 
No screening - - £3.15 - - 
Screening at 5 
years - Pap 54.04 54.04 £60.97 
£57.82 
£390 
          - LBC 54.92 0.88 £65.86 £4.89 £2,033 
Screening at 3 
years - Pap D D D D D 
          - LBC 55.09 0.17 £10.06 £34.70 £73,388 
  D: Dominated 
 
It is clear that the inclusion of the reference case discount rates and the valuation of health 
outcomes as QALYs has a considerable impact upon the cost-effectiveness of these 
screening programmes. 
 
Figure 6.1 shows the cost-effectiveness acceptability curve (CEAC) for the analysis carried 
out in Scenario 3. This analysis discounted both costs and QALYs at 3.5%.  
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Figure 6.1 Scenario 3 - Cost-effectiveness acceptability curve 
 
Beyond a threshold of around £10,000, LBC is always the optimal screening strategy. The 
probability of LBC being cost-effective at a threshold of £30,000 is approximately 70%, with 
Pap testing only 30% likely to be cost-effective. Beyond this threshold, the probabilities of 
LBC and Pap testing remain relatively stable at these values. The no screening strategy is 
consistently unfavourable.  
 
The analysis from Scenario 1 used a discount rate of 6% for both costs and LYG respectively. 
From the EVPI analysis, a global EVPI value of £28.24 per patient was derived (using a cost-
effectiveness threshold of £20,000), which equates to a population estimate of £2,824,000 
(using a population base of 100,000 women). Sensitivity analyses were carried out to 
determine the impact on the global EVPI of varying the cost-effectiveness threshold; the EVPI 
was found to decline approximately linearly either side of the £20,000 threshold, declining to a 
value of around £1.8 million at a threshold of around £50,000. 
 
Partial EVPI analyses were also carried out to identify those parameters within the model 
around which further research would be beneficial. These partial EVPI estimates are 
summarised in the  Figure 6.2. 
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Figure 6.2  Partial EVPI estimates (Scenario 1) 
 
By far the most value can be found in the parameter which measures the marginal cost of 
taking a sample using LBC, compared to via the Pap method. This reflects the uncertainty in 
the maximum and minimum parameters used in the triangular distribution representing this 
cost. Other areas of further research suggested by the analyses include the inadequacy rates 
of both LBC and Pap testing, the improvement in specificity associated with LBC (compared 
to Pap) and the mortality rate associated with cervical cancer.  
 
One of the key areas of interest is in how the additional data from the LBC pilot study reduced 
the uncertainty surrounding the adoption decision. The EVPI analysis from Scenario 2 
resulted in a global EVPI of £2.80 per patient, equivalent to a total population EVPI of 
£280,000 (based on a population of 100,000). Figure 6.3 shows the population EVPI for 
Scenario 2 across a range of willingness to pay thresholds. The inclusion of this additional 
information within the Scenario 2 model suggests that there is limited benefit in carrying out 
further research as LBC is almost always preferable to conventional Pap screening . This is 
supported by the results of partial EVPI analyses, which suggests that further research on 
only two parameters (the mortality rate associated with cervical cancer, and the marginal cost 
of taking a sample using LBC) is likely to yield any further value..  
 
The population EVPI value of £280,000 can be read directly off the graph at a threshold of 
£20,000. Broadly speaking, the EVPI continues to decrease steadily beyond this threshold. 
This plot is somewhat different to the plot derived from Scenario 1 in terms of the peak in the 
EVPI. The Scenario 2 plot shows a peak of approximately £1.5 million at a threshold of 
£5,000, compared with a peak of £2.8 million at a threshold of £20,000 for Scenario 1. These 
results demonstrate the value of the additional data obtained from the pilot study. Partial EVPI 
analyses were also conducted within Scenario 2, the results of which are shown in Figure 6.4. 
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Figure 6.3 Population EVPI (Scenario 2) 
 
 
 
Figure 6.4 Partial EVPI estimates (Scenario 2) 
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Only two parameters were found to have any value associated with further research. It is 
evident from Figures 6.3 and 6.4 that further research concerning the cost of obtaining a LBC 
sample and the mortality rate associated with cervical cancer are likely to yield some value, 
but this value has decreased in Scenario 2 by an approximate factor of 10.  
 
The analyses for Scenarios 1 and 2 both assumed a relevant population for the decision of 
100,000 women; Scenario 3 however assumed a relevant population of 360,000 women to 
reflect the true female population eligible for screening. The per-patient global EVPI for 
Scenario 3 was £7.38. Figure 6.5 shows the population EVPI estimates generated under 
Scenario 3 across a decision lifetime of 5, 10 and 15 years. 
 
Assuming a willingness to pay threshold of £20,000 and decision lifetime of 10 years, the 
overall decision EVPI is just below £20,000,000 across the entire relevant population. It 
should be noted here that as the value of λ increases, the so too does the population EVPI; 
the difference between Scenarios 1-3 is due to the way in which the relevant population is 
defined. In Scenarios 1 and 2, the population is assumed to be the number of women eligible 
for screening within a given year (and is thus not discounted), whereas for Scenario 3, a new 
cohort of screen-eligible women are included for each year and discounted over the selected 
decision lifetime.   
 
 
Figure 6.5 Population EVPI across different decision lifetimes (Scenario 3) 
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Figure 6.6 Partial EVPIs for Scenario 3 
 
Figure 6.6 shows that the areas in which further research may be warranted in particular in 
terms of the costs associated with taking a LBC sample and the improvement in specificity of 
LBC over the conventional Pap smear test. Whilst some value may be associated with 
obtaining further information on cancer progression and the mortality rate associated with 
invasive cancer, this value is low and is unlikely to justifiy the cost of obtaining such 
information. It is reasonable to suggest that the value of further information on the cost of LBC 
and the improvement in specificity of LBC may outweigh the costs of undertaking such 
research. 
 
6.4 Discussion 
 
Prior to the pilot study, numerous areas of valuable further research were identified, in 
particular with regard to the costs of taking a sample using LBC, and the inadequacy rates of 
LBC and Pap testing. A comparison of Figures 6.2 and 6.4 illustrates the reduction in 
uncertainty of these particular parameters, and demonstrate the value of the pilot study (the 
updated model (Scenario 2) incorporated data from the pilot study up until mid-2002, by which 
time the study was estimated to have cost approximately £1.2 million). Indeed, only two 
parameters were found to have any value from the analyses in Scenario 2. Although some 
structural differences exist between the two models used in Scenarios 1 and 2 in the way in 
which costs are estimated, a significant reduction in the uncertainty in the model was derived 
through the addition of the pilot study data. 
 
The use of the Reference Case discount rates (Scenario 3) has been shown to impact 
significantly on the expected value of further research. The analysis in Scenario 2 produced a 
population EVPI estimate of £2.80 per patient, compared with an EVPI of £7.38 per patient 
under the analysis in Scenario 3. This difference is attributable to two factors:- 
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? the measurement of health benefits through QALYs in Scenario 3 rather than life-
 years gained; 
? the alternative discount rates used in Scenario 3. 
 
One of the key uncertainties surrounding this policy decision concerns the identification of the 
relevant population for the EVPI analysis. For the original NICE assessment (and indeed the 
comparative analysis presented in Scenario 2), a ‘one-off’ cohort of 100,000 women was 
assumed to represent the screen-eligible population. However, owing to unresolved 
methodological issues concerning the identification of the relevant population, and the implicit 
assumption of a 1-year decision lifetime, this figure appears arbitrary and may be of limited 
use in policymaking. A further problem arises however, in that the population affected by the 
intervention is essentially all asymptomatic women who are eligible for screening. For the 
sake of consistency across the 6 case studies presented within this report, the current 
updated EVPI analysis presented in Scenario 3 estimates the population over a 5,10 and 15 
year decision lifetime and includes a new cohort of women for each year. It remains unclear 
however whether this is more appropriate than the population used in the original analysis. 
 
A further methodological issue which is pertinent to this analysis concerns the use of the 1-
level EVPI approximation in order to estimate the true value of obtaining perfect information. 
This method was used because of the computationally expensive nature of using the 2-level 
sampling algorithm, and whilst there exists a strongly linear relationship between the sampled 
parameter inputs and the net benefits within the model (r2 = 0.91), it is unclear whether a 
higher degree of linearity is required to accurately estimate the true EVPI. It is possible 
therefore that the EVPI results presented here are distorted owing to this imperfectly linear 
relationship.  
 
In both the original and updated models, uncertainty in the model parameters was 
characterised using triangular distributions, which allow a range of values between an upper 
and lower limit to be sampled. Whilst this approach is open to criticism given the variety of 
statistical distributions available for characterising uncertainty in specific types of parameters, 
its justification is that it reflects the inherent uncertainty surrounding the true values of these 
parameters.  
 
It should be noted that the first 2 scenarios presented within this chapter fail to meet the 
criteria set out by the new NICE Reference Case6 on a number of counts. The inclusion of a 
new revised model which estimates the cost-effectiveness of LBC and Pap smear testing in 
terms of cost per QALY gained, discounted at a rate of 3.5% means that the updated version 
of the model closely adheres to the NICE Reference Case, and thus represents the most 
appropriate analysis for current decision making. 
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Reference case evaluation: Liquid-based cytology for cervical screening 
 
 
 
 
Element of health 
technology assessment 
Reference case Criteria met by 
assessment? 
Comments 
Defining the decision 
problem 
The scope developed 
by the Institute 
Yes  
Comparator Alternative therapies 
routinely used in the 
NHS  
Yes  
Perspective on costs NHS and PSS Yes  
Perspective on 
outcomes 
All health effects on 
individuals 
Yes  
Type of economic 
evaluation 
Cost-effectiveness 
analysis 
Yes  
Synthesis of evidence 
on outcomes 
Based on a systematic 
review 
Yes  
Measure of health 
benefits 
Quality adjusted life 
years (QALYs) 
Yes  
Description of health 
states for calculation of 
QALYs 
Health states described 
using a standardised 
and validated generic 
instrument 
No 
Method of preference 
elicitation for health 
state valuation 
Choice-based method, 
for example, time trade-
off, standard gamble 
(not rating scale) 
No 
Source of preference 
data 
Representative sample 
of the public 
No 
There is little robust evidence available , 
hence assumptions were made regarding 
the assignment of utilities to health states 
in the models. 
Discount rate An annual rate of 3.5% 
on both costs and 
health effects 
Yes/No The 3.5% discount rate was agreed 
following the completion of the original 
EVPI methods work; the most recent 
analyses (Scenario 3), however, used 
these new rates 
Equity position An additional QALY has 
the same weight, 
regardless of the other 
characteristics of the 
individuals receiving the 
health benefit 
Yes The use of QALYs in the updated model 
are discussed in the HTA monograph 4 
86 A pilot study of value of information analysis 
References 
 
1. National Institute for Clinical Excellence, Technology Appraisal 69. Guidance on the use of 
Liquid-Based Cytology for Cervical Screening. National Institute for Clinical Excellence, 
Technology Appraisal 69 . 2003.  
2. Department of Health. Cervical Screening Programme, England 2002-03. Statistical 
Bulletin, 2003/24 . 2003.  
3. Payne N, Chilcott J, and McGoogan E. Liquid-based cytology in cervical screening: a rapid 
and systematic review. Health Technology Assessment 4(18). 2000.  
4. Karnon J, Chilcott J, Peters J, and McGoogan E. Liquid-based cytology in cervical 
screening: an updated and systematic review. Health Technology Assessment In press. 
2004.  
5. Moss SM, Gray A, Legood R, and Henstock E. Evaluation of HPV/LBC Cervical Screening 
Pilot Studies (First report on evaluation of LBC).  2002.  
6. National Institute for Clinical Excellence. Guide to Methods of Technology Appraisal.  2003.  
7. Sherlaw-Johnson C, Gallivan S, Jenkins D, and et al.  Cytological screening and 
management of abnormalities in prevention of cervical cancer: an overview with stochastic 
modelling. Journal of Clinical Pathology 47, 430-435. 1994.  
CHE Research Paper 4 87 
  
7. Disease-modifying therapies for the management of multiple sclerosis 
 
7.1 Background 
 
7.1.1 Condition and technology 
 
Multiple sclerosis (MS) is a chronic debilitating disease of the central nervous system, which 
is characterised by progressive disability and intermittent relapse. Evidence suggests that MS 
results from an autoimmune response, resulting in inflammation, demyelination and axonal 
loss.1 MS is one of the most common neurological conditions affecting young adults, and is 
approximately twice as common in women than men.1 The prevalence of MS in England and 
Wales is estimated to be around 110-120 per 100,000, although this varies geographically, 
with a higher prevalence in the north of England.2 This translates to between 58,000 and 
63,000 cases of MS in England and Wales, although this is conservative in comparison to 
other published estimates.2 The annual incidence of MS in England and Wales is estimated to 
be around 3.8 per 100,000 people (around 2,000 new cases each year). 
 
The management of MS is aimed at improving quality of life through relieving the symptoms 
of the disease; conventional management typically consists of drug therapy, physiotherapy, 
psychiatric and social support, and disability aids. Whilst there is no cure for MS, a set of 
drugs known as ‘disease-modifying therapies’ (DMTs), namely the interferon-betas and 
glatiramer acetate, are aimed at slowing disease progression and reducing the number and 
severity of relapses experienced. 
 
7.1.2 .Technology Assessment Review 
 
The cost-effectiveness of DMTs in the management of MS have been the focus of significant 
attention for much of the last 10 years owing largely to the substantial annual cost of these 
therapies, which at the time of the assessment ranged from £6,500 to £12,500 per patient per 
year, combined with the length of time for which patients might continue to take these drugs. 
To date, independent and company sponsored evaluations of these therapies have produced 
a range of cost-effectiveness estimates from in excess of £1 million per QALY gained to cost 
saving. A review of current economic evidence highlighted significant flaws in the modelling of 
natural history, efficacy, discontinuation of therapy, mortality and the treatment of 
uncertainty.3  
 
One of the key differences between existing independent and company-sponsored models 
related to the time horizon used.3 In general, those models which produced very high cost-
effectiveness estimates tended to have shorter time horizons (less than 10 years) or assumed 
that all benefit ceased when the patient stopped therapy. Conversely, models that assumed 
long time horizons and sustained benefit after the cessation of therapy produced 
economically attractive cost-effectiveness estimates.  
 
In 2001, The National Institute for Clinical Excellence (NICE) commissioned a new model 
from a consortium of universities, using current best available evidence, to explicitly address 
the limitations of existing models. The ScHARR cost-effectiveness model estimated the cost-
effectiveness of four products across six licensed indications, as shown in Table 7.1.    
 
Table 7.1  Interventions evaluated by ScHARR MS model 
Product name Drug Manufacturer Dosage  (units per week) 
Licensed for 
RRMS? 
Licensed for 
SPMS? 
Avonex® Interferon beta-1a Biogen 6MIU Yes No 
Betaferon® Interferon beta-1b Schering  8MIU Yes Yes 
Rebif® Interferon beta-1a Serono 
a) 22µg 
b) 44µg Yes No 
Copaxone® Glatiramer-acetate TEVA/Aventis 20mg Yes  No 
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7.1.3 Guidance issued  
 
As a result of the scientific and non-scientific evidence made available to the NICE Appraisal 
Committee, on the basis of their clinical and cost-effectiveness neither beta interferon nor 
glatiramer acetate were recommended for the treatment of MS in the NHS in England and 
Wales.4 The guidance recommended that all NHS patients already receiving these therapies 
should be given the option to continue treatment until they and their consultant consider it 
appropriate to stop, in accordance with the Association of British Neurologists Guidelines 
(ABN).5  
 
7.1.4 Further research recommendations 
 
The NICE guidance4 recommended that NHS trusts and health authorities should be 
encouraged to collect data on all people with MS who continue on beta interferon or 
glatiramer acetate. It was recommended that such information should include the preparation 
used, the patient’s relapse frequency and disease progression whilst receiving treatment, the 
development of adverse effects and neutralising antibodies, compliance with the therapy, the 
reasons for discontinuing therapy and the subsequent rate of progression of the disease.  
 
Following the dissemination of this guidance,4 the Department of Health entered into price 
negotiations with the manufacturers of these therapies. The result of these negotiations was 
the development of Risk Sharing Scheme (RSS), designed to monitor the cost-effectiveness 
of these DMTs in the management of MS.6 The scheme involves the detailed monitoring of a 
cohort of patients to collect further data on the impact of DMTs on disease progression and 
the severity and frequency of relapses experienced. The therapies are thus available to all 
patients with relapsing/remitting multiple sclerosis (RRMS), and those with secondary 
progressive disease (SPMS) in which relapses are the dominant clinical feature, given their 
eligibility according to the ABN guidelines.5 The monitoring process and associated price 
adjustments are expected to continue for 10 years. 
 
In 2002, the National Co-ordinating Centre for Health Technology Assessment (NCCHTA) 
commissioned methodological work (HTA Project 02_29_01)7 to develop methods for 
undertaking Expected Value of Perfect Information (EVPI) analysis for computationally 
expensive models. This work involved the development of an outline methodological 
framework for undertaking EPVI analysis for any health economic model and the direct 
application of the framework to an updated version of the ScHARR MS cost-effectiveness 
model.  
 
7.2 Methods 
 
7.2.1 Model structure 
 
The ScHARR model uses the state transition methodology to simulate the natural history of 
MS over the Expanded Disability Status Scale (EDSS)8 across RRMS and SPMS. The model 
evaluates the cost-effectiveness of the six licensed indications of beta interferon and 
glatiramer acetate using a 20-year time horizon and an annual cycle length. Patients progress 
through the model according to instantaneous hazard rates derived from a 25-year study 
undertaken in London, Ontario.9 The transitions possible during any model cycle are shown in 
Figure 7.1. Patients who drop off therapy remain in the same EDSS state but transit to the 
conventional management quadrants of the matrix.  
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Figure 7.1 Progression diagram fro the ScHARR model 10 
 
Costs were estimated from the perspective of the NHS, and health outcomes were measured 
in terms of cost per quality adjusted life year (QALY) gained. Costs and health benefits are 
discounted at 6% and 1.5% respectively. Costs and utilities are applied directly to the state 
populations within each of the health states over each model cycle. During any particular 
model cycle, patients may also experience relapse, whereby a disutility is applied. For those 
patients receiving DMT therapy, a disutility is also applied to account for the experience of 
treatment-related side effects.  
 
The effect of beta interferon and glatiramer acetate on disease progression and relapse were 
modelled using relative risks derived from published studies.11-15 as well as a re-analysis of 
commercial-in-confidence trial data made available by two of the manufacturers of these 
therapies. 
 
A list of parameters values, and their sources is available elsewhere.10;16 All assumptions 
made in constructing the model favour the DMTs over conventional management. All 
transitions are assumed to be progressive only, hence patients cannot regress back to ‘better’ 
health states. A sustained effect of treatment on both progression and relapse beyond the trial 
duration was modelled. Thus, any patient who discontinues therapy subsequently progresses 
according to natural history rates but retains any benefits received at no additional cost of 
therapy.  Thus, on the EDSS, these patients never 'catch up' with those patients who only 
receive conventional management. Due to the paucity of evidence concerning the long-term 
efficacy of any of these therapies, the effects of treatment are assumed to be fixed and did 
not deteriorate or increase over time. The annual relative risk of 'all-cause' mortality for the 
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MS cohort is assumed to be the same as a normal healthy population, minus the MS death 
observed in the natural history cohort. Patients started treatment according to ABN guidelines 
and are treated until they reach EDSS 7.0 or drop off therapy. 
 
7.2.2 Probabilistic analysis 
 
The model developed for the NICE appraisal was fully probabilistic and all uncertain model 
parameters were described using appropriate distributional forms. However, the cost and 
utility data used within the NICE assessment were held as commercial-in-confidence. 
Furthermore, the version of the model presented to the NICE Appraisal Committee did not 
recognise correlations between EDSS states for either utilities or costs (i.e. as costs increase, 
utilities decrease in a systematic pattern reflecting the change in the underlying clinical 
condition). For the subsequent NCCHTA-funded work,7 these values were replaced with 
functions for costs and utilities to ensure that these correlations were reflected in the model 
appropriately. The specification of these functions drew from data reported in the literature,17-
20 our own experience of analysing cost and quality of life data in MS, as well as our 
knowledge of methodological issues around cost and quality of life assessment in chronic 
disabling conditions. The revised version of the model also uses adjusted prices for each of 
the DMTs, to reflect the current prices assumed within the ongoing Department of Health Risk 
Sharing Scheme. 
 
7.2.3 Value of information analysis  
 
Although the original assessment model included probabilistic analysis, value of information 
analysis was not undertaken as part of the original NICE appraisal.  Owing to the 
computational expense of the MS model, this precluded a comprehensive EVPI analysis 
using the 2-level Monte Carlo algorithm, which would have required around 2,841 years of 
analysis time. Hence, further methodological work was commissioned by the NCCHTA in 
order to develop methods for undertaking sensitivity analysis (principally EVPI analysis) within 
computationally expensive health economic models. As part of this work, a methodological 
framework for undertaking EVPI analysis was developed and directly applied to the ScHARR 
MS model. Partial EVPIs were thus generated using 3 separate models: 
 
? the original ScHARR MS cost-effectiveness model (using a 1-level approximation) 
? a linear regression metamodel  
? a Gaussian Process metamodel  
 
The first two of these models assume a linear relationship exists between sampled parameter 
inputs and resulting net benefits for each treatment strategy. Conversely, the Gaussian 
Process methodology is a Bayesian non-parametric regression technique which is particularly 
effective in approximating highly non-linear models. Despite the considerable potential 
improvements in predictive accuracy possible using the Gaussian approximation, the method 
is restricted in terms of the number of model parameters that can be included in the model. 
Owing to limitations of the current MATLAB® software used to calibrate Gaussian Processes, 
only 30 model parameters could be specified within the metamodel. As the original ScHARR 
MS model contains 128 input parameters, Standardised Regression Coefficient analysis, 
Partial Contribution to Variance analysis, and Partial Rank Correlation Coefficient analysis 
were used to identify those model parameters that describe the greatest amount of 
uncertainty in the model.  
 
An additional issue relating to undertaking value of information analysis within the MS model 
concerns the potential correlations between the efficacies of the six indications of beta 
interferon and glatiramer acetate. Whilst differences exist between the products being 
considered, there are also marked similarities; in these circumstances some level of 
correlation between treatment efficacies must be expected. In order to include efficacy 
correlation within the model it would be necessary to handle the set of six treatment efficacies 
as a multivariate normal distribution and to incorporate an uncertain covariance matrix into the 
model. Sampling using this multivariate distribution would then be facilitated by sequentially 
sampling a series of standardised normal distributions, and linearly transforming these 
samples using the Cholesky square root of the covariance matrix. This situation is further 
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complicated by the necessity to also sample the covariance matrix in order to capture the 
uncertainty in the correlations between treatments. 
 
On a practical note however, there is a complete absence of quantitative information on the 
correlations between all treatments; the only option therefore would be to use subjective 
judgement in defining distributions for the correlation terms. Given these practical difficulties it 
was decided to take two approaches to the analysis of EVPI for the model: 
 
a) To include all treatment options but assume independence in treatment efficacy. This 
approach therefore provides an upper estimate to the overall EVPI. 
b) To consider a single drug treatment option, i.e. that with the highest incremental net 
benefit compared to conventional management. The results provided by this analysis will 
be equivalent to assuming a perfect correlation between treatment efficacies since the 
rank ordering of expected net benefits will be maintained. This analysis therefore provides 
a lower estimate for the overall EVPI. 
 
7.3 Results 
 
7.3.1 Adoption decisions 
 
Tables 7.2 and 7.3 show the deterministic results generated using the version of the model 
used in the NICE appraisal and the revised ‘public domain’ version of the model used for the 
EVPI analysis respectively. Owing to the uncertainty surrounding the efficacy of individual 
therapies, these results consider only the marginal cost-effectiveness of each DMT compared 
to conventional management. Table 7.2 shows the cost-effectiveness results using public 
domain efficacy data as presented to the NICE Appraisal Committee. Under the base case 
assumptions, the cost per QALY ranges between £42,000 and £98,000 
 
Table 7.2 Base-case results for original ScHARR model   
Per Patient Results Marginal Results Treatment Strategy 
Costs QALYs Costs QALYs 
Cost per 
QALY (£) 
T1 Beta Interferon 1-a (Avonex, Biogen) £111,954 10.20 £43,500 1.03 £42,041 
T2 Beta Interferon 1-a 22mcg (Rebif, Serono) £112,982 9.89 £44,529 0.73 £60,963 
T3 Beta Interferon 1-a 44mcg (Rebif, Serono) £130,949 10.03 £62,496 0.87 £71,732 
T4 Beta Interferon 1-b 8MIU: Treating RR 
(Schering) £101,726 9.83 £33,272 0.67 £49,664 
T5 Glatiramer Acetate (Copaxone, TEVA) £101,273 9.50 £32,820 0.34 £97,636 
T6 Beta Interferon 1-b 8MIU: Treating RR & 
SP (Schering) £107,022 10.03 £38,569 0.87 £44,390 
T0 Conventional management £68,453 9.16    
 
Table 7.3 shows the central estimates of cost-effectiveness generated using the updated 
version of the model. As discussed within Section 7.2, the difference in the results shown in 
Tables 7.2 and 7.3 concern the inclusion of revised cost and utility estimates for each EDSS 
health state together with the current adjusted prices for the Department of Health Risk Share 
Scheme. Table 7.3 shows that the revised cost per QALY estimates range between £39,000 
and £92,000.  
 
Table 7.3 Base case results using revised EDSS cost and utility estimates 
alongside RSS drug price 
Per Patient Results Marginal Results Treatment Strategy 
Costs QALYs Costs QALYs 
Cost per 
QALY (£) 
T1 Beta Interferon 1-a (Avonex, Biogen) £128,997 10.68 £39,874 1.02 £39,277 
T2 Beta Interferon 1-a 22mcg (Rebif, Serono) £121,966 10.36 £32,843 0.69 £47,318 
T3 Beta Interferon 1-a 44mcg (Rebif, Serono) £129,363 10.51 £40,240 0.84 £47,828 
T4 Beta Interferon 1-b 8MIU: Treating RR 
(Schering) £120,788 10.30 £31,665 0.63 £49,973 
T5 Glatiramer Acetate (Copaxone, TEVA) £114,956 9.94 £25,833 0.28 £92,279 
T6 Beta Interferon 1-b 8MIU: Treating RR & 
SP (Schering) £126,148 10.47 £37,026 0.80 £46,097 
T0 Conventional management £89,123 9.66       
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Figure 7.2 presents cost-effectiveness acceptability curves (CEACs) and the cost-
effectiveness frontier. The CEACs detail the probability that each strategy is cost-effective 
over a range of threshold values, and the frontier details the probability that the optimum 
strategy is cost effective.  For values of lambda less than around £40,000, conventional 
management is the optimal strategy. For values of lambda higher than £40,000, Avonex 
becomes the optimal strategy. It should be noted here however, that these CEACs do not 
take account of efficacies between therapies and must therefore be interpreted with caution. 
 
 
 
Figure 7.2 CEACs and Frontier for the ScHARR MS model 
 
7.3.2 Research recommendations 
 
Table 7.4 shows the epidemiological data, estimates of treatment eligibility and estimates of 
uptake from the Department of Health Risk Sharing Scheme; these estimates are used to 
estimate the relevant population for the EVPI analysis. 
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Table 7.4 Epidemiological and eligibility parameters used to estimate the relevant 
population 
Variable Value  Source 
Prevalence 5,700  Estimated using data collected from the 64 centres participating in the MS RSS Monitoring Study 
Incidence 
3.8 per 
100,000 
population 
Richards et al2 
% RRMS at onset 80% National Clinical Multiple Sclerosis Guidelines for NICE Management in Primary and Secondary Care 
Percentage of patients 
eligible for DMTs  40-50% 
Proportion of newly diagnosed RRMS who progress to DMTs 
(Personal communication: Dr Mike Boggild, The Walton Centre 
for Neurology and Neurosurgery, 13/11/2003) 
Annual incidence of DMT 
use 800 Calculated from: Incidence x Population x %RRMS x Uptake 
Discount rate 3.5% NICE Guide to Methods of Technology Appraisal – Consultation document21 
 
Table 7.5 shows the global ‘per patient’ and ‘population’ EVPI estimates for the two scenarios 
relating to assumptions concerning correlations between treatment efficacies: (1) EVPI 
estimates for each treatment strategy versus conventional management; and (2) decision 
EVPI across all 7 treatment strategies.  
 
Table 7.5  Global EVPI results for the ScHARR MS model  
 
These estimates assume a £30,000 willingness to pay threshold and a lifetime for the 
decision of 10 years. Assuming independent treatment effects the per patient EVPI results 
shown in Table 7.5 suggests that the value of obtaining perfect information for all uncertain 
parameters within the case study model is £8,855. This results in a population EVPI of 
£86,208,936 across the relevant MS population, which represents an upper estimate for the 
EVPI. The population EVPI estimate for Avonex versus conventional management is 
£41,583,273; this assumes that treatment efficacies are perfectly correlated and hence 
represents a lower estimate for the EVPI. 
 
Figure 7.3 shows the population EVPI for the decision over a range of willingness to pay 
thresholds (λ) over a lifetime for the decision of 5,10 and 15 years. 
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Figure 7.3 Population EVPI for the ScHARR MS model 
 
It is evident from Figure 7.3 that as the value of λ increases, so too does the value of 
obtaining further research. It should be noted that the anticipated decision lifetime has a 
considerably greater impact upon the overall population EVPI as this value of λ increases. 
 
7.3.3 EVPI for individual parameters 
 
The key focus of the further methodological work undertaken on behalf of the NCCHTA7 
concerned the estimation of partial EVPIs for parameters. The partial EVPI results generated 
using all three approaches are reported in full in the monograph.7 A direct comparison of the 
1-level EVPI approximation, the linear regression metamodel and the Gaussian Process 
metamodel suggested that the Gaussian metamodel enabled a substantially better 
approximation than both the linear regression metamodel and the 1-level EVPI algorithm, 
despite the existence of a strong linear relationship between sampled parameter inputs and 
net benefits. Figure 7.4 shows the ‘per patient’ partial EVPI for individual parameters within 
the model as calculated using the Gaussian Process metamodel uplifted to the relevant 
population for a decision lifetime of 10 years. The partial EVPI analysis clearly suggests that 
large uncertainties surround many of the model parameters.  
Figure 7.4 Partial EVPI for individual parameters for the ScHARR MS model 
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Figures 7.4 suggests that further research is merited on the relationship between the EDSS 
and the cost of care, the relationship between the EDSS and quality of life, the rate at which 
patients drop off therapy, and in particular, the long-term impact of DMT therapy on MS 
progression. 
 
7.4 Discussion 
 
The EVPI analysis presented here has identified a number of areas in which further research 
on the impact of beta interferon and glatiramer acetate is merited. For a £30,000 willingness 
to pay threshold, the global EVPI is in the range £41,581,273 to £86,208,936. Even at the 
lower estimate of EVPI, the potential value of obtaining further information is likely to 
considerably outweigh the costs of funding such research. The partial EVPI analysis suggests 
that research should focus specifically on the relationship between the EDSS and the cost of 
care, the relationship between the EDSS and quality of life, the rate at which patients drop off 
therapy, and in particular, the long-term impact of these therapies on disease progression. 
Whilst further information on costs associated with particular EDSS states and the rates at 
which patients drop off therapy may be obtained through non-experimental designs such as 
observational studies, further useful information on the impact of disease-modifying therapies 
on disease progression and associated health outcomes would be most reliably obtained 
through a long-term randomised controlled trial which includes a direct assessment of quality 
of life. 
 
The large difference in the EVPIs obtained from the completely correlated and independent 
model assessments indicates that further knowledge on the correlation between treatment 
efficacies would be highly valuable in commissioning decision making. This is intuitively 
sensible as learning something about the treatment efficacy of one of the disease modifying 
therapies is likely to give information about other drugs in this set. Furthermore, the EVPI 
assessment incorporating all treatment options assumes that a single treatment is identified 
as optimal and selected for commissioning on the basis of its maximum net benefit. Given the 
high degree of uncertainty and the likely small differences in treatment efficacy and 
consequential net benefit an exclusive commissioning recommendation identifying one 
specific product is unlikely; a broad commissioning decision covering groups of or all products 
is more probable. Given this, the lower estimate for the expected value of information is likely 
to give a better estimate for the value of further research than the upper estimate. 
 
Due to the vast computational expense of undertaking comprehensive partial EVPI analysis 
using the ScHARR MS model, estimates of partial EVPI were generated using three different 
approaches. The Gaussian Process metamodel suggested the closest approximation to the 
original simulation model, hence the partial EVPI estimates generated using this model are 
likely to be the most reliable and robust. However, the Gaussian methodology itself is 
restricted in terms of the number of parameters that may be specified in the metamodel 
(typically less than 30). Although the three separate factor screening techniques undertaken 
to identify the most influential model parameters identified the same 30 parameters to be 
important, there remains a chance that these importance analysis techniques failed to identify 
some of the important model parameters and these may have thus been excluded from the 
metamodel. 
 
Furthermore, there exists an intrinsic problem in that due to the computational time required 
to perform comprehensive EVPI analysis using the correct 2-level EVPI algorithm within the 
original ScHARR MS model, there exists no basis for validation of the results of the Gaussian 
Process metamodel. Whilst the Gaussian Process methodology has previously been 
validated using a simpler case study,22 this issue should be addressed in further policy 
problems. 
 
An additional issue concerns the epidemiological and eligibility parameters used to estimate 
the population EVPI. The primary focus of this analysis has been on estimating the ‘per 
patient’ value of information, however the population scaling factors are also highly uncertain. 
In particular, the eligibility for and uptake of DMTs is particularly uncertain, and is currently 
based entirely upon subjective judgement. This should be highlighted as an area for further 
research. In addition, it should be noted that previous value of information studies have 
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calculated the population EVPI by simply multiplying the ‘per patient’ EVPI by a fixed number 
of patients over an assumed lifetime of the decision/technology. However, as the population 
relevant to a particular decision is itself uncertain, there remains an unresolved 
methodological issue concerning whether the uncertainty in the epidemiological parameters 
should also be accounted for within the sensitivity analysis. 
 
It should also be noted that the model deviates from the criteria set out in the NICE reference 
case21 on 2 counts (See Appendix ??). Firstly, whilst the model used within the NICE 
assessment used quality of life data valued using the EQ-5D, these data were held as 
commercial-in-confidence. The clear need for transparency in the application of EVPI 
methods to the MS model meant that these data were no longer available for use in the 
subsequent methodological work. As a result, a functional form describing the relationship 
between the EDSS and utility was specified from a review of the current literature and our 
own experience in analysing quality of life data in MS. In addition, the recommendation for 
discounting both costs and health outcomes at 3.5% was not agreed until after the EVPI 
methods work was completed; instead the discount rates recommended at the time of the 
assessment were used throughout.  
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Reference case evaluation: Disease-modifying therapies in the management of 
MS 
 
 
Element of health 
technology assessment 
Reference case Criteria met by 
assessment? 
Comment 
Defining the decision 
problem 
The scope developed 
by the Institute 
Yes  
Comparator Alternative therapies 
routinely used in the 
NHS  
Yes  
Perspective on costs NHS and PSS Yes  
Perspective on 
outcomes 
All health effects on 
individuals 
Yes  
Type of economic 
evaluation 
Cost-effectiveness 
analysis 
Yes  
Synthesis of evidence 
on outcomes 
Based on a systematic 
review 
Yes Systematic review undertaken previously 
on behalf of NICE23 by Clegg and 
colleagues. 
Measure of health 
benefits 
Quality adjusted life 
years (QALYs) 
Yes  
Description of health 
states for calculation of 
QALYs 
Health states described 
using a standardised 
and validated generic 
instrument 
No 
Method of preference 
elicitation for health 
state valuation 
Choice-based method, 
for example, time trade-
off, standard gamble 
(not rating scale) 
No 
Source of preference 
data 
Representative sample 
of the public 
No 
The original NICE assessment included the 
results of a utility survey undertaken by the 
MS Research Trust. These data were held 
as commercial-in-confidence and were not 
used in the EVPI analysis. Functional 
relationships between quality of life and the 
EDSS were re-specified following a review 
of current literature and our experience in 
analysis utility data in MS. 
 
Discount rate An annual rate of 3.5% 
on both costs and 
health effects 
No The 3.5% discount rate was agreed 
following the completion of the EVPI 
methods work; instead the discount rates 
for costs and health outcomes 
recommended at the time of the NICE 
assessment were used. 
Equity position An additional QALY has 
the same weight, 
regardless of the other 
characteristics of the 
individuals receiving the 
health benefit 
Yes  
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8. Implications, methodological issues and challenges 
 
8.1 Demonstration of benefits 
 
The framework proved by DA-VOI was successfully implemented for each of the 6 case 
studies and provides the value of additional information, which may be generated by further 
research.  This is consistent with the objectives of the heath care system (maximise the 
health gains of the population of England and Wales) and is based on the same resource 
constraints (the cost-effectiveness threshold which is used to develop guidance on use of the 
technology).   
? For a particular assessment, this allows comparison of the potential benefits of further 
research (EVPI) with the costs of further investigation.  If the potential benefits 
exceed the additional costs (including opportunity costs to patients) then further 
investigation maybe required to support guidance on use.  The EVPI associated with 
the groups of parameters indicates the type of evidence that will be most valuable 
and therefore the type of studies that should be recommended. 
? It also allows comparisons to be made across different technology assessments and 
prioritisation between alternative research recommendations, as well as a 
comparison between the value of investing resources in research or other activities 
such as the provision of health service.  In this sense it provides a unified and 
coherent framework for prioritisation of both research and the use of heath care 
technologies 
 
8.2 Implications for research prioritisation 
 
The value of research differed substantially across the 6 technology appraisals and ranged 
from £2.8m (LBCs scenario 2) to £865m (ClO scenario 2). The results for selected scenarios 
for each of the case studies are reported in table 8.1. 
 
Table 8.1:  Summary of EVPI results  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relative risk of progression for 
copaxone, Betaferon and rebif
(22mg) (£14m, £13.6m and £7m 
respectively)
Also the cost of care, costs of 
relapse and quality of life (£10m, 
£7m and £6m respectively)
£86.2mRelapsing remitting and 
primary progressive 
multiple sclerosis (scenario 
2)
Disease modifying 
therapies for multiple 
sclerosis
Specificity (£3.6m)£20mWomen aged 18 to 64 
years (scenario 3)
Liquid Based Cytology
Relative risks of vascular and non 
vascular death 
(£780m for ASA-MR-dipridamole 
compared to clopidogrel in the 
stroke subgroup)
£865m
£250m
£710m
£240m
Stroke
Transient Ischaemic Attack 
Myocardial Infarction
Peripheral Arterial Disease
(scenario 2)
Clopidogrel and 
dipyridamole for 
secondary prevention
Quality of life with influenza, the 
effect of oselatimivir and 
amantadine (£44.3m, £0.43m and 
£0.23m respectively)
£66.7mOtherwise healthy adults 
not at elevated risk of 
complications
Neurominidase inhibitors
Relative risk of death for non 
acute PCI for GPA as medical 
management and for Clopidogrel
(£85,041,000, and £68,137,000 
respectively)
£171mAcute treatment following 
non-ST-elevation acute 
coronary syndrome 
(scenario 2)
Glycoprotein IIb/IIIa
Quality of life with and without 
PDT (£3,370,000 for 20/40) 
£6.2m
£15.3m
Visual acuity 20/40
Visual acuity 20/80
AMD Screening
EVPI for parametersPopulation EVPIPatient GroupCase Study
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 In some cases the analysis indicated that further research should not be regarded as a 
priority, e.g., the EVPI surrounding LBC following the evidence from the pilot study was low 
(£2.8m scenario 2).  In other cases it indicated that additional research should be regarded as 
a priority, e.g., the EVPI surrounding CLO for stroke patients was high (£865).  In other cases 
the analysis re-focuses the original research recommendations, e.g., in the AMD case study, 
although further research appears to be potentially worthwhile, it is additional evidence about 
quality of life with and without photo dynamic therapy rather than the performance of self 
screening itself which is valuable. 
 
The analysis indicated which comparators should be included in future research and also 
suggested other parameters that could be excluded, For example, the value of information for 
NIs was significant (£66.7m) but it is further evidence about quality of life with influenza which 
is most important (£44.3) rather than additional evidence about the effect on symptoms.  
Although there is some value in further RCTs of the effect of oselativir and amantadine on 
symptoms (0.43m and 0.23m respectively) there is no value in further trials of Zanamivir.  
Similarly in the MS case study, although there is value in additional RCT evidence of the 
effect on progression of the disease, it is the effect of copaxone and betaferon which should 
be regarded as a priority (£14m and £13.6m respectively).  However, in this case evidence 
about cost of care and relapse, and quality of life are also valuable.  In these cases further 
research will not require experimental design and may be less costly to acquire (£10m and 
£6m respectively) so maybe regarded as priorities. 
 
Estimates of value of information for the decision problem and for groups of parameters were 
also presented for relevant patient sub groups, e.g., for example the value of information 
different across the patient groups considered in the CLO case study (from £856m to £240m).  
This suggests that further research on the stroke and MI subgroups should be regarded as a 
priority although research on the TIA and PAD subgroups may also be worth while.  Similarly 
the value of additional evidence for AMD differs by visual acuity (from £6.2m to £15.3m), and 
suggests that additional research should include those subgroups with lower starting visual 
acuity. 
 
The analysis also indicates which endpoints should be included in further research. For 
example, in the GPA case study further research is valuable and should be regarded as a 
priority. It also indicated that it is RCT evidence of the effect of GPA as medical management 
and Clopidogrel which is most valuable. However, it also indicates that it is the mortality 
endpoint for patients with non-acute PCI which should be the primary endpoint in any future 
trial.  
 
A number of case studies presented scenarios to explore alternative views of the relevant 
evidence e.g., inclusion of related and “unrelated events” in the assessment of CLO and 
impact of restricting consideration of evidence at 6 months in GPAs ; different structural 
assumptions regard mechanism of action, e.g., additive nature of information gains during 
screening for AMD;  as well as the impact on value of information when relevant alternative 
may have been excluded from the original scope of the appraisal, e.g., the including the 
potential role of clopidigrel in the GPA case study.   
 
A more detailed discussion of the implications for research prioritisation including the 
implications for the design of any future research in terms of features such as the relevant 
patient groups and comparators, and whether experimental design was likely to be required in 
each of the areas, can be found in chapters 2 to 7.  
 
8.3 The reference case as a sufficient basis for VOI 
 
The results of any analyses are conditional on the use of appropriate model structure, 
appropriate synthesis of evidence and characterisation of other uncertainties.  This is 
important for estimates of expected cost-effectiveness but even more important for estimates 
of value of information which are particularly sensitive to these issues.  The existing reference 
case and methodological guidance requires supplementary guidance on the detailed use of 
methods to ensure that the adequacy of reference case submission can be assessed and that 
an adequate reference case analysis will provide sufficient basis for value of information 
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analysis.  This process of developing detailed methodological guidance is underway, 
coordinated by the National Decision Support Unit.  It is important that in identifying and 
recommending methods the full characterisation of decision uncertainty should be a primary 
concern. 
 
Although each case study was selected to be as close as possible to the new reference case 
there were a number of departures where the existing TAR model fell short of the new 
requirements.  These are detailed at the end of each case study chapter.  However, in 
general the most common and significant departures surrounded the quality of the evidence 
on quality of life available in the original TAR analysis.  In addition and unsurprisingly the 
difference in discount rate between the original and new methods guidance was common to al 
case studies.  It should be noted that even when the differences in discounting have a modest 
effect on estimated of cost-effectiveness then can have a substantial impact on value of 
information, e.g., in LBC case study changing the discount rate had a significant impact on he 
value of information.  
 
8.3.1 Feasibility and resource implications 
 
The pilot demonstrates that VOI is feasible within reasonable time lines, even based on pre 
reference case analysis.  The use of VOI as part of the reference case (taking account of the 
recommendations made above) is for most types of models limited, not by time and resource 
requirements, but by the capacity to conduct this type of analysis and the dissemination of 
these methods.  Therefore training in VOI methods should be considered as a cost-effective 
means of easing these capacity constraints.  However it should be recognised that the key 
constraint is the capacity to conduct adequate probabilistic decision analytic modelling.   
 
However, complex and computationally expensive models (particularly patient level 
simulations) make probabilistic analysis and therefore VOI potential very time and resource 
intensive.  There are therefore 3 issues that should be addressed: 
 
? It should be recognised that using patient level simulation is very costly in the sense 
that it may prevent reliable estimates of cost-and effect, and decision uncertainty as 
well as VOI being presented.  In these circumstances it should be avoided if possible 
(by use of alternative structures and programming techniques).  More work is 
required to establish those circumstances were the use of patient level simulation 
unavoidable. 
? Where patient level simulation is required then there are techniques available to solve 
computationally expensive models, characterise uncertainty and estimate VOI.  
Indeed these have been used in NICE submissions.  Further work is required to pilot 
their feasibility when patient level simulation is unavoidable and dissemination of 
appropriate methods.  
? Non of the case studies included patient level simulation.  However the MS and LBC 
case studies included computational expensive models and both used different 
techniques to overcome the computational problems.  For example LBC  attempted to 
estimate a linear relationship between model inputs and output, MS case study 
evaluated a number of approaches including a Gaussian process which does not 
impose linearity.  Linear approximations maybe adequate for estimating costs and 
effect but my perform less will when estimating the value of information. The use of 
Gaussian process performs better than linear regression particularly when estimating 
value of information but the number of parameters, which can be included is limited.  
Again further works is required to pilot the use of techniques to evaluate 
computationally expensive models.  
 
8.4 Critical issues and methodological challenges 
 
It should be recognised that the key challenges for this type of analysis are not the VOI 
methods themselves but structuring decision problems, synthesis of evidence and the 
characterisation of uncertainty (required for estimating costs and effects as well as VOI).  The 
development of methods in these areas is ongoing and will require continued support from a 
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variety of sources.  Particular issues, many of which have been highlighted in the case 
studies, include: 
 
8.4.1 Structuring decision problems 
 
• Ensuring a sufficiently wide scope for the assessment to include all the relevant 
alternative strategies.   
This includes other technologies as well as different clinical policies (start and stop 
criteria) for a single technology.  The exclusion of alternative strategies may not 
change the overall guidance on use of a technology but in some cases it may have a 
substantial impact on the value of information and on research recommendations. For 
example, excluding clopidogrel as an alternative in the GPA case study would have 
lead to an underestimate of the EVPI.  The full range of clinical policies must also be 
included.  For example, the CLO case study was restricted to evaluating 2 year 
treatment policies.  However, if other policies such as life time treatment was 
evaluated then although the cost-effective strategy may not change the value of 
information may be higher and may focus on the longer term effect of secondary 
prevention 
• Exploring and reflecting the additional uncertainty surrounding alternative but credible 
structural assumptions.  
For example, in the AMD case study three scenarios of alternative structural 
assumptions about how the information from self screening would change the chance 
of self referral to an ophthalmologist were modelled. Although the alternative 
assumptions had limited impact on estimates of cost-effectiveness (the overall cost-
effectiveness of the strategies were unchanged) they did have a more substantial 
impact on the value of information (from £6.3m to £30.5m for visual acuity 20/40).  
This suggests that uncertainty and therefore evidence about the structural 
relationship may be as valuable as evidence about the value of the model 
parameters.  In this pilot these types of uncertainty have been modelled as scenarios.  
However it is possible to assign probabilities (priors) to alternative assumptions and 
generate a value of information this for uncertainty.  This would require elicitation of 
probabilities from experts and decision makers within an iterative process of analysis. 
Another example of these issues are found in the NI case study, e.g., whilst the base 
case value of information is driven by the uncertainty in quality of life, when this is 
modelled solely as a function of length of influenza illness, the value of information is 
reduced substantially.  
• Model complexity and characterising uncertainty.  
The MS and LBC case studies included computational expensive models and both 
used different techniques to overcome the computational problems.  For example, the 
LBC case study attempted to estimate a linear relationship between model inputs and 
output, the MS case study evaluated a number of approaches including a Gaussian 
process which does not impose linearity.  Linear approximations maybe adequate for 
estimating costs and effect but my perform less will when estimating the value of 
information. The use of Gaussian process performs better than linear regression, 
particularly when estimating value of information, but the number of parameters which 
can be included is limited.  Again further work is required to pilot the use of 
techniques to evaluate computationally expensive models. 
 
8.4.2 Evidence synthesis and characterising uncertainty 
 
• The synthesis of both direct and indirect evidence for measures of effect but also for 
other model parameters. 
This is a key issue for all the case studies. The GPA case study demonstrates that 
only considering the 6 month trial evidence (scenario 1) would overestimate the 
uncertainty and value of information.  The more appropriate analysis (scenario 2), 
which included all the trial evidence, required more sophisticated methods of 
evidence synthesis. The CLO case study employed an indirect comparison of the two 
main treatments of interest, clopidogrel and modified-release dipyridamole, because 
no direct trial data were available.  Such indirect comparisons are necessary for a full 
comparison of all treatment options, but are always subject to an increased level of 
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uncertainty.  It is not surprising then that the relative treatment effect of clopidogrel 
compared to modified-release dipyridamole on mortality was associated with 
significant value of information. 
• Dealing simultaneously with heterogeneity (variability by observed patient 
characteristics), variability (variability by unobserved characteristic) and uncertainty. 
In the GPA case study, if higher and lower risk patients could have been identified 
then sub group analysis could have been conducted.  However, this was not possible 
and the analysis was conducted for average risk patients.  It should be recognised 
that the current analysis is for patients with the average risk not the group of patients 
with variability in risk which make up the average. The latter is more policy relevant 
but requires both variability and uncertainty to be modelled. 
• Reflecting the additional uncertainty due to potential biases in the evidence, which 
may come from different types of study and/or suffer from publication bias.  
The AMD case study used alternative structural assumptions to explore the 
substantial uncertainty and potential bias is estimates of self referral rates.  This type 
of scenario analysis indicated that value of information was sensitive to these issues. 
• Modelling the exchangeability of the evidence with the parameters required in the 
model and reflecting any additional uncertainty. 
For example, a meta regression was conducted to establish whether relative risk was 
related to base line risk in the GPA case study.  This enabled the evidence from US 
trial (where baseline risks differed from the UK) to be used in the UK context. 
However the additional uncertainty introduced by using the US evidence was not 
explicitly modelled. 
• The inclusion or exclusion of unrelated events from the evidence and the potential 
role of prior elicitation from “experts”. 
The CLO case study illustrated that the cost-effective treatment strategy and value of 
information can be significantly affected by the inclusion (exclusion) of unrelated 
(related) events.  Where there is considerable uncertainty about how to include 
effects on events which may not be connected to the treatments under consideration, 
as with non-vascular mortality in the antiplatelets, trial.  In such instances expert 
opinion on the validity of excluding the event from the model, or prior beliefs on the 
magnitude and extent of any potential treatment effects may have an important role in 
augmenting trial data. 
• The potential role of using priors elicited from “experts” within the NICE process and 
appropriate methods of elicitation of priors. 
In the AMD case study expert judgements for the probabilities of self referral conditional on 
loses in visual acuity were used.  The distributions assigned to these estimates were diffuse to 
represent the substantial uncertainty in the value of the parameters.  However, more formal 
methods of elicitation for the whole prior distribution are available and would be more 
appropriate for future reference case analysis.  
• Establishing efficient methods of searching for evidence on all model parameters not simply 
those associated with measures of effect.  
Each case study was based on a TAR which included a systematic review of the evidence on 
effect.  However, the models and the probabilistic analysis rely on estimates of many 
parameters other than measures of effect.  Clearly methods of systematic and efficient 
searching for all model parameters must be considered if all evidence is to be used to estimate 
costs and effects and fully characterise uncertainty. 
 
Many of these issues are being addressed though various programmes of research around 
the UK.  However these areas of research require further development and continued 
support.  In additional it should be recognised that these issues require multidisciplinary 
working with collaboration across many different centres.  Infrastructure support to facilitate 
full collaboration across these areas of work should be sort from a variety of sources.   As all 
these methods evolve, it should be recognised that the detail of what is required within an 
adequate reference case analysis will also develop over time.  
 
8.4.3 Issues specific to VOI 
 
Although the key challenges are more general and relevant to estimating cost, effect and 
decision uncertainty there are a number of issues which are specific to VOI which need to be 
addressed 
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• Estimating the effective population that may benefit from additional evidence, 
including estimating time horizons for different technologies and incorporating this 
uncertainty in the estimates of value of information. 
For example, the CLO case study considered only modified-release dipyridamole, as 
it is now considered superior to the standard release formulation.  Following the 
technological advance which allowed an extended release formulation, standard 
release dipyridamole, will likely fall out of use.  In contrast, aspirin has been in use for 
more than the 15 years considered in the current EVPI calculations, and is still 
recommended for use in the guidance from the CLO appraisal despite the arrival of 
newer, competing technologies (clopidogrel and dipyridamole).  Thus there is 
uncertainty around the effective future lifetime of these technologies and there is 
likely to be different effective life times for different technologies relevant to the same 
decision problem. In the NI case study the size of the population are based on the 
numbers of people currently presenting to the GP classified as influenza like illness. 
But the drugs need to be used within 48 hrs of symptom onset and are likely present 
similarly to a common cold. Therefore true “population” could be much greater than 
estimated once the technologies are available. 
• Estimating the value of information for correlated parameters. 
The methods of evidence synthesis required to make comparisons between 
technologies generates correlation between estimates of effect.  For example, in the 
CLO case study the relative risks were correlated and it should be recognised that the 
EVPI for these relative risks individually  did not account for the correlation and could 
either under or over estimate EVPI.  Similarly in the MS case study two scenarios 
were used to explore the impact of regarding each of the treatments as independent 
or as perfectly correlated (the same drug) and showed the effect on the estimates of 
value of information.  Work is ongoing into accounting for correlations when 
calculating EVPI for parameters.  
• Estimating the overall value of information based on estimates of the value of 
information for patient subgroups 
The AMD, GPA and CLO case studies included a number of patients sub groups.  
The EVPI for each patient group is useful in identifying were research will be most 
valuable. However it must be recognised that further evidence about one sub groups 
may inform other patient groups. Therefore the subgroup EVPI is likely to be a lower 
bound on the value of conducting research on that sub group alone.  Similarly the 
summation across subgroups will overestimate the value of research for all patient 
groups together.  What is required is to model the exchangeability between 
subgroups and indeed to other decision problems.    
• Develop methods to assess the stability of estimates and required iterations. The 
number of iterations required to provide stable estimates of the EVPI and the EVPI for 
particular parameters depends on the nature of the model (non linearity) the number 
of parameters and their distributions.  No clear general “rule” is available.  Further 
work on measures of stability would be useful  
• Presenting the value of information and the value of full implementation of guidance 
on use with in the same framework of analysis. 
The value of information conducted in this pilot focuses on the value of evidence 
about what is a cost-effective intervention.  There is clearly a separate issue of the 
value of ensuring that clinical practice is consistent with the current evidence of cost-
effectiveness and indeed that if additional research is commissioned that clinical 
practice will respond to the results. 
 
Again work is currently ongoing on all of these issues but continued support from a number of 
sources for this methods work as well as support for an infrastructure of collaboration is 
needed. 
 
8.4.4 Challenges in context 
 
The challenges detailed above are not, with a few exceptions, specific to value of information 
analysis or indeed to decision modelling generaly. The issues of interpretation of evidence, 
synthesis, potential bias, exchangeability etc, have always been present in any informal and 
partial review of evidence.  In fact until quite recently these challenging issues could be 
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conveniently ignored by both policy makers, clinicians and analysts while decision making 
was opaque and based on implicit criteria and unspecified “weighing” of the evidence. These 
challenges must be faced as more to explicit and transparent approaches to decision making 
are being taken.   Indeed one of the many advantages of taking more transparent and explicit 
approach to decision making is that it exposes many important methodological issues which 
have previously been ignored or avoided by presenting partial analysis which do not directly 
address the decisions which must be made. 
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9. Implementing value of information analysis in the NICE research and 
development process 
 
9.1 Introduction 
 
Value of Information is not specified as part of the Reference case in the latest edition of the 
Appraisal Methods Guide, despite the fact that Probabilistic Sensitivity Analysis is.xxxii5 The 
use of health economics and decisions analysis within the NICE Clinical Guidelines 
programmes is in its infancy, although the Institute has a strong commitment to addressing 
this issue in the medium term.  Against this background, this chapter considers whether Value 
of Information Analysis could be incorporated into the standard processes of the Institute, and 
particularly how it could be used by the Research and Development Committee, (RDC).  
 
The analyses presented in chapters 2 to 7 of this report demonstrate the feasibility of the 
routine incorporation of value of information analysis into analyses undertaken by Technology 
Assessment teams for the NICE Appraisal Programme.  There are two important aspects of 
these demonstration projects that are worth highlighting at this point.  
 
Firstly, these analyses were undertaken in a very short time scale. The results were available 
to the Institute approximately 5 weeks after the projects were approved. Thus, when 
probabilistic sensitivity analyses have been undertaken for the Technology Assessment 
Report (TAR), the additional burden of producing a Value of Information Analysis is not as 
large as might be expected, and is certainly small in relation to the value of the information 
obtained.   
 
Secondly, the same individuals who had produced the TARs, and not a few specialists in VOI 
analysis, undertook these analyses. This is important, as it indicates that VOI analyses can be 
produced by any team that is capable of producing the probabilistic sensitivity analysis that is 
now required in the reference case analysis for NICE appraisals.  
 
Based on the case studies presented above, the starting point for this chapter is that Value of 
Information Analysis is a pragmatically feasible output cost effectiveness models produced for 
the NICE Appraisal Programme. 
 
9.1.1 The promise of Value of Information Analysis 
 
VOI analysis is an internally coherent framework for assessing the value of investing in 
research to reduce decision uncertainty and identifying which research would be most 
valuable. Assuming a consistent decision criterion across all the decisions the Institute has to 
make, VOI can be used to identify the most valuable research questions to be addressed 
across the portfolio of the Institute’s activities. VOI analyses can also be used to optimise the 
design of additional research.  Given that resources for research, like all other resources, are 
limited, the prospect of prioritising research in a coherent and defensible manner is an 
appealing one. 
 
9.1.2 Function of the NICE Research and Development Committee 
 
The Strategy Document for the NICE RDC is clear that its primary role is not to fund research, 
but rather to promote research that it identifies as being important, to the established funding 
bodies such as the Medical Research Council, the Wellcome Trust and the NHS Research 
and Development Programme.xxxiii 
 
The use of Value of Information Analysis to identify the research questions to be promoted to 
the research funding bodies, would imply that the objective of the RDC is to assist the 
Institute in its objective of maximising health gain from the expenditure of the NHS budget 
(subject to certain constraints), as VOI will only be available from analyses which have been 
                                                 
5 Value of Information analysis is specifically referred to as a possible source of information on the 
research needs. 
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undertaken to inform the appraisal or guidelines programmes.  The RDC may wish to 
consider whether it wishes to adopt such a narrow definition of its function.  
 
It has been shown that the value of information is heavily dependent upon the comparators 
considered in the evaluation. Therefore, the question as it is defined in the Scope for an 
appraisal will play a crucial role in determining which research questions are identified as 
having a social high value. Experience of the NICE appraisal process leads us to believe that 
the scope of an appraisal is determined as many factors  inter alia,  process issues, resources 
available for the production of the assessment report and the availability of data. There is a 
risk that the research prioritisation based upon VOI analysis will not be robust to changes in 
the assumptions. This said, the introduction of the new appraisal process, notably, the 
stakeholder workshop; should lead to scope that are appropriate and therefore, robust value 
of information analyses. 
 
It is unclear how research in to methods  of health technology assessment and appraisal 
would be considered in a VOI framework. If the RDC were to use these methods to identify 
research priorities, it is unclear whether this would entail the exclusion of methods research 
from its remit. Given the Institute’s pivotal role in the promotion and adoption of innovative 
research methods it would seem somewhat perverse for these activities be effectively 
excluded from the RDC’s remit.xxxiv However, it is  likely that such research would represent a 
very small proportion of the material that the RDC would be consider, and therefore its 
exclusion from the standard processes may be a reasonable price to pay for the application of 
robust analytical methods to the majority of the RDC’s considerations. 
 
The RDC has an equal responsibility to promote the research questions identified by all the 
programmes; not just those from the Appraisal Programme.  Currently only the Appraisal 
Programme would be able to furnish VOI data in support of its research concerns. The work 
undertaken within the Guidelines, Interventional Procedures and Confidential Enquiries 
Programmes would not currently be in a position to do so. Either the RDC would need to 
develop a method for comparing VOI ‘apples’ with Confidential enquires’ ‘pears’ etc… or the 
Institute would have to make a substantial investment in the provision of decision science 
expertise to these programmes. The feasibility of either of these strategies, in the short term 
requires careful consideration. This said, there is considerable external pressure for the 
incorporation of high quality decision science expertise in to the clinical guidelines processes. 
Therefore this potential problem may be resolved, to the benefit of the RDC processes.  
 
9.1.3 Alternatives to EVPI for prioritising research 
 
Given the issues highlighted in the previous sections of this chapter, it would seem sensible to 
briefly consider the alternatives to EVPI for prioritising research within a decision science 
framework. 
 
Traditional research prioritisation processes have focussed upon the ‘importance’ of the 
question being addressed, the feasibility of undertaking research to address the question, and 
the quality of the methods of the proposed research study. 
 
In clinical trials funding and health technology assessment more generally, the importance of 
the question has tended to be addressed in terms of the burden of the disease under 
consideration and the impact of the intervention upon that burden. Such information tends to 
be presented to the research funder as a portfolio. In order to make a decision, the funder 
must in some way attach a value to the burden of the disease, and to the change in that 
burden of disease.  Such decisions are usually made by committees, and each member of the 
committee will their own assessment of the burden of the disease and the impact of the 
intervention. In such circumstances, simple voting mechanisms are used to establish a 
hierarchy of alternative research projects. 
 
In essence, the research funder must undertake an informal and unstructured value of 
information analysis in their head, in deciding whether the commission a piece of research. 
The payoff function used by the research funder, is not necessarily have to relate to the 
decision of whether to reimburse a therapy or not, but it must attach a value, implicitly or 
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explicitly, the expected change in the state of knowledge that will result from the research.  
Each member of a research funding committee is likely to have their own pay off function, and 
the voting mechanism leads to the use of the mode as the estimate of the payoff, rather than 
the mean. 
 
Thus, traditional research prioritisation mechanisms are merely informal, unstructured and 
opaque value of information processes.  The parallels with previous arguments about Quality 
Adjusted Life Years and then Cost Effectiveness models in health care resource allocation 
decisions, are striking. The consideration must be whether research prioritisation processes 
informed by formal, structured and transparent value of information analyses are likely to lead 
to better research resource allocation decisions than informal, unstructured and opaque ones. 
 
9.1.4 Acceptability of value of information analysis to research funding agencies 
 
VOI is firmly based in statistical decision theory.xxxv The objective of VOI is to establish the 
value of requiring more information to support a decision. A fundamental precept of the 
decision theory framework is that traditional (frequentist) statistical inference is arbitrary and 
irrelevant decision making. By contrast the research funding organisations are not primarily 
concerned with supporting decisions and are firmly founded in the frequentist paradigm of 
statistics.  There is clearly an issue about the acceptability to these bodies of conclusions 
drawn from an analytical framework with which they are at best unfamiliar and may actively 
reject. 
 
The extent to which the results of VOI will be acceptable will vary from funder to funder. 
Whilst the NHS HTA programme is relatively familiar with the approach having funded a pilot 
study to run alongside a recent commissioning exercise,xxxvi the MRC and Wellcome Trust are 
less familiar. As the latter two bodies control by far the largest health care research funding 
streams, their lack of familiarity with the method represents a substantial challenge to its utility 
in the context of the RDC promoting research. However, the MRC is aware of the potential of 
these methods and has recently funded a 5 year programme grant to conduct methodological 
and applied research using value of information methods. 
 
It seems likely that the Institute generally, and the RDC in particular would need to engage 
with the research funding bodies to promote understanding of the concepts underlying the 
framework, the techniques for implementing these concepts and the value of the results from 
such analysis.  Such activities will take time, in the interim, VOI is unlikely to be effective as a 
means of promoting specific research questions to the research funding bodies. This said, the 
provision of VOI as supporting information to the Institute’s arguments for undertaking specific 
research projects may act as an effective tool for engaging the funding bodies in discussions 
about the method. It may be that the provision of a quantitative assessment of the value of 
research identified by the Institute will challenge the funding bodies demonstrate, in some 
manner, that the research they propose to support has more value to society. This in itself will 
represent a valuable contribution to research investment decisions in the UK. 
 
9.1.5 Implementing value of information analysis within NICE 
 
Value of Information Analysis requires the construction of high quality cost effectiveness 
models, with appropriate probabilistic sensitivity analysis. It is not clear that the cost 
effectiveness analyses currently provided to the NICE Appraisal programme. In part this is 
due to a limited supply of the necessary skills and in part it reflects the view of some analysts 
that probabilistic sensitivity analysis is not necessary to support decision making.  
 
In addition to the logistical problems posed by Assessment teams and collaborating centres 
that are currently unable or unwilling to provide PSA and VOI  analyses to the Institute, there 
are substantial technical difficulties in the application of PSA which need to be addressed. 
 
All existing PSA analyses, including those reported here, are likely to systematically under 
estimate the degree of decision uncertainty, and therefore the value of investing in additional 
research.  This is because the data used to parameterise cost effectiveness analyses are 
approximations to the parameter that the decision maker is actually interested in, rather than 
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the parameter itself.  The most widely known example of this problem is the use of efficacy 
data from clinical trials when the decision maker is interested in effectiveness. However, what 
O’Hagan describes as the Data Gap, xxxvii  applies to all parameters in cost effectiveness 
analyses. For example, we use uninformed general population health state values when we 
want informed general population values; xxxiixxxviii we use trial based resource use when we 
are interested in service resource use;(example ref required)  we use trial based compliance 
rates when we are interested in compliance rates seen in the treated population;xxxiv and so 
on… With each parameter we use an approximation, we increase the total uncertainty about 
how accurate an estimate of the cost effectiveness of the intervention the model provides.  An 
extension of this observation is that if research undertaken in response to VOI analyses 
gathers data on the approximation to the parameter of interest, rather than the parameter 
itself, (e.g. if a double blind placebo controlled clinical trial is undertaken to improve the 
evidence on effectiveness) the value of the information obtained will be less than the standard 
VOI analysis would suggest (A. O’Hagan, Personal communication May 2004).6  
 
Additional technical problems exist in the application of PSA and VOI more generally. The 
methods of evidence synthesis are in their infancy and there are many types of data which we 
are unsure how to synthesise; e.g. observational data and trial data. Whilst global and partial 
VOI calculations are relatively straightforward, the methods for estimating the value of sample 
information are still under development. 
 
A further challenge to the implementation of VOI is the requirement for a single well defined 
decision criterion, expressed in terms of a willingness to pay for a unit of health gain. It is 
quite clear from the most recent Methods Guidance that the Appraisal programme does not 
have a single fixed decision criterion. xxxii With a decision criterion that varies between 
appraisals, the VOI analyses will not be comparable across appraisals. For decisions on the 
Value of further research to inform that specific decision, this is may not be important, 
however, the RDC will be deliberating over the whole range NICE activities and comparability 
is an important aspect of any analytical tool the RDC adopts.  The other programmes within 
the Institute do not use an explicit cost effectiveness threshold as the decision criterion, and 
therefore it is not possible to estimate the value of reducing the uncertainty around their 
decisions.  
 
9.1.6 Summary 
 
In this chapter we have attempted to consider the feasibility of the RDC adopting VOI as the 
primary source of data to inform its deliberations.  Whilst the case studies reported above 
demonstrate that it is possible to produce Value of Information analyses. Indeed, where the 
model has already been constructed and probabilistic sensitivity analyses undertaken, the 
marginal cost of producing global and partial value of information estimates is far from 
prohibitive. 
 
This said, we have identified a number of challenges to the routine use of VOI by the RDC. 
Some of these issues relate to process, whilst others are technical. 
 
9.1.7 Process Issues in the adoption of VOI by the RDC 
 
The case studies reported above are all taken from the NICE Appraisal Programme, and were 
undertaken by TAR teams who have established expertise in PSA and VOI. Whilst the new 
methods mandate the use of PSA in the reference case analysis for all appraisals, many of 
the TAR teams are currently ill-equipped to undertake such analyses and it will take a 
substantial period of time before high quality PSA is routinely provided in all the TARs. Even 
                                                 
6 It may be that research on the nature of the relationship between the approximation and the parameter 
of interest will be of more value than research on the true value of the approximation. Analyses which 
addressed this data gap would require a major change in the way that cost effectiveness models are 
built, with the explicit incorporation of structures linking the approximation of the parameter of 
interest, to the real parameter. Current VOI analyses assume that that parameter of interest and the 
approximation are identical. 
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when this is the case, VOI will not be routinely provided. If the RDC wishes to receive VOI, it 
is likely that it will have to find resources to support the additional work. 
 
The RDC has defined is function as the promotion of research priorities to the conventional 
research funding bodies. It will be necessary to convince these bodies of the validity of the 
VOI framework before promotion of research priorities based on such analyses will be 
acceptable. This is likely to take a substantial amount of time and effort. 
 
The RDC has responsibilities to promote the research priorities identified by all programmes 
within the Institute, not just the research priorities identified through the appraisal programme.  
None of the other programmes routinely undertaken substantial cost effectiveness analysis, 
never mind probabilistic sensitivity analysis and VOI. Either these types of analyses need to 
be implemented across all the Institutes programmes or the RDC will have to find a means of 
comparing the research prioritisation outputs of the different programmes, when they are 
identified and expressed using incompatible processes. 
 
9.1.8 Technical issues in the adoption of VOI by the RDC 
 
There are three substantial technical issues in the adoption of VOI by the RDC. The first 
relates to the technical state of knowledge on probabilistic sensitivity analysis. PSA requires 
the synthesis of evidence from a variety of sources in order to identify the expected value and 
the uncertainty around that expectation. For many types of evidence, analysts know how to 
undertake such synthesis. However, there are some types of evidence for which we do not 
have adequate techniques.  Thus VOI will not always be possible. In part this is using 
perfection as an argument against the merely good. However, it is important to recognise that 
PSA and VOI methods are ‘works in progress’. 
 
The second technical challenge to the use of VOI is what O’Hagan describes as the ‘Data 
Gap’. The uncertainty expressed in current probabilistic sensitivity analyses is always an 
under assessment of the true uncertainty, because the data used are from approximations to 
the parameters of interest to the decision maker, not the parameters of interest.  This under 
assessment of uncertainty will lead to a mis-specification of the value of information and to 
the degree that further research actually collects information on the approximation rather than 
the parameter, the value of that information will be less than the analysis indicated.  
Addressing the problem of the data gap will require a fundamental recasting of cost 
effectiveness models, such that the model structure includes a function relating the 
approximation to the parameter of interest to the decision maker. The incorporation of 
uncertainty around this relationship will allow the analyst to establish the value of further 
research on the approximation to the parameter compared to research on the relationship 
between the approximation and the parameter. 
 
VOI requires the specification of a single decision criterion; lambda. This single criterion does 
not exist even with the appraisal programme, never mind the other programmes of the 
institute. The adoption of VOI by the RDC would imply substantial changes in the way in 
which the other programmes within the Institute undertake their analyses, and push the 
Appraisal Committee towards a much more uniform cost effectiveness decision criterion. 
 
Whilst there are many challenges associated with the use of Value of Information Analysis by 
the RDC, the alternatives are difficult to defend as they are in essence; informal, unstructured 
and opaque value of information analyses, which do not have a specified payoff function. 
Against this background, the RDC has the opportunity to challenge current research resource 
allocation decisions to improve by incorporating Value of Information Analysis into its 
processes for the assessment of future research needs. 
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10. Conclusions 
 
The framework proved by DA-VOI was successfully implemented for each of the 6 case 
studies and provides the value of additional information, which may be generated by further 
research.  This value is consistent with the objectives of the heath care system (maximise the 
health gains of the population of England and Wales) and is based on the same resource 
constraints i.e., the cost-effectiveness threshold which is used to develop guidance on use of 
the technology.   
 
For a particular assessment, this allows comparison of the potential benefits of further 
research (EVPI) with the costs of further investigation.  If the potential benefits exceed the 
additional costs (including opportunity costs to patients) then further investigation maybe 
required to support guidance on use.  The EVPI associated with the groups of parameters 
indicates the type of evidence that will be most valuable and therefore the type of studies that 
should be recommended. 
 
It also allows comparisons to be made across different technology assessments and 
prioritisation between alternative research recommendations, as well as a comparison 
between the value of investing resources in research or other activities such as the provision 
of health service.  In this sense it provides a unified and coherent framework for prioritisation 
of both research and the use of heath care technologies 
 
The results of any analyses are conditional on the use of appropriate model structure, 
appropriate synthesis of evidence and characterisation of other uncertainties.  This is 
important for estimates of expected cost-effectiveness but even more important for estimates 
of value of information which are particularly sensitive to these issues.  The existing reference 
case and methodological guidance requires supplementary guidance on the detailed use of 
methods to ensure that the adequacy of reference case submission can be assessed and that 
an adequate reference case analysis will provide sufficient basis for value of information 
analysis.   
 
It should be recognised that the key challenges for this type of analysis are not the VOI 
methods themselves but structuring decision problems, synthesis of evidence and the 
characterisation of uncertainty (required for estimating costs and effects as well as VOI).  The 
development of methods in these areas is ongoing and will require continued support from a 
variety of sources.   
 
The pilot demonstrates that VOI is feasible within reasonable time lines, even based on pre 
reference case analysis.  The use of VOI as part of the reference case is, for most types of 
models limited, not by time and resource requirements, but by the capacity to conduct this 
type of analysis and the dissemination of these methods.  Therefore training in VOI methods 
should be considered as a cost-effective means of easing these capacity constraints.   
 
There is a range of possible options to implement DA-VOI within the NICE process, to inform 
research recommendations.  In general there a two levels at which DA-VOI could be 
implemented. DA-VOI could be implemented at the TAR stage of the process, either 
selectively or ultimately becoming part of the reference case for the Assessment Report.  
Alternatively DA-VOI could be implemented in a similar way to the case studies presented 
here: as a supplementary analysis to and existing TAR once guidance on use and research 
recommendations has been made.  This maybe regarded as the most feasible way of 
progressing in the short run. But, as capacity and methods develop, a move towards making 
DA-VOI a routine part of the TAR and the research recommendations in the guidance more 
firmly grounded on evidence and an explicit analysis may be achievable in the medium term. 
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